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Background:  Herpes simplex virus, type 1 (HSV-1) establishes latency in human sensory 
ganglia following primary infection through mucosal tissues.  Once latent, the virus persists for 
the host’s lifetime, with periodic reactivations that cause lytic lesions.  First-line medications like 
acyclovir (ACV) abort lytic reactivations, but drug resistance has been reported and second line 
drugs may cause serious side effects.  These facts, together with inefficacy of antivirals against 
latency, compel new drug screens; human neural tissues that model aspects of latency are 
arguably well-suited for such screens. 
Studies: 
Study 1.  Human induced pluripotent stem cell-derived neurons (iPSC-neurons) were 
used to model HSV-1 infection employing an HSV-1 construct that incorporates dual fluorescent 
reporter genes from different kinetic expression groups.  Lytic infection was demonstrated 
initially.  ‘Quiescent’ infection was next established using protocols from animal models of 
latent infection.   The quiescent infection fulfilled most criteria for latency, including viral gene 
expression and heterochromatization patterns.   
Studies 2 and 3:  The antiviral activity of two series of compounds was investigated using 
monkey epithelial cells and iPSC-neurons.  Anti-lytic activity that reduced viral copy number 
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and protein levels was induced by four compounds, of which two compounds also inhibited 
reactivation of HSV-1 from quiescence/latency.  Four compounds were also efficacious against 
varicella zoster virus and/or human cytomegalovirus infections. 
Study 4:  Moderate throughput platforms for antiviral drug screens based on iPSC-
neurons were designed, with readouts based on high content analysis and flow cytometry. 
Conclusions:  Lytic and latent HSV-1 infection was modeled in human iPSC-neurons, 
with features similar to animal models.  Compounds with novel effects against HSV-1 infections 
were identified using the iPSC-neuron model.  Platforms for moderate throughput drug screens 
are feasible using human iPSC-neuron models. 
Public Health Significance:  Herpesviruses are highly prevalent, with rates exceeding 
95% in some populations.  Recurrent HSV-1 eye infections are the leading cause of infectious 
corneal blindness in the USA.  HSV-1 encephalitis that is particularly devastating to neonates 
can be fatal.  Associations between HSV-1 seropositivity and cognitive impairment have been 
reported even without encephalitis.  There are no effective HSV-1 vaccines and there are 
growing concerns about antiviral drug efficacy.  In view of the enormous burden, there is a 
compelling need for novel drug screens. 
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1.0  INTRODUCTION 
1.1 PUBLIC HEALTH SIGNIFICANCE 
Herpesvirus infections are highly prevalent in human populations globally.  The 
prevalence of seroconversion by age 15 is 40% worldwide; furthermore, seropositivity increases 
with age and is estimated at greater than 70% in older US adults (Whitley, 1996; Smith et al., 
2002).  HSV-1 primary infection often presents as herpetic gingivostomatitis (Mohan et al., 
2013).  In addition to recurrent facial lesions, HSV-1 infection can infect other areas of the body, 
such as the eyes or brain, leading to ocular keratitis  (Farooq & Shukla, 2012), and rarely, 
encephalitis, respectively (Whitley, 2006).  Moreover, data from the United States National 
Health and Nutrition Examination Surveys (NHANES) indicates HSV-1 is an emerging genital 
infection with an increasing incidence  (Xu et al., 2006); additionally, individuals with genital 
herpes have a two- to four-fold increased risk to acquire the human immunodeficiency virus 
(HIV; Holmberg et al., 1988; Wald & Link, 2002; Freeman et al., 2006; Anuradha et al., 2008; 
Patel et al., 2012).  A wealth of evidence points to associations of HSV-1 seropositivity and 
cognitive decline in individuals without prior history of encephalitis, diagnosed with 
schizophrenia, their first-degree relatives, and unrelated controls of different ethnicities (Prasad 
et al., 2012; Fruchter et al., 2015).  The burden of disease is much greater for 
immunocompromised patients. 
 2 
1.1.1 Herpes Keratitis 
Herpes keratitis (HK) is an infection of the eye caused by HSV-1 and it is the leading 
cause of infectious corneal blindness in developed countries (Dawson & Togni, 1976; reviewed 
in Farooq & Shukla, 2012).  Its global incidence is approximately 1.5 million cases per year 
(Farooq & Shukla, 2012) and 40,000 new cases of visual impairment or blindness are reported 
per year (Flagg & Weinstock, 2011; Farooq & Shukla, 2012).  Visual impairment and blindness 
are due to corneal opacification, a result of tissue scarring caused by recurring viral insults that 
trigger host immune damage (Halford et al., 2004)  ACV is the preferred treatment for HK, taken 
orally or topically.  Rates of viral reactivation can be reduced when treating HK with 
prophylactic, long-term antivirals (Herpetic Eye Disease Study Group, 1998).  Following 
primary HSV-1 infection at the oromucosal surface, latency is established in the nerves of the 
trigeminal ganglia where the virus can reactivate and enter the ophthalmic nerves and infect the 
cornea (Hill et al., 2014).  Alternatively, there is controversial evidence that corneal cells may 
serve as a site of latency, beside the trigeminal ganglia and dorsal root ganglia (Zheng, 2002; 
Polcicova et al., 2005). 
1.1.2 Herpes Simplex Encephalitis 
Herpes simplex encephalitis (HSE) is a devastating lytic HSV-1 infection of the brain.  
HSV-1 is the most common agent to cause acute, sporadic encephalitis worldwide (Whitley, 
2006) with a prevalence rate in the United States of approximately 1 in 300,000 individuals 
(Whitley, 2006).  HSE infection, with or without proper treatment of intravenous acyclovir, 
results in mortality rates of approximately 30% and 70%, respectively (Whitley, 2006).  
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Individuals that survive infection will carry life-long, devastating neurological sequelae, 
including, but not limited to: neurological deficits, seizures, and neuropsychological 
dysfunctions (McGrath et al., 1997).  During HSE infection, the virus is undetectable in the 
peripheral blood using current testing methods; therefore, HSE is tested clinically in 
cerebrospinal fluid (CSF) sample using polymerase chain reaction (PCR) to amplify viral nucleic 
acid fragments (Debiasi & Tyler, 2004)  
There is mounting evidence of a Mendelian predisposition to develop HSE.  As a vital 
part of the innate immune system, the toll-like receptor (TLR) family mediates interferon and 
cytokine production after the detection of pathogen-associated molecular patterns (PAMPs) on 
antigens (Doyle et al., 2002).  TLR3 recognizes double-stranded RNA, an intermediate nucleic 
acid present in most viral infections, including HSV-1 infection (Jacobs & Langland, 1996).  
Inborn errors of TLR3 and other molecules of the TLR3 signaling pathway can result in a 
predisposition to develop childhood HSE upon primary infection and an overall increased 
susceptibility to HSV-1 infection in some children (Lafaille et al., 2012; Zhang et al., 2013; Lim 
et al., 2014).  
Missense mutations in TLR3 were identified in two unrelated patients who developed 
HSE, the mutations were not detected among control individuals (Zhang et al., 2007).  However, 
these mutations show incomplete penetrance as relatives of the two cases were HSV-1 
seropositive, but were never diagnosed with HSE (Zhang et al., 2007).  Similarly, exonic 
mutations in other genes of the TLR3 signaling pathway also confer increased risk of HSE 
development including UNC93B1 (Casrouge et al., 2006), TRIF (Sancho-Shimizu et al., 2011), 
and TRAF3 (Pérez de Diego et al., 2010)  These studies suggest that either the HSV-1 primary 
infection is inadequately controlled in CNS-resident non-haemopoietic cells during the primary 
 4 
infection (Zhang et al., 2013), or viral reactivation is inadequately controlled (Zhang et al., 
2007).  Both possibilities confer risk due to diminished interferon production. 
1.1.3 Neonatal Herpes Simplex 
Herpes simplex can infect neonates at birth by vertical transmission of the virus to the 
neonate from the mother.  The incidence of neonatal HSV disease ranges from 1:1,500 
(Kimberlin, 2004) to 1:3,200 in the United States (Brown et al., 2003).  The most common form 
of neonatal exposure is by contact with the virally infected birth canal, especially in mothers who 
have seroconverted in their 3rd trimester (Brown et al., 1997). Patterns of neonatal herpes fall into 
three categories.  The most severe pattern is viral infection of the internal organs; this is usually 
fatal.  Among survivors, the greatest morbidity is associated with CNS infection that manifests as 
seizures, lethargy, failure to thrive, or encephalitis.  Lesions that occur only on the neonatal 
external skin surfaces have the best prognosis, but if left untreated, the infection may lead to 
more serious infections to the internal organs and/or CNS.  Similar to post-neonatal HSE 
infection, the death rate in the first 12 months of life is 85% for disseminated disease and 50% 
for CNS infection (Whitley et al., 1980).  However, the advent of high-dose antiviral therapy has 
reduced the 24-month mortality rate to 31% for disseminated disease and 6% for CNS infection, 
among survivors, no neurological sequelae occurred in 83% and 31%, respectively (Kimberlin et 
al., 2001). 
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1.1.4 Herpes Simplex Virus and Cognitive Dysfunction 
The cognitive dysfunction observed in survivors of herpesvirus encephalitis resembles 
the cognitive dysfunction in those with schizophrenia (SZ), but is milder (Kapur et al., 1994; 
Hokkanen & Launes, 2000).  Furthermore, HSV-1 has been detected in the post mortem brains 
of SZ patients (Kudelova et al., 1988) and Alzheimer’s disease patients, who also manifest 
cognitive decline (Wozniak et al., 2009).  There is a growing body of evidence indicating a 
robust association of HSV-1 seropositivity with cognitive dysfunction, even among individuals 
without a prior history of encephalitis or dementia (Dickerson et al., 2003; Dickerson et al., 
2008; Shirts et al., 2008; Schretlen et al., 2010; Yolken et al., 2011; Thomas et al., 2013; D'Aiuto 
et al., 2015; Fruchter, et al., 2015).  HSV-1 seropositivity in SZ patients is associated with a 
greater reduction in the gray matter volume in distinct brain regions, compared with seronegative 
patients (Prasad et al., 2007; Prasad et al., 2011; D’Aiuto et al., 2014), with cognitive deficits 
including difficulty with memory, such as challenges to learn new verbal and visual stimuli; 
executive functioning, such as reasoning; and difficulties performing day-to-day tasks (Aleman 
et al., 1999; Weickert et al., 2000).  A double-blind, placebo-controlled study revealed improved 
cognition in SZ patients who received the antiviral valacyclovir as an adjunct to their 
antipsychotic medication for 18 weeks (Prasad et al., 2012).  Cognitive decline over time has 
been noted also among African-Americans (Watson et al., 2012), or Caucasian individuals who 
are not diagnosed with psychoses such as SZ (Dickerson et al., 2008; Watson, 2012). 
These associations suggest that HSV-1 latency may not be as benign as once thought.  
Given the high prevalence of HSV-1 in the general population, increased risk of cognitive 
decline from infection resulting in neuronal cell death warrants further investigation, as well as 
new treatment options (Becker, 1995). 
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1.2 HERPESVIRIDAE 
The Herpesviradae family comprises eight viral species that infect Homo sapiens.  These 
viruses have linear, double-stranded DNA genomes, an icosahedral capsid, a proteinaceous 
tegument layer, and a lipid envelope (Chisholm & Lopez, 2011).  Additionally, they can 
establish latency in a variety of cell types following primary infection.   Herpesviruses are 
divided into three subfamilies.  
Human alphaherpesvirinae viruses include herpes simplex virus, type 1 (HSV-1), type 2 
(HSV-2), and varicella zoster virus (VZV).  An individual contracts HSV by close, physical 
contact with another HSV-positive individual who is shedding the virus.  HSV-1 and -2 display 
lytic viral infection as grouped vesicles on mucosal membranes and establish latency in sensory 
neurons of cranial nerves, such as trigeminal ganglia (HSV-1; Warren et al., 1978) or sacral 
ganglia (HSV-2); however these sites of latency are not exclusive to either type of virus.  
Primary HSV-1 infection usually occurs during childhood or adolescence and most commonly 
infects oromucosal surfaces, whereas primary HSV-2 infection generally is delayed until the 
onset of sexual activity and most commonly occurs at genital mucosal surfaces. 
Primary VZV infection is commonly known as chickenpox and may reactivate later in 
life, when it is called called zoster (shingles), usually following a decline in age-related 
immunity; symptoms include skin lesions that resolve within 12-14 days and neuralgia that may 
resolve within 4-6 weeks, but may last longer.  However, some individuals may experience 
neuralgia lasting longer than 6 weeks, as well as other complications like myelitis, 
meningoencephalitis, or vasculopathy (Nagel & Gilden, 2014).  VZV maintains a latent state in 
sensory neurons of the dorsal root or nerve ganglia along the entire neuraxis (Gilden et al., 
2009). Reactivation is commonly restricted to specific neurons of viral activity that innervate that 
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particular dermatome in immunocompetent individuals (Gnann et al., 2002),  Antiviral treatment 
is required for individuals who experience ophthalmic zoster, due to tissue scarring and a 
potential for permanent visual impairment.  Following the US approval of the live attenuated 
varicella vaccine in 1995, the mortality of VZV infection has plummeted to less than 20 per year 
(Horien & Grose, 2012).  The vaccine is based on the Oka strain, which has reduced reactivation 
compared with the wild-type VZV and thus may also reduce incidence of zoster (Hardy et al., 
1991; Hambleton et al., 2008; Vere et al., 2013).  Individuals who are seropositive for VZV and 
are between the ages of 60 – 80 years may benefit from a booster vaccination by the zoster 
vaccine, reducing shingles risk by 51% (Gilden, et al., 2009).  The US prevalence for VZV, 
estimated in the National Health and Nutrition Examination Survey (NHANES) study 
(n=16,050), is 93% for children aged 6-19 years and 98% for adults aged 20-49 years (Reynolds 
et al., 2010). 
Human betaherpesvirinae viruses include human cytomegalovirus (HCMV), human 
herpesvirus type 6 (HHV-6), and type 7 (HHV-7).  HCMV infects a broad range of human 
tissues and likely establishes latency in macrophages and lymphocytes.  Primary HCMV 
infection are asymptomatic in the majority of individuals, but can lead to serious disease in the 
immunocompromised population, with fever, pneumonia, seizures, hepatitis, and visual 
impairment.  Congenital HCMV infection can result from seroconversion of the mother during 
pregnancy and is devastating to neonates; HCMV is a significant infectious cause of infantile 
intellectual disability and hearing loss (Damato & Winnen, 2002).  HCMV infection is estimated 
to be present in over 95% of the global adult population (Cannon et al., 2010). 
HHV-6 variant B (HHV-6B) and HHV-7 cause roseola infantum, typically presenting 
with fever, rash, and febrile convulsions (Ward, 2005).  HHV-6 variant A (HHV-6A), HHV-6B, 
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and HHV-7 each have an estimated prevalence of greater than 90% in developed countries by 6 
years of age (Hall et al., 1994; Huang et al., 1997; Agut, et al., 2015).  HHV-6 has a wide cell 
tropism in vivo, and replicates in the brain, salivary glands, tonsils, kidneys, liver, endothelial 
cells, and macrophages; HHV-7 is a T-lymphotropic virus (Ponti et al., 2008).  Like other 
herpesviruses, HHV6 maintains a latent state and is capable of reactivation; unlike other 
herpesviruses, HHV-6 can integrate into subtelomeric regions of host cell chromosomes with a 
prevalence of about 1% in developed nations (Agut et al., 2015).  While there is little difference 
between the HHV-6 variants in genomic sequence (<4%), there are differences in their patterns 
of infection.  Variant 6A is not readily found in saliva, unlike 6B, which is more likely to be 
detected in leukocytes and saliva; and 6B may not result in development of a rash, unlike variant 
6A (Ward, 2005). 
Human gammaherpesvirinae viruses include Epstein-Barr virus (EBV) and Kaposi’s 
sarcoma-associated herpesvirus (KSHV).  EBV infects epithelial cells and then B-lymphocytes, 
where the latter is the site of latency as the virus can persist following memory B-cell maturation 
(Vere et al., 2013).  Primary EBV is asymptomatic in the majority of infected individuals, but 
some individuals can experience infectious mononucleosis.  EBV can reactivate from B-
lymphocytes, manifesting as an epithelial cell infection (Hadinoto et al., 2009).  EBV infection is 
also associated with many cancers, including Burkitt’s lymphoma, a neoplastic proliferation of 
B-lymphocytes and nasopharyngeal carcinoma (Lo et al., 2012).  Approximately 200,000 new 
cases of EBV-associated cancers are reported each year, worldwide (Parkin, 2006; Fukayama, 
2010).  EBV is prevalent in up to 90% of the global adult population (Hislop, 2015). 
KSHV is likely the causative agent of Kaposi sarcoma (KS), an endothelial cell tumor of 
blood and lymphatic vessels.  KS presents as isolated lesions on the limbs, lymph nodes, mucosa, 
 9 
and/or internal organs.  KSHV is necessary but not sufficient for the presence of Kaposi 
sarcoma; the immunocompromised are at elevated risk.  Progression to cancer is most prominent 
in HIV/AIDS patients and organ transplant recipients.  Like other herpesviruses, KSHV supports 
cycles of latency and lytic infection, and viral transcripts are found in B-lymphocytes, 
macrophages, keratinocytes, endothelial and epithelial cells in vivo (Boshoff & Weiss, 1998). 
KSHV prevalence is unlike the other ubiquitous herpesviruses; in developed countries, it is 
disproportionally prevalent in HIV-infected men and range from 30% to 65% (Martin, 2011).  It 
is most frequently found in Middle Eastern and African individuals, where the prevalence in the 
general population is between 15% and 60% (Martin, 2011). 
The viruses that belong to the Herpesviradae family are highly prevalent in the human 
population and represent a significant public health importance.  A common feature of 
herpesviruses is their ability to establish and maintain persistence in the host in the face of 
immunity.  They can remain in this state for the entire life-span of the host.  However, specific 
stimuli can result in viral reactivation and produce recurrent diseases. 
1.3 HSV-1 LYTIC CYCLE 
The HSV-1 virion consists of a 152 kilobase, linear, double stranded DNA genome 
housed in an icosahedral capsid.  Surrounding the viral capsid is a proteinaceous tegument 
consisting of viral encoded proteins, and the tegument is enclosed by an envelope.  The envelope 
is derived from the host cell embedded with viral glycoproteins. 
The HSV-1 genome is characterized by a guanosine:cytosine content ratio of 
approximately 68% (J. C. Brown, 2007) and contains two unique DNA sequences (UL and US), 
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which are flanked by two inverted repeats (TRL and IRL; IRS and TRS; FIGURE 1).  The viral 
genome contains approximately 74 open reading frames of which three are present in two copies 
(Dolan et al., 1998); the majority of these transcripts do not undergo splicing (Wagner, 1985). 
 
 
Figure 1.  Representation of the HSV-1 genome. 
 
The HSV-1 lytic lifecycle begins with attachment and entry into permissive host cells.  
Viral glycoproteins embedded in the viral envelope bind to various surface receptors—these 
include:  heparan sulfate chains on cell surface proteoglycans (Shukla et al., 1999), herpesvirus 
entry mediator (HVEM; Montgomery et al., 1996), or nectin1 (Cocchi et al., 1998; Geraghty et 
al., 1998); entry may occur via endocytosis by fusion of the plasma membrane (Nicola et al., 
2003).  There are 12 viral envelope proteins containing glycan chains, and are classified as viral 
glycoproteins; of which four have been shown to be essential for viral attachment and fusion 
with the host membrane (Turner et al., 1998; Cocchi et al., 2004).  After the viral envelope fuses 
with the host cell plasma membrane, the tegument proteins (Radtke et al., 2010; G. Smith, 2012) 
and the nucleocapsid are released into the host cell cytoplasm.  The nucleocapsid, containing the 
viral DNA, transits to the host cell nucleus via processes mediated by the dynein (Sodeik et al., 
1997) and dynactin motor protein complexes (Döhner et al., 2002).  Next, the viral nucleocapsid 
docks to the host nuclear pore complex on the outer nuclear membrane, rapidly releasing DNA 
into the host cell nucleus (Ojala et al., 2000; Sae-Ueng et al., 2014), where a portion of incoming 
genomes circularize (Jackson & DeLuca, 2003), or adopt a branched structure (Martinez et al., 
1996) and serve as the template for DNA replication (Lemaster & Roizman, 1980; Batterson et 
al., 1983; Fenwick & Everett, 1990; Zhang & McKnight, 1993; Strang & Stow, 2005). 
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During productive infection, host RNA polymerase II transcribes viral genes in a 
temporal manner, beginning with the five IE genes, designated as Infected Cell Polypeptides 
(ICP) 0, ICP4, ICP22, ICP27, and ICP47 (Honess & Roizman, 1974, 1975).  Transcription of IE 
genes occurs independently of de novo viral protein synthesis (Weir, 2001).  The IE gene 
transcription is initiated by a multiprotein transcription factor complex comprised of viral 
tegument protein VP16 (Pellett et al., 1985) and host proteins HCF1 (Kristie & Roizman, 1987) 
and Oct1 (O'Hare, 1993). VP16 associates with Oct1 (Kristie & Roizman, 1987) and binds to a 
common core sequence that is shared among IE gene promoters, known as the TAATGARAT 
regulatory element (Stern et al., 1989).  The IE proteins are required for the transcription of early 
(E) proteins, which are involved in the production and regulation of viral DNA synthesis 
(Honess & Roizman, 1974).  Following DNA synthesis, late (L) genes are expressed, which in 
general, encode proteins that contribute to virus structure and assembly.   
While HSV-1 requires the use of host cell transcription machinery, it also encodes six 
proteins that comprise the DNA replisome (a two subunit DNA polymerase (DNA pol; UL30 
and UL42), a single stranded DNA binding enzyme (ICP8), and a three subunit helicase-primase 
complex (UL5, UL52, and UL8; Muylaert et al., 2011)).  Viral gene UL9 encodes the origin 
binding protein that binds and unwinds viral DNA at one or more of the three origin sites (Aslani 
et al., 2002). The helicase-primase complex travels in the 5’ to 3’ direction at the replication fork 
and the DNA pol presumably carries out leading and lagging strand synthesis while ICP8 binds 
the single-stranded DNA during polymerization.  UL30 is the catalytic subunit of HSV DNA pol 
and is necessary for production of progeny virions (Dorsky & Crumpacker, 1988).  Viral DNA 
has been hypothesized to replicate by several mechanisms, including theta replication (Roizman, 
1979), rolling circle mechanism (FIGURE 2; Skaliter et al., 1996) , and trombone mechanism of 
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replication (Bermek et al., 2015) at one or more of the three origin sites.  Additionally, viral 
DNA also exists as a complex, branched structure during replication (Martinez et al., 1996) and 
evidence suggests recombination of viral DNA may lead to this branched structure (Wilkinson & 
Weller, 2003; Weller & Sawitzke, 2014).  DNA replication results in concatemeric units that are 
later cleaved into single genomes during encapsidation (Weller & Coen, 2012).  The genes 
required to construct the viral capsid are translated by host ribosomes and transported back into 
the host nucleus where assembly of the nucleocapsid occurs.  Following capsid maturation, the 
terminase packages an HSV-1 genome into the viral capsid (Bauer et al., 2013). 
 
 
Figure 2.  Representation of the rolling circle DNA replication model for HSV-1. 
 
Once the viral DNA is encapsidated, the resulting nucleocapsid begins egress from the 
cell.  The nucleocapsid is too large to transverse nuclear pore complexes, thus a different route is 
taken.  During primary envelopment, the nucleocapsid buds through the inner nuclear membrane 
into the perinuclear space, along with selected tegument proteins VP16, vhs, pUL11, UL37, and 
pUS3 kinase (Baines et al., 1995; Reynolds et al., 2002; Naldinho-Souto et al., 2006; Read & 
Patterson, 2007).  The viral particle proceeds to de-envelopment by fusion with the outer nuclear 
membrane (Lycke et al., 1988; Reynolds et al., 2002).  In the cytoplasm, a secondary 
envelopment of the viral particle occurs at the trans-Golgi network (TGN), where viral particles 
associate with tegument proteins and bud into the TGN membranes, thus acquiring its envelope 
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(Wisner & Johnson, 2004; Turcotte et al., 2005; Sugimoto et al., 2008).  The viral particles 
continue egress utilizing kinesin protein motor proteins (Diefenbach et al., 2002) to the host cell 
membrane and can fuse with resulting exocytosis (Johnson & Baines, 2011) or spread cell-to cell 
by tight junctions to adjacent cells (Johnson, et al., 2001).  Lytic cycles are typically lethal for 
the host cells. 
1.4 HSV-1 LATENCY 
A hallmark of herpesviruses is their ability to persist for the entire lifetime of their hosts 
in a latent, but reactivatable form.  For HSV-1, a reservoir of latent viral genomes is typically 
established and maintained in the nuclei of sensory neurons of the peripheral nervous system 
(PNS) following the primary infection.  HSV-1 DNA does not integrate into the host genome, 
but exists in the nucleus as a circular, heterochromatic episome (Bloom et al., 2010), probably in 
specific nuclear compartments that allow for heterochromatin formation (Catez et al., 2012).  In 
a mouse model of latency, approximately 5-20% of neurons harbor latent viral genomes, where 
viral DNA copy number is estimated at 1 to 100 per neuron (Mehta et al., 1995; Yang et al., 
2000).  A small fraction of neurons harbor more than 1,000 copies of viral genomes per cell 
(Sawtell, 1997). 
After the virus infects peripheral epithelial cells, it enters the axon termini of the nerves 
in the infected tissues, and viral components are retrogradely transported to the sensory neurons 
of the trigeminal ganglia or dorsal root ganglia (Baringer & Swoveland, 1973; Smith, 2012).  
HSV-1 latency is established in the nuclei of these PNS neurons.  The entry site of the virus 
determines the ability to establish latency:  if HSV-1 directly enters the neuronal soma instead of 
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the neuronal termini, a productive infection is favored (Hafezi et al., 2012).  Establishment of 
latency when the virus enters the axon termini may be due to the progressive loss of VP16 during 
the retrograde transport of the virus to the soma.  As a consequence, IE gene transcription could 
be delayed due to insufficient quantities of VP16, resulting in viral latency.  However, 
productive infection can be induced by superinfection with other viruses, suggesting that the 
viral genome reaches the nucleus and is poised for replication (Hafezi et al., 2012). 
Hallmarks of HSV-1 latency include i) heterochromatinization of the viral genome, with 
the exception of the region encompassing latency-associated transcripts (LAT) sequence; ii) lack 
of infectious virion production; and iii) transcriptional repression of the viral genes with the 
exception of LAT, and its splicing products (Spivack & Fraser, 1987; Stevens et al., 1987). 
Viral lytic genes are silenced during latency; however, low levels of lytic transcripts can 
be detected in addition to latency associated transcripts (LAT) in latently infected neurons 
(Kramer & Coen, 1995; Kramer et al., 1998; Feldman et al., 2002).  In fact, single cell analysis 
revealed expression of one or more lytic genes in greater than one-third of latently infected 
neurons, albeit at low copy numbers (Ma et al., 2014).  This observation supports the model of 
reactivation described by Kim and colleagues as ‘animation’: a continuous attempt of the virus to 
reactivate despite the repressive action of the host (Kim et al., 2012).  The animation model 
describes a biphasic viral gene program, in contrast to the lytic HSV-1 infection (which 
postulates a temporal gene transcription program).  Phase I of the animation model describes a 
reactivation stimulus that produces a temporary, albeit extensive de-repression of lytic transcripts 
that is independent of the VP16-inducing complex.  During this phase, HSV-1 lacks the ability to 
produce infectious viral particles (Kim et al., 2012).  Indeed, if conditions during Phase I are 
favorable for lytic infection, the virus proceeds to a lytic infection.  However, if viral products 
 15 
are not able to accumulate to a sufficient supply, the virus retreats back to a latent state; a 
minority of Phase I events proceed to Phase II, where an ordered cascade of viral genes are 
transcribed, DNA is replicated, and infectious viral particles are produced (Kim et al., 2012). 
LAT is an 8.3 kb capped and polyadenylated noncoding viral RNA, which is spliced into 
more stable 2.0 kb fragments in the nucleus (Stevens, et al., 1987; Zwaagstra et al., 1990; Farrell 
et al., 1991).  LAT transcripts can be detected in approximately one-third of latently infected 
mouse neurons (Mehta, et al., 1995), but its exact mechanism on viral latency is unknown.  LAT 
transcripts are expressed during the late stages of lytic infections in murine models of infection 
(Spivack et al., 1988; Rodahl & Stevens, 1992; Chen et al., 1995).  LAT has multiple effects in 
the establishment or maintenance of latency (Javier et al., 1988; Steiner et al., 1989; Block et al., 
1990; Kramer et al., 2011).  LAT has been shown to function as a primary microRNA (miRNA) 
precursor that encodes several viral miRNAs  (Umbach et al., 2008; Umbach et al., 2009).  Some 
of these LAT-derived miRNAs (miRNA-H2 and –H6) are antisense to HSV-1 immediate early 
genes, and can down-regulate IE lytic genes ICP0 and ICP4, thus suggesting a regulatory role of 
LAT in latency (Umbach, et al., 2008).  Recent observations lead to the suggestion that LAT 
may enhance the formation of repressive H3K27me3 on lytic promoters during latency (Cliffe et 
al., 2009).  The presumptive role of LAT in the epigenetic regulation of HSV-1 latency raises the 
possibility that chromatin modifications are mediated in part by specific miRNAs transcribed 
from the LAT region.  Additionally, LAT may increase neuronal survival by blocking apoptosis.  
Infections using a LAT-null strain results in a reduced establishment of latency and greater 
neuronal morality (Thompson & Sawtell, 2001).  Likewise, reactivation is also reduced, which 
may be due to the decreased number of surviving neurons (Hill, et al., 1990; Perng et al., 2000; 
Sawtell & Thompson, 1992; Thompson & Sawtell, 1997, 2001). 
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HSV-1 Chromatin in Lytic and Latent Infection. 
HSV-1 chromatin composition varies during lytic and latent infections.  Histone proteins 
are not bound to viral DNA within infectious virions (Cohen et al., 1980; Pignatti & Cassai, 
1980; Oh & Fraser, 2008).  During lytic infection, viral DNA binds cellular histones upon host 
nuclear entry (Cereghini & Yaniv, 1984).  However, the histone occupancy is low, and viral 
chromatin does not display a regular chromatin pattern (Conn & Schang, 2013).  Similar to host 
chromatin, histone modifications of viral chromatin, such as acetylation or methylation, are 
dynamic.  As early as one hour post infection, HSV-1 DNA is associated with histones bearing 
marks of active transcription (H3K9ac); however, methylated H3K9 is associated with viral 
DNA as lytic infection proceeds (Kent et al., 2004; Silva et al., 2008), suggesting that 
nucleosomes are not absent from viral DNA during lytic infections, but are unevenly dispersed 
along the viral genome. 
During latency, HSV-1 DNA is maintained as a non-integrated, heterochromatic episome 
highly enriched in repressive marks H3K9me3 and H3K27me3 (Bloom et al., 2010; Cliffe, et al., 
2009).  Lytic genes are transcriptionally repressed and exhibit classical features typical of 
heterochromatin (Rock & Fraser, 1983; Efstathiou et al., 1986; Deshmane & Fraser, 1989; Knipe 
& Cliffe, 2008).  Furthermore, association of viral genome with heterochromatic proteins HP1 
(Canzio et al., 2011) and Bmi1 (a member of the polycomb repressor complex) has been 
documented (Kwiatkowski et al., 2009).  LAT is enriched in epigenetic marks typical of 
transcriptionally active regions in latent infections, such as dimethyl H3K4 and acetyl H3K9, 
H3K14 (Bloom, et al., 2010).  In animal studies, HSV-1 silencing occurs by heterochromatin-
like formation without DNA methylation (Dressler et al., 1987; Kubat et al., 2004; Quina et al., 
2006), which is typical in invertebrates, but not in mammals (Deaton & Bird, 2011).  The 
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upstream epigenetic mechanism(s) leading to the heterochromatization of the viral genome are 
largely unknown. 
 
Reactivation from Latency. 
While the exact cause(s) of viral reactivation is unknown, several external stimuli have 
been associated with viral reactivation, such as tiredness and emotional stress (Lorette et al., 
2006; Stock et al., 2001), UV light (Spruance, 1985; Spruance et al., 1995), and menstruation 
(Spruance et al., 1995).  Upon reactivation, viral progeny are anterogradely transported back and 
infect the cells proximal to the primary infection, giving rise to recurrent infection. 
The ability of HSV-1 to maintain in a latent, but reactivatable state is fundamental to its 
ability to persist in human populations.  The latent form of HSV-1 is composed of 
heterochromatic, circular viral DNA.  In this state, the host immune response does not seem to 
have the capability to detect the virus.  Identification of novel antiviral drugs may be expedited 
by using cell types that are the most relevant for HSV-1 infections:  human neurons.  Currently, 
the use of induced pluripotent stem cells to differentiate neurons provide a useful model to 
screen for high throughput drug screening using human neuronal cells. 
1.5 ANIMAL AND HUMAN MODELS 
1.5.1 Animal Models 
Although HSV-1 can infect a variety of mammalian species, humans are the natural host 
and reservoir of infection.  Still, much valuable information has been obtained from mouse and 
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rabbit models of lytic and latent HSV-1 infection.  Variations among the animal models are 
dependent on the viral strain, the animal, and its gender  (Webre et al., 2012).  For example, the 
viral strains 17syn+ or McKrae are considered frequent ‘reactivators’, compared with strain KOS 
(Sawtell et al., 1998), so they are commonly used to infect animals for reactivation studies.  
Though animal models have yielded valuable information in the past, they cannot recapitulate 
many features of human infections, such as the cognitive deficits; furthermore, HSV-1 evolved 
mechanisms of latency in human neurons.  Thus, a human model of HSV-1 infection would be a 
valuable complement to the herpes virologist’s toolkit.  In the following section, popular animal 
models of HSV-1 infection, as well as in vitro cell models, including induced pluripotent stem 
cell-derived neurons are reviewed. 
 
Murine models 
Due to their small size, the relatively low cost to house, and modest levels of care, murine 
models are the most frequently investigated animal models of HSV-1 infection.  Infections are 
introduced through the cornea (Dyson et al., 1987), the nose (Tan et al., 2014), the skin (Salinas-
Jasmin et al., 2015), the ear (Smith et al., 2001), the oral mucosa (Dyson et al., 1987; Kastrukoff 
et al., 2012), or the footpad (McKendall, 1980).  Inoculation on the oral mucosa, which 
represents the mode of inoculation most resembling the natural course of disease in humans, 
results in a burst of viral activity at the site of entry (Kastrukoff et al., 2012).  In animals that 
survive HSV-1 infection, latency is established in the trigeminal ganglia or the brainstem 
(Kastrukoff et al., 1982; Barnett et al., 1995; Labetoulle et al., 2000; Decman et al., 2005; 
Kastrukoff et al., 2010), which can occur within 24 hours post-infection (Steiner et al., 1990).  
Studies focusing on immune response, primary infection, or vaccine efficacy are well suited for 
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murine models.  Despite the aforementioned advantages, rodents have small eyes, making slit 
lamp examination of corneal HSV-1 infections difficult.   Furthermore, assessing viral activity 
can be difficult as mice produce less tear fluid and have smaller CNS tissue mass or corneas 
compared with rabbits.  
In addition to the anatomical disadvantages, HSV-1 infection differs in mouse from 
human hosts. For example, the rate of spontaneous shedding of HSV-1 in the mouse is relatively 
low to non-existent compared with humans and the development of recurrent lesions during 
spontaneous reactivation has not been described (Webre, et al., 2012).  In addition, herpes 
simplex encephalitis (HSE) produces diffused lytic foci in the mouse brain, but in the human 
brain, distinct pockets of lytic activity are observed (Meyding-Lamadé et al., 2003; Barker et al., 
2014).  Furthermore, there are 4 amino acid substitutions in the coding sequence of mouse Oct-1 
(which interacts with viral protein VP16 and facilitates viral immediate early gene transcription) 
compared to human Oct-1.  The difference in the amino acid sequence causes a lower binding 
affinity of murine Oct-1 to VP16 than the human homolog (Cleary et al., 1993).  Moreover, 
mouse cells that are infected with HSV-1 undergo RIP-3-mediated necroptosis as a means to 
eliminate virally-infected cells (Wang et al., 2014; Huang et al., 2015); but RIP3 is not activated 
in infected human cells, hindering downstream necroptotic actions (Guo et al., 2015), further 
highlighting the differences in mouse and human. 
HSV-1 reactivation in the mouse can be induced by several methods.  After the initial 
infection, surviving mice are assumed to house latent HSV-1 in the trigeminal ganglia or the 
CNS (Burgos et al., 2002; Thompson & Sawtell, 1997, 2001).  Experimental methods of in vivo 
viral reactivation include heat stress by submerging the animal in a 42°C waterbath (Sawtell & 
Thompson, 1992; Higaki et al., 2009), administering epinephrine (Willey et al., 1984) or sodium 
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butyrate (NaB; Neumann et al., 2007; Neumann et al., 2007), and ultraviolet radiation following 
immunosuppression (Shimeld et al., 1990).  Murine latent HSV-1 infections can also be 
reactivated by excising, sectioning and culturing the trigeminal ganglia or superior cervical 
ganglia (Gussow et al., 2006; Kobayashi et al., 2012).  Removal of the tissue is sufficient to 
consistently produce reactivation of the latent HSV-1 in the excised neurons (Schang et al., 
2002). 
Reactivation can also be induced by exposing explanted latent TGs to heat stress (Halford 
et al., 1996), sodium butyrate (NaB; Danaher et al., 2005), trichostatin A (TSA; Danaher, et al., 
2005), phosphatidylinositol 3-kinase inhibitor (PI3Ki; Camarena et al., 2010; Kobayashi et al., 
2012), or withdrawal of nerve growth factor (NGF) from the cell culture medium (Wilcox & 
Johnson, 1987; Kobayashi, et al., 2012). 
 
Rabbit models 
A key advantage of the rabbit model is the relatively large size of the eye, thus 
facilitating post-infection examination of corneal lesions.  Similar to human infection (Kaufman 
et al., 2005; Kumar et al., 2009; Choudhary et al., 2015), latently infected rabbits shed viral 
particles in their tears (Nesburn et al., 1998; Perng et al., 2015) and saliva (Hill et al., 2012).  
Rabbits provide more cells, tears, saliva, and neuronal tissue than the mouse, but incur more 
costs to house and care and lack the diverse genetic strains that is present in mouse models.  
Additionally, latently infected rabbits experience spontaneous reactivation (Bloom et al., 1994), 
however not all latently infected humans experience reactivation (Al-Dujaili et al., 2011). 
Application of HSV-1 virions to scarified corneas is a common mode of inoculation in 
the rabbit model.  Following infection, surviving animals contain latent HSV-1 in the trigeminal 
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ganglia (Nesburn et al., 1972).  Though spontaneous reactivation occurs in latently infected 
rabbits (Nesburn et al., 1972), experimental methods can also be used to induce reactivation, 
such as administration of epinephrine (Kwon et al., 1981; Hill et al., 1985; Rivera et al., 1988; 
Danaher et al., 2005; Bloom et al., 2010; Creech & Neumann, 2010), sodium butyrate (Neumann 
et al., 2007), nicotine patch (Myles et al., 2004), latanoprost (Gordon et al., 2003), 
cyclophosphamide/ dexamethasone (Gordon et al., 2003; Haruta et al., 1989), or by inducing 
mechanical (Nesburn et al., 1977) or electrical (Green et al., 1981) stimulation.  Similar to the 
murine model of reactivation, latent HSV-1 infections can be reactivated by excising the 
trigeminal ganglia and culturing the cells in vitro (Trousdale et al., 1991). 
Comparisons between the mouse and rabbit models have disclosed key host related 
differences in infection outcomes.  For example, experiments utilizing LAT-deletion viral 
mutants produced opposing effects between the species where the mouse displayed a reduction 
in H3K27me3 on IE viral promoters and robust viral activity (Cliffe et al., 2009), but the rabbit 
model showed decreased lytic gene production and reactivation (Giordani et al., 2008).  Perng 
and colleagues also described variations of viral activity in the mouse and rabbit when studying 
LAT-mutant viruses (Perng et al., 2001). 
 
Non-human primate models 
Modeling HSV-1 infection in non-human primates is less popular, because of the high 
maintenance cost.  Furthermore, primates, such as owl monkeys (Aotus trivirgatus) or marmosets 
(Callithrix jacchus), have a high fatality rate from HSV-1 encephalitis (Deisboeck et al., 2003).  
These models are better suited for Herpes Simian B virus (B virus) infection.  B virus naturally 
infects non-human primates, and it is pathologically and genetically similar to HSV-1 infection 
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in humans.  B virus infection of humans results in severe encephalitis of the central nervous 
system and is frequently fatal, therefore, working with this virus exposes staff to considerable 
risks and require biosafety level 4 facilities.  Because of such protective measures, cases of 
zoonotic transmission to humans are rare (Nsabimana et al., 2008). 
1.5.2 Cellular Models 
In vitro models of HSV-1 infection circumvent the costs and the ethical concerns 
associated with animal models, but, critically, simple in vitro cell models do not account for the 
influence of the immune system.  Productive infection can occur in most cell types, including 
African green monkey kidney epithelial (Vero) cells, murine neuron-like cells (PC-12; Hogk et 
al., 2013), human fibroblasts, human neuron-like cells (SH-SY5Y), human neurons generated 
from aborted fetuses, or derived from human embryonic stem cells (Dukhovny et al., 2012) or 
from human induced pluripotent stem cells (D'Aiuto et al., 2012). 
 
PC-12 cells 
The PC-12 cell line is derived from a pheochromocytoma in the adrenal gland of a male 
Rattus novegicus (Greene & Tischler, 1976).  When cultured in the presence of nerve growth 
factor (NGF), PC-12 cells form neuron-like cells (Greene & Tischler, 1976; Tischler et al., 
1983).  Exposure of HSV-1 infected PC-12 cells to NGF induces a state similar to viral latency 
that is reactivatable once NGF is removed from the cell culture (Block et al., 1994).  NGF is 
critical to block productive viral infection.  After an initial peak in viral activity, HSV-1 
quiescence is established in infected PC-12 cells cultured in the presence of NGF.  A robust 
HSV-1 reactivation is induced following NGF withdrawal (Block, et al., 1994).  The NGF 
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withdrawal model for reactivation was initially described by Wilcox and colleagues who utilized 
primary neuronal cultures (Wilcox & Johnson, 1988).  However, a significant LAT production 
has not been observed in quiescent PC-12 model (Block, et al., 1994).  Another PC-12 model 
utilized acyclovir to induce a quiescent/latent state, followed by the induction of reactivation by 
heat stress (43°C for 3 hours), histone deacetylase inhibitors sodium butyrate or trichostatin A 
(Danaher et al., 2005).  Several investigators have used the PC-12 model of HSV-1 infection to 
study aspects of viral lifecycle (Danaher et al., 2013), 3-dimensional cell culture systems (Hogk 
et al., 2013), and HSV-1 DNA damage repair (Millhouse, et al., 2012). 
 
Non-neuronal human cell systems.   
Non-neuronal cell types used in HSV-1 quiescence models include human fibroblasts and 
erythroblasts.  These quiescence models mimic some, but not all aspects of an in vivo latent 
infection. 
Human fibroblasts repress HSV-1 activity at 42°C when infected with ultra-low 
multiplicities of infection (MOI=0.003).  In these culture conditions, viral reactivation can be 
induced by superinfection with other herpesviruses (Russell & Preston, 1986) or an adenovirus 
vector which supplies ICP0 (a protein which effectively promotes reactivation) at 37°C (Zhu et 
al., 1990).  Alternatively, HSV-1 quiescence can be induced in fibroblasts in the presence of (E)-
5-(2-bromovinyl)-2'-deoxyuridine combined with human interferon alpha (5BVdU+IFNα); 
superinfection with HCMV leads to HSV-1 reactivation (Wigdahl et al., 1982).  This approach 
has also been successfully used in cultured rat fetal neurons (Wigdahl et al., 1984). 
Alternatively, HSV-1 quiescence can be established by infecting fibroblasts that are 
cultured at 41°C with a relatively low concentration of fetal bovine serum (0.2%).  The quiescent 
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infection is maintained at 41°C for six days; after this period of time, reactivation can be induced 
by infection at 37°C with adenovirus vector that supplies ICP0 (McMahon & Walsh, 2008). 
Human erythroblasts enter a quiescent state following an infection with a mutant HSV-1 
virus that does not express immediate early (IE) genes (d109; Samaniego et al., 1998).  The IE 
genes are essential for the downstream production of early and late genes, and as a result, 
infection with a virus deficient for these critical proteins induces a quiescent state characterized 
by heterochromatization of viral DNA (Ferenczy & DeLuca, 2009) and marked reduction in viral 
mRNA production (Harkness et al., 2014). 
 
SH-SY5Y neuroblastoma epithelial cells 
SH-SY5Y is a human cell line is derived from a neuroblastoma.  The cell line contains a 
trisomy of chromosome 1q (Ross et al., 1983).  Following exposure to retinoic acid, these cells 
display some features of human neurons (Biedler et al., 1978), including the dopamine 
transporters, dopamine receptors (Colapinto et al., 2006), and other proteins commonly 
expressed in neurons, like synaptophysin, beta III tubulin, and tyrosine hydroxylase (enzyme 
catalyzing L-tyrosine to L-DOPA, the dopamine precursor; Higashi et al., 2015).  Given their 
origin and ability to produce components of dopamine neurons, SH-SY5Y cells are commonly 
used in neurodegeneration research (Xie et al., 2010).  This cell model has also been sparsely 
used in HSV-1 research to analyze i) aspects of lytic HSV-1 infection in regards to LAT 
expression (Kang et al., 2003); ii) nucleosome deposition on the viral genome (Oh & Fraser, 
2008); and iii) feasibility for the use of HSV-1 vector system to deliver therapeutic genes (Xu et 
al., 2014).  A model of HSV-2 latency was established in SH-SY5Y cells using ACV treatment, 
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which was reported to be sustained for 14 days; viral reactivation was induced by the use of heat 
stress (43°C) for 1.5 hours and forskolin (Sun et al., 2010). 
 
Primary neuronal cultures 
As the most relevant cell type that supports HSV-1 latency, primary human neurons have 
been used, albeit infrequently (Bastian et al., 1972; Baringer & Swoveland, 1973; Wigdahl et al., 
1984; Li et al., 2011).  Post-mortem human brain tissues from the trigeminal ganglia can be 
explanted and infectious virion production occurs within 3 weeks post-autopsy from individuals 
who harbor latent viral genomes (Bastian et al., 1972; Baringer & Swoveland, 1973).  A human 
primary neuron model of HSV-1 latency was initially described by Wigdahl and colleagues 
(Wigdahl et al., 1984).  Human fetal neurons were plated and incubated with mitotic inhibitors to 
eliminate contaminating non-neuronal cell types.  HSV-1 was added to the primary neurons and 
viral replication and cytopathic effect was observed 24 to 48 hours after infection.  To induce a 
quiescent infection in the human primary neurons, cells were pretreated with HSV-1 replication 
inhibitors 5BVdU+IFNα, followed by infection the next day.  The combination of 
5BVdU+IFNα inhibited viral gene expression and established a latent-like state for 7 days.  
After this 7-day period, viral inhibitors were removed, and latency was maintained for a further 
nine days until a fraction of neurons sporadically reactivated (Wigdahl et al., 1984). 
 
Human induced pluripotent stem cell-derived neurons 
Induced pluripotent stem cells (iPSC) are derived from somatic cells, i.e., fibroblast 
(Takahashi & Yamanaka, 2006; Fusaki, et al., 2009), keratinocytes (Aasen et al., 2008; Petit et 
al., 2012), adipose tissue (Sugii et al., 2010) and other cell types.  Originally described in 2006 
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by Takahashi and Yamanaka, mouse fibroblasts are induced into a pluripotent state by the 
expression of four factors, Oct3/4, Sox2, c-Myc, and Klf4 (Takahashi & Yamanaka, 2006).  
These proteins function in the early embryo to maintain a pluripotent state for some cells 
(Nichols et al., 1998; Avilion et al., 2003; Cartwright et al., 2005; Li et al., 2005).  Remarkably, 
iPSCs show similar morphology and protein expression as pluripotent embryonic stem cells 
(ESC; Takahashi & Yamanaka, 2006).  In addition, these cells have the ability to self-renew and 
to further differentiate into the three germ layers of the human body (endoderm, mesoderm, and 
ectoderm; Takahashi & Yamanaka, 2006). 
Differentiating human iPSCs into neurons is based on the pattern of gene expression in 
the developing embryo.  By the 4th week of life, the neural plate has folded over itself and fused, 
creating the neural tube, which will form the central nervous system.  Thus, neurons are derived 
from the ectodermal germ layer.  Multipotent neural stem cells (NSC) develop from the ESCs, 
which are further differentiated into neuronal cells.  By exposing iPSCs to the growth factors N2 
(ThermoFisher, catalog 17502048) and rhFGFβ (R & D Systems, catalog 233-FB-025), NSCs 
can be derived, and then differentiated into neurons over the course of 4-12 weeks (D'Aiuto et 
al., 2014).  In vivo, neurons follow a step-wise path that begins with neural progenitor cells and 
can continue to mature neurons (von Bohlen Und Halbach, 2007).  At each stage of 
neurogenesis, cells produce an array of proteins that wax and wane over time.  By utilizing 
antibodies that recognize these neural antigens, the stages of in vitro neurogenesis can be 
analyzed in the neuronal differentiation of iPSCs.  Human iPSC-derived neurons begin as 
multipotent neural stem cells that express neuroectoderm markers Musashi, Nestin, and Sox1.  
After exposing the NSCs to culture medium supplemented with B27 and BDNF (factors that 
promote neuronal growth) for 4 weeks, the cells display a neuron morphology and express TUJ1 
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(neuron-specific class III beta-tubulin that is expressed in neuronal precursors, early post-mitotic, 
and mature neurons; Yang et al., 2004), MAP2 (microtubule associated protein in dendrites of 
mature neurons; Harada et al., 2002), VGLUT (vesicular glutamate transporter mediates packing 
glutamate into synaptic vesicles; Herman, et al., 2014), and NR1 (a subunit of the NMDA, or 
glutamate, receptor; Furukawa et al., 2005).  In addition, neurons respond to the neurotransmitter 
glutamate and agonists of the NMDA receptor (AMPA and NMDA) in whole-cell patch-clamp 
experiment (D'Aiuto et al., 2014). 
HSV-1 infection models utilize human iPSC-neurons derived from human fibroblasts 
(Lafaille et al., 2012; D'Aiuto et al., 2015; McClain et al., 2015; McNulty et al., 2016).  HSV-1 
quiescence is induced adopting the method described by Wigdahl and colleagues (Wigdahl et al., 
1982).  Briefly, iPSC-neurons are pretreated with antiviral compounds 5BVDU+IFNα for 24 
hours.  The cells are then infected and maintained for 7 days in the presence of 5BVDU+IFNα.  
The virus can be reactivated by histone deacetylase inhibitor sodium butyrate for 5 days 
(D'Aiuto, et al., 2015; McClain, et al., 2015; McNulty, et al., 2016). 
Alternatively, neurons can be directly differentiated from fibroblasts (Vierbuchen et al., 
2010).  This direct conversion bypasses the need for NSC generation.  The “i-N cells” have not 
yet been employed to model HSV-1 infections. 
These models have been of tremendous importance to the understanding of HSV-1 
biology and the development of antiviral drugs.  Despite their undeniable importance in 
developing antiviral therapies, finding novel drugs exhibiting higher efficacy compared to the 
current therapies may be achieved by using disease-relevant human cell types.  The advent of 
iPSC technologies provides for the first time an opportunity to generate human neurons to a scale 
compatible with drug screening platforms. 
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1.6 ANTIHERPETIC DRUGS AND DRUG RESISTANCE 
No effective vaccines for HSV-1 infections are currently available (Kuo et al., 2014), 
therefore we are forced to rely on drugs for treatment.  Acyclovir (ACV) and its derivatives are 
the most effective drugs available for acute infection with HSV-1 and are therefore considered 
the first-line treatment.  ACV is a guanosine analogue lacking a 3’ hydroxyl that is necessary for 
the reaction with the phosphate group during DNA synthesis.  Thus, the absence of the 3’ 
hydroxyl group results in the inability of adjacent nucleosides to bind into the growing DNA 
strands during replication.  ACV is also a potent inhibitor of viral DNA polymerase.  ACV is 
activated to ACV-triphosphate where the first phosphorylation is carried out by the viral kinase, 
thymidine kinase (tk).  This initial reaction ensures that ACV inhibits DNA replication in virally 
infected cells.  Subsequent phosphorylations occur via host kinases.  Once incorporated into the 
growing viral DNA templates, replication stalls and dismantles, ultimately shutting down viral 
production.  ACV is a potent antiviral for acute infections, but cannot eliminate the HSV-1 latent 
reservoir (Field & Thackray, 2000). 
ACV has modest bioavailability when taken orally, estimated at 6% to 10% (Biron, 
2006).  To improve bioavailability, modifications were made to the parent chemical structure, 
leading to the generation of Valacyclovir (VACV, the L-valine ester of ACV), which increased 
oral bioavailability to 55% (Biron, 2006).  Severe HSV-1 infections such as encephalitis require 
high-dose intravenous ACV, but the majority of other infections such as common cold sores 
require oral or topical VACV dosing only.  ACV and VACV are also effective against other 
herpesviruses, but with decreasing efficacy.  In decreasing order of highest therapeutic index, 
they are HSV-1, HSV-2, and VZV.  VACV or ACV are commonly prescribed for infections 
caused by these viruses.  ACV has some antiviral activity for other human herpesviruses, such as 
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EBV, HHV-6, HCMV, or HHV-8, although to a much lesser extent (De Clercq et al., 2001).  
ACV and VACV are well tolerated, though uncommon adverse effects include neurotoxicity 
(Asahi et al., 2009) and nephrotoxicity (Izzedine et al., 2005). 
Viral resistance to ACV is rare, with estimates of less than 1% in immunocompetent 
individuals.  Resistance manifests as sustained viral shedding or progressive disease in the 
presence of the drug.  In the case of immunocompetent individuals with herpes keratitis, the 
prevalence of ACV-resistant virus is higher (~6.4%; Duan et al., 2008).  Drug resistance is more 
common among patients who are immunocompromised (prevalence is 4% to 10%; Piret & 
Boivin, 2014).  DNA sequences of clinical isolates revealed that 95% of resistant cases harbor 
viruses with mutations in the gene encoding viral tk (van Velzen et al., 2012), resulting in 
infections displaying a reduced pathogenicity, a reduced establishment of latency, and an 
impaired potential to reactivate lytic infection (Coen, 1994; Besecker et al., 2007).  Alternative 
first-line drugs are the guanosine analog, Penciclovir (PCV) and its prodrug, Famciclovir (FCV).  
PCV has a mechanism of action similar to ACV, as well as the likelihood of PCV-resistant 
viruses through selection of tk mutants. 
Other second-line drugs have been developed to inhibit the infection of ACV-resistant 
viral strains, e.g., Foscarnet and Cidofovir, but they cause varying degrees of host toxicity.  
Foscarnet (FOS) reversibly inhibits viral DNA polymerase of several herpesviruses.  FOS 
interferes with pyrophosphate cleavage from the incoming nucleosides, which are blocked from 
binding to the growing DNA strand.  Because DNA replication requires pyrophosphate cleavage 
to proceed, viral replication is inhibited.  FOS does not require viral tk phosphorylation and is 
useful for tk-mutant viruses that are resistant to first-line antivirals; however, mutations in viral 
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DNA polymerase at pyrophosphate binding sites may confer resistance.  FOS is administered 
intravenously and side effects may occur in the kidney and CNS. 
Cidofovir (CDV) is an antiviral that is active against several DNA viruses.  CDV is an 
acyclic nucleoside phosphonate and does not require involvement by viral tk.  Host kinases 
complete the phosphorylations and then CDV can be incorporated into the growing viral DNA 
strand with a consequent block of DNA replication.  CDV has a very low bioavailability (5%; 
Cundy et al., 1996) and must be administered intravenously.  However, nephrotoxicity (Safrin et 
al., 1997), neutropenia, and hypospermia have been associated with CDV treatment.  It is also 
considered a carcinogen and teratogen. 
Brincidofovir is a prodrug of CDV, in which a lipid side-chain is conjugated to the parent 
CDV molecule, improving cellular uptake and bioavailability (Painter et al., 2012).  
Brincidofovir is less toxic than CDV, and side effects are mostly limited to gastrointestinal-
related symptoms.  It also has broader spectrum of antiviral effects, against HSV, VZV, HCMV, 
and other DNA viruses.  It is presently being investigated in clinical trials.  Considering that FOS 
and CDV do not require activation by phosphorylation of a viral tk, they may also incorporate 
into the growing host DNA strands during replication, leading to cellular toxicity and the 
aforementioned system-wide toxic profiles.  
Ganciclovir (GCV, a guanosine analog) and its prodrug valganciclovir (VGCV) represent 
the current standard therapy for HCMV and has comparable efficacy against HSV-1 as ACV 
(Frank et al., 1984).  Due to poor oral bioavailability of GCV (5%), VGCV was developed to 
increase drug oral bioavailability (60%; Pescovitz et al., 2000).  Their mechanism of action is 
similar to ACV, and can also inhibit cellular DNA polymerases (Kimberlin & Whitley, 2007).  
Due to this, GCV and VGCV are associated with considerable adverse reactions on many organ 
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systems including kidney, bone marrow, gastrointestinal tract, CNS, and other side effects; GCV 
is also considered a potential human carcinogen (Laboratories, 2016).  Second-line drugs, such 
as FOS and CDV, are available to treat resistant strains and HCMV-retinitis.  HCMV resistance 
is estimated in the immunocompromised population at 13% to >25% (Jabs et al., 1998; Limaye, 
2002). 
In addition, other nucleoside analogs show promise against HSV-1 and other 
herpesviruses.  Valomaciclovir, a guanine nucleoside analog confers antiviral effects against 
HSV-1, HSV-2, EBV, and VZV, with the latter two viruses showing the greatest sensitivity 
(Lowe et al., 1995).  N-methanocarbathymidine (N-MCT), a thymidine analog has encouraging 
effects in HSV, EBV, and KSHV infections (De Clercq, 2013).  Valomaciclovir and N-MCT 
have a mechanism of action similar to ACV in requiring viral tk phosphorylation, and therefore 
run the risk of viral resistance via tk mutations. 
New antiviral compounds against HSV-1 and HSV-2 in clinical trials target the viral 
helicase/primase complex.  They include Pritelivir or Amenamevir.  The HSV helicase/primase 
complex is a heterotrimer that includes viral products UL5, UL52, and UL8.  This complex 
functions during DNA replication to create a replication fork and to prime the leading and 
lagging strands for polymerization (Chattopadhyay et al., 2006).  Hence, helicase/primase 
inhibitors (HPI) interfere with the complex to bind to the DNA, reducing DNA unwinding, 
priming, and ultimately viral DNA replication.  These new compounds produce a potent anti-
HSV-1 or HSV-2 response.  HPIs operate in a tk-independent manner and can serve as 
alternatives to ACV-resistant viruses (Field et al., 2013).  However, DNA mutations in any of the 
proteins in the viral helicase/primase complex derived from selection pressure can confer HPI-
resistance (Biswas et al., 2007). 
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Other new drugs in development for HCMV are Maribavir, an inhibitor of viral protein 
kinase and Letermovir, a terminase inhibitor that have both shown effective antiviral results.  
Maribavir exerts antiviral effects by inhibiting DNA packaging and nuclear egress of 
encapsidated HCMV DNA (Biron et al., 2002).  Maribavir has also been used to treat GCV-
resistant HCMV infection (Biron et al., 2002) and also inhibits EBV infection in vitro (Williams 
et al., 2003).  Clinical trials revealed neurological adverse reactions in healthy individuals, where 
taste disturbances (80%) was the most common and appears to be dose-dependent (Lalezari et 
al., 2002).  Letermovir is a potent inhibitor of viral HCMV terminase (a viral protein complex 
that cleaves single genomes from post-replicated viral DNA and facilitates genome packaging 
into the viral capsid prior to egress; Bogner, 1998, 2002).  Letermovir is specific to HCMV-
infected cells and remains active against GCV-resistant viral strains (Marschall et al., 2012).  
Unlike GCV, toxicity studies of recipients of solid organ transplants or hematopoietic stem cell 
transplants were generally well tolerated and reduced HCMV infection (Chemaly et al., 2014; 
Stoelben et al., 2014). 
In summary, antiviral compounds have greatly reduced the morbidity and mortality 
associated with HSV-1 disease, including keratitis and encephalitis and improved the quality of 
life for infected individuals.  Additionally, antivirals like ACV or VACV are safe and efficacious 
for the majority of the population.  However, antivirals like GCV or CDV have serious side 
effects with limited antiviral effectiveness, and no drug exists to eliminate the latent virus.  
Modifications to parent molecules may decrease toxicity and increase efficacy, but viral 
resistance will remain or increase, especially among immunocompromised individuals.  A new 
generation of chemotherapeutics is needed that has different mechanisms of action, with high 
potency, low toxicity, and high oral bioavailability. 
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2.0  AIMS & RATIONALE 
Aim 1.  Characterize and evaluate a quiescent HSV-1 infection model in human iPSC-
derived neurons.  Most of our knowledge of HSV-1 biology comes from animal or cellular 
models.  Yet, HSV-1 causes human specific infections and humans are the only natural reservoir 
for HSV-1 latency.  Hence, a human neuronal cell model of HSV-1 infections could usefully 
complement currently available animal and cell models.  Since it is difficult to obtain living 
human neurons that harbor latent viral genomes for scientific research, an alternate route to 
generate relevant models was investigated.  Here, we have generated and optimized a human 
cellular model of HSV-1 infection using human induced pluripotent stem cell-derived neurons 
(iPSC-neurons).  The model was used to investigate aspects of lytic infection, quiescent 
infection, chromatin accessibility of selected viral genes, and patterns of host gene expression.  
Future applications of modeling HSV-1 infections in human iPSC-neurons include testing 
compounds for novel antiviral effects.  This section will also cover the general method sections 
and two peer-reviewed manuscripts that detail i) a method to generate neural stem cells and their 
differentiation into iPSC-neurons, and ii) evaluating lytic and latent HSV-1 models in human 
iPSC-neurons. 
 
Aim 1a.  Characterize a human iPSC-based cellular model of HSV-1 lytic and latent 
infections.  We acutely infected iPSC-neurons for a 24-hour time period.  To induce a 
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quiescent infection in iPSC-neurons, an antiviral cocktail of (E)-5-(2-Bromovinyl)-2′-
deoxyuridine along with human interferon alpha was applied to infected cells for a period 
of 7 days.  The level of viral repression was gauged by withdrawal of the antiviral 
compounds.  We used a histone deacetylase (HDAC) inhibitor to reactivate quiescent 
infections.  Viral copy number, viral gene expression, and the production of infectious 
virions were quantified.  Patterns of viral genome occupation in the host nuclei were 
evaluated.  Additionally, neuronal gene expression changes were assessed in the 
aforementioned models of HSV-1 infection.  
 
Aim 1b.  Evaluate the chromatin accessibility state of selected viral gene promoters 
in HSV-1 acutely and quiescently infected iPSC-neurons.  To further evaluate models 
of lytic and latent HSV-1 infections, we used acutely and quiescently infected iPSC-
neurons to assess whether certain viral loci are competent for transcription.  We have 
used quantitative PCR to amplify viral gene promoters after exposing viral DNA to 
micrococcal nuclease (MCN).  In addition, we also investigated the co-localization of 
proteins that are associated with transcriptional repression and with viral DNA by 
combining immunocytochemistry (using an anti-heterochromatin protein-1 mouse 
monoclonal antibody) with fluorescent in situ hybridization (FISH, using a probe that is 
complementary to viral genomes). 
 




Aim 2. Antiviral screening and groundwork for high-content drug screening.  Viral 
resistance to current antivirals occurs more frequently in immunosuppressed individuals.  
Moreover, the use of antiviral acyclovir may harmful to renal failure patients.  Therefore, 
obtaining novel antivirals with different mechanisms of action are warranted.  To enable 
moderate throughput screening for antiviral compounds to treat HSV-1 infections, a robust and 
cost-effective cellular platform was evaluated.  Initial cell-based drug screening platforms 
require: (i) generation of large numbers of neurons in a multi-well culture systems and (ii) 
meaningful readouts to assess drug efficacy. This section will also cover two peer-reviewed 
manuscripts that detail our initial efforts to screen small compound libraries in HSV-1 infected 
human iPSC-neurons for antiviral effects i) using molecules that were previously reported to 
have lysosomotropic activities and ii) using novel, naturally occurring alkaloids derived from the 
Amaryllidaceae plant family.  Following these studies, we sought to optimize methods to allow 
for future moderate throughput agnostic compound antiviral screening campaign. 
 
Aim 2a.  Generation of culture plates containing human iPSC-neurons distributed 
in monolayer fashion.  We evaluated seeding densities of human iPSC-neurons on 96- 
or 384-well culture plates conducive to acutely and quiescently infected HSV-1 cultures. 
 
Aim 2b.  Automated analysis of the viral state in infected cells.  High content 
microscopy analysis methods were used to compare the feasibility of using an HSV-1 
viral construct that expresses fluorescent reporter genes during lytic infections or using 




HYPOTHESIS:  Human iPSC-neuronal cultures and HSV-1 infection conditions can be adapted 
to high-content screening in 384-well plates. 
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3.0  AIM 1. CHARACTERIZE AND EVALUATE A QUIESCENT HSV-1 INFECTION 
MODEL IN HUMAN IPSC-DERIVED NEURONS 
Aim 1.  Characterize and evaluate a quiescent HSV-1 infection model in human iPSC-derived 
neurons.  Most of our knowledge of HSV-1 biology comes from animal or cellular models.  Yet, 
HSV-1 causes human specific infections and humans are the only natural reservoir for HSV-1 
latency.  Hence, a human neuronal cell model of HSV-1 infections could usefully complement 
currently available animal and cell models.  Since it is not feasible to obtain living human 
neurons that harbor latent viral genomes for scientific research, an alternate route to generate 
relevant models were investigated that were based on human fetal neuron models (Wigdahl, 
1984).  Here, we generated and optimized a human cellular model of HSV-1 infection using 
human induced pluripotent stem cell-derived neurons (iPSC-neurons).  The model was used to 
investigate aspects of lytic infection, quiescent infection, chromatin accessibility of selected viral 
genes, and patterns of host gene expression.  Future applications of modeling HSV-1 infections 
in human iPSC-neurons include testing compounds for novel antiviral effects.   
 
This section will also cover the general method sections and two peer-reviewed manuscripts that 
detail i) a method to generate neural stem cells and their differentiation into iPSC-neurons, and 
ii) evaluating lytic and latent HSV-1 models in human iPSC-neurons. 
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Aim 1a.  Characterize human iPSC-based cellular model of HSV-1 lytic and latent 
infections. 
 
Aim 1b. Evaluate the chromatin accessibility state of viral gene promoters in HSV-1 
acutely and quiescently infected iPSC-neurons. 
3.1 GENERAL METHODS SECTION 
The following section will describe the general methods, as well as the methods utilized 
to investigate Aim 1. 
3.1.1   Cell Propagation 
African green monkey kidney fibroblast cells (Vero) were grown in “Vero medium” 
(Eagle’s Minimum Essential Medium (EMEM; Lonza, catalog 12611F), supplemented with 10% 
fetal bovine serum (FBS; HyClone, GE Healthcare Life Sciences, catalog SH3054103), and 5% 
antibiotic/antimycotic (HyClone, GE Healthcare Life Sciences, catalog SV3007901).  Cells were 
grown in an incubator under standard conditions (5% CO2, 37°C, and 100% humidity) and the 
cell culture medium was changed every 2-3 days. 
CV-28 cells are Vero cells that have been transformed to express the wild-type viral gene 
UL28.  These cells were used to propagate Dr. Homa’s HSV-1 virus that contains a 1,881 bp 
deletion in viral gene UL28, an essential gene for viral assembly (Tengelsen et al., 1993). 
 39 
3.1.2 Viral Propagation 
Human herpesvirus type 1 is considered a Biosafety Level 2 (BSL-2) pathogen.  The 
virus was handled in accordance to standard and special practices, safety equipment, and 
facilities for BSL-2 pathogens. 
Infection.  Vero cells (80% confluent) were infected at an MOI of 3 in a T-75 flask.  The 
quantity of virus for cell infection was calculated utilizing the following formula (Blaho et al., 
2005): 
 
(MOI= 3) x (cell count) x (1/HSV-1 titer in pfu/μl) = amount of HSV-1 stock to add (μl) 
 
The virus was adsorbed on the Vero cells for 2 hours at 37°C.  Following the infection, 
the inoculum was removed and cells were washed with phosphate buffered saline (PBS).  Fresh 
Vero medium was added to the flask (13 ml) and cells were incubated for 2-3 days, until the 
appearance of cytopathic effect (CPE).  The cells and supernatant were transferred into 15 ml 
conical tubes following detachment with a cell scraper.  Cells were centrifuged at 1000 rpm for 5 
minutes.  The supernatant medium was removed, leaving behind 1.5 ml and the cell pellet was 
resuspended using a vortex for 1-2 min.   The tube was then placed into liquid nitrogen bath to 
freeze.  The tube was then transferred into a 37°C water bath to thaw the cell lysates.  The 
freezing/thawing method was repeated for a total of 3 times.  During the freezing/thawing cycles, 
the cells were lysed to release intracellular virus into the supernatant.  After the last thaw, the 
tube was centrifuged at 3000 rpm for 5 minutes and the top medium containing cell-free viral 
particles was transferred into sterile 1.5 Eppendorf tubes.  The viral titer was determined by 
plaque assay on Vero cells as follows. 
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3.1.3 HSV-1 Quantitative Titrations 
 Three 6-well plates with 2.5 x 105 Vero cells per well were prepared the day before the 
titration procedure.  Ten microliters of freshly prepared viral stock supernatant was added to 10 
ml of Vero medium (dilution = 10-3).  The viral suspension was mixed by gentle inversion (Tube 
1).  One hundred microliters of viral suspension from Tube 1 was transferred in another tube 
containing 10 ml of Vero medium (Tube 2; dilution = 10-5).  Viral suspension was further diluted 
to 10-6, 10-7, 10-8.  One milliliter of each dilution was used to infect the aforementioned Vero 
cells.  Infections were performed in triplicate.  The virus was adsorbed on the cells for 2 hours at 
room temperature on a Belly Dancer shaker.  After the infection, medium was removed and 
overlaid with 3 ml of Vero medium containing 1% carboxymethyl cellulose (CMC; Fisher, 
catalog 150560).  The cells were cultured in standard culture conditions until viral plaques 
appeared (36-48 hours after infection).  When infecting with the viral construct carrying EGFP 
and RFP reporter genes, plaques are counted under the fluorescent microscope.  For HSV-1 KOS 
strain that does not contain fluorescent reporter genes, the cells were cultured until viral plaques 
appeared (3-5 days after infection).  The CMC medium was removed and wells were gently 
washed with PBS.  Crystal violet was added to each well to quantify plaques.  The wells with the 
dilution that contained between 30 and 300 plaques were counted and utilized as viral titer using 
the following formula: 
 
(number of plaques) x (dilution) = PFU/ml 
 
NOTE 1: Preparation of 3% CMC.  In a clean glass bottle, 3 grams of CMC was added to 
100 ml PBS.  The mixture was placed on a heated (40°C) stirplate (Sybron Barnstead 
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Thermolyne Nuova II Stirrer, catalog SP18425) and stirred for 2-3 h or until dissolved.  The 3% 
CMC solution was autoclaved and diluted with Vero medium to 1% prior to use on cell cultures. 
NOTE 2:  Preparation of crystal violet.  Five milliliters of formaldehyde (37% stock 
solution) was mixed with 0.5 g Gentian Violet, 0.9 g NaCl, 52.6 ml 95% ethanol, and 42.4 ml 
distilled water.  The preparation was stirred overnight with a stir bar on a Nuova II stir plate. 
3.1.4  HSV-1 Infections 
HSV-1 infections proceeded similarly, unless otherwise stated.   
1. The viral construct used in the majority of the experiments in this work was based on 
an HSV-1 construct that incorporated green and red fluorescent reporter genes under 
the control of the promoters for ICP0 and glycoprotein C, respectively (FIGURE 3; 
courtesy of Dr. Paul Kinchington, Ph.D., University of Pittsburgh; Ramachandran et 
al., 2008).  The EGFP expression designates the virus has entered a lytic infection as 
it is driven by a viral immediate early gene promoter.  The RFP is driven by a viral 
late gene promoter, signifying the virus is committed to viral replication.  During a 
lytic infection on either Vero (MOI=1) or iPSC-neurons (MOI=0.3), EGFP can first 
be observed after 24 hours after infection, while RFP expression can be observed 
after 48 hours after infection (FIGURE 4). 
 
 




2. A viral construct with a 1,881 bp deletion in the UL28 gene and a GFP reporter gene 
tagged to VP26 was used for viral infections on Vero and iPSC-neurons (Tengelsen, 
et al., 1993; courtesy of Dr. Fred Homa, Ph.D., University of Pittsburgh).  UL28 is a 
viral protein that plays an essential role in cleaving and packaging viral DNA.  Thus, 
the deletion in this viral construct results in progeny virions that lack the viral genome 
and the construct is replication defective (Tengelsen, 1993; Yu & Weller, 1998).  The 
resulting progeny virions are unable to produce secondary infections (Tengelsen, 
1993).  During a lytic infection on Vero cells (MOI=1), EGFP was detected after 24 
hours (FIGURE 5). 
 
3. KOS is a wild-type HSV-1 strain that was obtained from a lesion on a human oral 
mucosa (ATCC VR-1493).  This virus does not contain fluorescent reporter genes. 
 
Lytic Infection.  Acute infections in Vero cells and iPSC-neurons were performed at 
MOI=1 and 0.3, respectively.  A lower MOI was chosen for the iPSC-neurons due to increasing 
cytotoxicity at higher MOIs (data not shown).  The virus adsorbed on the cells for 2 hours at 
37°C with gentle swirling every 30 minutes.  Following the infection, the inocula were removed, 
cells were washed with PBS, and then cultured with the corresponding culture medium.   The 









Figure 5.  EGFP expression in acutely infected Vero cells.   
 
Quiescent infections.  Unless otherwise stated, quiescent infection proceeded as follows:  
Human iPSC-neurons were pretreated with (E)-5-(2-Bromovinyl)-2′-deoxyuridine along with 
human interferon alpha (5BVdU+IFNα, 30 µM and 125 u/ml, respectively) for 24 hours and 
then infected with HSV-1 (virus containing reporter genes for EGFP and RFP, and HSV-1 strain 
KOS) at indicated MOIs for 2 hours in medium containing 5BVdU+IFNα.  The inocula were 
The virus expressed EGFP and RFP under the control of viral promoters ICP0 and glycoprotein C, respectively 
(48 hours post infection; MOI=0.3; Courtesy of Dr. Paul Kinchington, Ph.D., University of Pittsburgh).  Scale 
bar is 50 µM. 
The viral construct was based on a replication defective HSV-1 that incorporated a green fluorescent reporter 
gene tagged to VP26, a capsid protein (24 hours post infection; MOI=1; Courtesy of Dr. Fred Homa, Ph.D., 
University of Pittsburgh).  Scale bar is 50 µM. 
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removed, cells were washed in PBS, culture medium containing 5BVdU+IFNα was added, and 
cells were cultured for 7 days.  Half volume of culture medium was replaced with fresh medium 
every other day.  After this period of time, the cell culture medium was removed and cells were 
washed with PBS.  Next, viral reactivation was induced by culturing cells with culture medium 
containing sodium butyrate (NaB; 5 mM; a histone deacetylase inhibitor) for 5 days (FIGURE 
16).  The number of fluorescent cells was analyzed by flow cytometry.  Note: The replication 
defective virus was not able to sustain a quiescent infection; the neurons displayed significant 
cytopathic effect the day after the infection (data not shown).  Thus, this virus was not used to 
model quiescent HSV-1 infections further. 
3.1.5  Cell Preparation for Flow Cytometry  
Cell supernatants were collected into sterile 1.5 Eppendorf conical tubes and kept at         
-70°C until required for plaque reduction assay.  To create a single-cell suspension, cells were 
dissociated by treatment with accutase for 2 minutes (for iPSC-neurons) or 10 minutes (for Vero 
cells) at 37°C.  Proteolytic enzymes were diluted by adding Dulbecco’s Modified Eagle 
Medium:F12, 1:1 mixture (DMEM/F12; Lonza, catalog 12-719F).  Cells were collected and 
centrifuged at 1,200 rpm for 5 minutes.  Cells from each sample were resuspended in PBS and 
transferred into a 96-well V-bottom plate (Corning™ Costar™, catalog 3894).  Cells were 
pelleted by centrifugation at 2,500 rpm for 5 minutes.  Supernatant was removed and cells were 
incubated with PBS containing LIVE/DEAD® Fixable Viability Aqua dye (ThermoFisher 
Scientific, catalog L34957) for 20 minutes per the manufacturer’s instructions to measure cell 
viability.  The cell suspension was diluted 3-fold with PBS and then centrifuged at 2,500 rpm for 
5 minutes.  Following centrifugation, the supernatant was discarded and the cells were 
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resuspended in 240 µl of fixative solution (3:1 PBS:10% Formalin).  Cells were centrifuged as 
described above and kept in the dark by wrapping with aluminum foil to avoid fluorescence 
quenching. 
3.1.6 Immunocytochemistry (ICC)  
DAY 1.  Cells were fixed in 4% paraformaldehyde (PFA) at room temperature for 20 
minutes.  Three washes of PBS were performed for 5 minutes each.  Cells were incubated for 
one hour in 10% goat serum containing 0.02% Triton X-100 to permeabilize cell membranes.  
Cells were washed three times for 5 minutes in PBS.  The primary antibody diluted in goat serum 
(per manufacturer’s recommendation) was added to each well and incubated overnight at 4°C. 
DAY 2.  The primary antibodies were removed and three washes of PBS were performed 
for 5 minutes each.  Fluorescent secondary antibodies were diluted in goat serum at indicated 
dilutions (Table 1) and added to cells for one hour at room temperature in the dark.  Three 
washes of PBS were performed for 5 minutes each.  Hoechst 33342 (ThermoFisher Scientific, 
catalog H3570; 1 to 1,000 dilution) was added for 2 minutes to counterstain the nuclei.  Cells 
were washed two times with PBS to remove residual Hoechst solution, mounted with 
VECTASHIELD mounting medium (Vector Laboratories, catalog H1200), and sealed with clear 
nail polish. 
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Table 1.  Primary antibodies. 
 
 
3.1.7 Viral Copy Number Measurement by Quantitative PCR (qPCR). 
Cells were harvested into 1.5 ml Eppendorf tubes and DNA was extracted using DNeasy 
Blood & Tissue Kit (Qiagen, catalog 69504) following manufacturer’s instruction.  The DNA 
was quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher, catalog 
P11496) and qPCR reactions were carried out by using 5 ng/reaction.  The EGFP locus within 
the HSV-1 viral construct genome was amplified in the qPCR reaction using custom-designed 
oligonucleotide primers. 
qPCR conditions.  In each assay for the standard curve and the unknown samples, the 
following reagents were added for the qPCR master mix in a 384-well plate (MicroAmp® 
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Optical 384-Well Reaction Plate with Barcode, ThermoFisher Scientific, catalog 4309849):  2X 
TaqMan® master mix (ThermoFisher Scientific, catalog 4370048), 1X probe master mix 
(Pereira et al, 2013), and 5 ng of DNA in a total reaction volume of 10 µl.  The probe master mix 
includes a final concentration of 18 µM EGFP forward primer (5’-
ccacatgaagcagcacgactt-3’), 18 µM EGFP reverse primer (5’-ggtgcgctcctggacgta-
3’), and 5 µM probe (5’-6FAM- ttcaagtccgccatgcccgaa-TAMRA-3’).  Samples were 
loaded on AB Prism 7900HT for the following conditions: 95°C for 3 min followed by 45 cycles 
of 95°C for 15 sec and 55°C for 30 sec, and finished with 72°C for 30 sec. 
Standard Curve.  pEGFP-N1 plasmid (Clontech) DNA was quantified by Quant-iT™ 
PicoGreen® dsDNA Assay Kit (ThermoFisher, catalog P11496) per manufacturer’s instruction 
and the resulting concentration was entered into the University of Rhode Island Genomics and 
Sequencing Center calculator to estimate copy number (http://cels.uri.edu/gsc/cndna.html).  The 
quantity of DNA (in nanograms) and the length of the plasmid (4,733 base pairs) is entered and 
approximate copy number is calculated.  Copy number of the diluted plasmid DNA samples 
ranged from 298 billion to 29.8 copies.  The resulting CT values for each condition were plotted 
in a scatterplot graph and the regression line was fitted to the data.  The standard curve was used 




Figure 6.  Standard curve generated using pEGFP-N1 plasmid. 
 
Test Samples.  Cells were mechanically harvested, and total DNA was extracted using 
DNeasy Blood & Tissue Kit following manufacturer’s instruction.  The DNA was quantified by 
Quant-iT™ PicoGreen® dsDNA Assay Kit per manufacturer’s instruction.  The final amount of 
DNA added to the qPCR reaction was approximately 5 nanograms.  In the qPCR reaction, 
technical triplicates were measured for each biological triplicate.  The viral copy number of each 
test condition was calculated using the standard curve. 
3.1.8 Fluorescent in situ Hybridization 
3.1.8.1 HSV-1 Probe Generation 
HSV-1 genomic DNA (10-20 ng) was amplified using GenomiPhi (GE Healthcare, 
catalog 25-6600-30) according to manufacturer’s instruction.  The resulting product was checked 
on a 1% agarose gel for the presence of high molecular weight DNA product.  One microgram of 
the GenomiPhi-amplified DNA was labeled with fluorescent dUTP via nick translation kit 
(Abbott Molecular, catalog 07J00-001) following manufacturer’s instruction and placed in a 
thermal cycler at 15°C for 12 hours, and then 65°C for 10 minutes.  The nick-translated product 
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was ethanol-precipitated along with 10 µg Cot-1 DNA® (ThermoFisher, catalog 15279011) and 
40 µg sheared salmon sperm DNA.  The supernatant was removed, the pellet washed with 200 µl 
of 70% ethanol, and air-dried in a dark environment at room temperature. 
DNA was dissolved in 3 µl of sterile water. The probe was then mixed with 9 µl of Vysis 
LSI/WCP hybridization buffer and stored at -20°C in the dark until ready for use (up to 1 year). 
3.1.8.2 Two-Dimensional (2D) Fluorescent in situ Hybridization (FISH) 
Cell Fixation.  Cells infected on matrigel-coated microscope slides or chamber slides 
(Nunc™ Lab-Tek™ Chambered Coverglass, Thermo Scientific™, catalog 155380) were washed 
three times with PBS and fixed in 4% paraformaldehyde (Fisher Scientific, catalog 15710-S) for 
10 minutes.  Slides were washed three times for 3 minutes each with 0.01% Triton™ X-100 
(Sigma Aldrich, catalog X100-5ML) and then washed in 0.5% Triton X-100 for 10 minutes.  
Slides were washed three times for 10 minutes each in PBS.  Slides were incubated in 50% 
formamide/2X SSC solution for at least one hour, preferably overnight.  Slides could be kept in 
this solution at 4°C for long-term storage up to 3-4 months. 
Probe Denaturation and Hybridization.  Slides were removed from the 50% 
formamide/2X SSC solution and drained on a paper towel to remove excess fluid.  The probe 
(250 ng) was pipetted onto the target area of the slide in a drop-wise fashion.  This area was 
covered with a coverslip.  Slides were protected from light during this and all subsequent steps.  
Bubbles were removed by guiding them to the edge of the coverslip by pressing a clean p1000 
pipette tip along the top coverslip.  Excess fluid was removed from the edge of the coverslip with 
a Kimwipe and the coverslip was completely sealed around its perimeter using Elmer’s rubber 
cement.  The slides were placed on a Vysis Hybrite at 75°C for 2 minutes to denature cellular 
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and probe DNA and then left overnight at 37°C for hybridization.  To prevent slides from drying 
out, paper towels soaked in water lined the Vysis Hybrite internal compartments. 
Slide Washing and Detection.  All steps were performed under light protection.  
Following hybridization, the rubber cement on the coverslips was carefully peeled away and the 
coverslip was slowly guided to the edge of the slide and removed.  The slides were placed in a 
Coplin jar filled with 2X SSC.  To remove cross-hybridization signals, the slides were washed in 
SSC three times for 5 minutes each in 2X SSC at 37°C, followed by three washes, 5 minutes 
each, in 0.1X SSC at 60°C.  Nuclei were counterstained with Hoechst 33342 (1 to 1,000 dilution) 
for 2 minutes, and mounted on microscope slides in VectaShield mounting medium (Vector 
Laboratories, catalog H-1000) and sealed with clear nail polish.  Slides were analyzed with a 
fluorescent microscopy and stored at 4° C in a covered slide box. 
3.1.9  Three-Dimensional (3D) FISH  
Cell Fixation.  Procedure was conducted at room temperature unless otherwise specified.  
Cells were fixed in 4% paraformaldehyde for 10 minutes and then washed three times with 0.5% 
Triton X-100 for 3 minutes each to increase cell membrane permeability.  Three rounds of PBS 
washing were performed for 30 seconds each.  Glycerol (20%) was added to the cells for 60 
minutes.  Cells were snap-frozen by dipping the slides into liquid nitrogen for 30 seconds and 
then thawed to room temperature on a clean paper towel.  The cells were frozen/thawed for a 
total of 5 times and then cells were washed in PBS for three rounds for 10 minutes each.  Cells 
were incubated twice in 2X SSC for 3 minutes each and then incubated in 50% formamide/2X 
SSC for one hour. 
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Probe Penetration Treatment with Pepsin Solution.  Slides were incubated in 2X SSC for 
2 minutes and then PBS for 3 minutes.  A pepsin solution (0.005% pepsin in 0.01 N HCl) was 
applied to the cells for 6 minutes at 37°C to aid in probe penetration via controlled protein 
degradation.  Cells were rinsed twice in PBS/50mM MgCl2 for 5 minutes each to inactivate the 
pepsin solution.  Cells were post-fixed in 1% paraformaldehyde for 10 minutes and then washed 
in PBS once for 5 minutes.  Slides were incubated twice in 2X SSC for 5 minutes each and then 
exposed for at least 1 hour in 50% formamide/2X SSC.   
Probe Denaturation and Hybridization and Slide Washing and Detection were performed 
identical to the master FISH protocol. 
3.1.10 FISH in Suspension 
The procedure of FISH on cells in suspension was identical to the 2D FISH protocol.  
The only difference was that between all washing steps, cells were pelleted in a microcentrifuge 
at 1,000 rpm for 2 minutes.  This speed reduced damage to the structures of the cells and 
significantly reduced sample loss.  After centrifuging, top medium was carefully removed with a 
p1000 pipette and cell pellet was gently resuspended by flicking the tube.  To perform the probe 
hybridization, cells were placed into a 0.2 µl PCR tube with 10 µl probe and a thermal cycler 
was used in place of the Vysis Hybrite under identical temperature and time conditions.  All 
subsequent steps were performed under light protection.  After the final washing step, cells were 
exposed to Hoechst 33342 (1 to 1,000 dilution) for 2 minutes and then two rounds of PBS 
washes to remove residual Hoechst solution.  After the final PBS addition, cells were centrifuged 
and the PBS removed.  The cell pellet was resuspended in one drop of VectaShield mounting 
medium, and transferred onto a Superfrost™ microscope slide (Fisher Scientific, catalog 12-550-
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123).  Cells were covered with a coverslip and sealed with clear nail polish.  Alternatively, cells 
were prepared for flow cytometry as previously described for quantification (see methods section 
3.1.5). 
3.1.11 Co-ICC/FISH 
The 2D FISH protocol was completed on cells affixed to microscope slides.  However, 
Hoechst staining and the subsequent two PBS washings were omitted.  Following the final 
washing step of 0.1 X SSC at 60°C, cells were exposed to 0.02% Triton X-100 in goat serum for 
one hour to permeabilize cell membranes and block non-specific antibody binding.  Slides were 
washed once in PBS for 5 minutes.  Primary antibody diluted in 10% goat serum (per the 
manufacturer’s recommendation) was added to each well and incubated overnight at 4°C in a 
dark environment.  The “Day 2” procedure outlined in ICC protocol is followed identically under 
light protection (see methods section 3.1.6). 
3.1.12 Reverse Transcriptase Quantitative Polymerase Chain Reaction 
The alterations of viral gene expression at the RNA level were analyzed by reverse 
transcriptase quantitative polymerase chain reaction (RT-qPCR).  Decreased transcription of 
viral genes were indicative of viral inhibition, or viral life cycle gene class inhibition.  As 
reported (McNulty et. al., 2016), cells were collected into a 1.5 ml Eppendorf tube and RNA was 
extracted using Qiagen RNeasy Mini kit (Qiagen, catalog 74104) following the manufacturer’s 
protocol.  RNA quality was checked by loading 1 µl on a 1% agarose gel.  A high quality RNA 
sample showed two sharp bands corresponding to the 28S and 18S rRNAs.  Any bands located 
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above the 28S rRNA band indicated genomic DNA contamination and smeared product at or 
below the 18S rRNA indicated degraded RNA.  Total RNA was converted to cDNA using 
random hexamer primers provided by the Qiagen RT kit (Qiagen, catalog 205311) following 
manufacturer’s protocol.  The resulting product was diluted to 0.5X with 20 µl PCR-grade water.  
The following reagents were mixed in a 384-well plate (MicroAmp® Optical 384-Well Reaction 
Plate with Barcode, ThermoFisher Scientific, catalog 4309849):  2X Taqman master mix, 20X 
probe mix, and 1 µl of the diluted cDNA for a total reaction volume of 10 µl.  Forward, reverse, 
and internal probe oligos specific to viral genes were custom designed.  The probe mix contained 
a final concentration of 18 µM forward, 18 µM reverse primer, and 5 µM internal probe.  Probe 
sequences are as follows: 
 
ICP4_Forward:  5’–CGA CAC GGA TCC ACG ACC C–3’ 
ICP4_Reverse:  5’–GAT CCC CCT CCC GCG CTT CGT CCG–3’ 
ICP4_probe:  5’–VIC–ACC GCC AGA GAC AGA CCG TCA GA–MGB-NFQ–3’ 
 
HSV DNA Pol_ Forward:  5’–AGA GGG ACA TCC AGG ACT TTG T–3’ 
HSV DNA Pol_ Reverse:  5’–CAG GCG CTT GTT GGT GTA C–3’ 
HSV DNA Pol_probe:  5’–6FAM–ACC GCC GAA CTG AGC A–MGB-NFQ–3’ 
 
LAT_Forward:  5’–GAC AGC AAA AAT CCC CTG AG–3’ 
LAT_Reverse:  5’–ACG AGG GAA AAC AAT AAG GG–3’ 
LAT_probe:  5’–6FAM–CGA CAC GGA TTG GCT GGT GT–MGB-NFQ–3’ 
 
 Endogenous control gene probes were specific to beta-actin (ACTB) and spanned exons 2 
and 3 (Applied Biosystems, catalog 4310881E).  Samples were loaded on Applied Biosystems 
Prism 7900HT for the following conditions: 95°C for 12 min followed by 40 cycles of 95°C for 
15 sec and 55°C for 60 sec.  Resulting cycle threshold (Ct) values were converted to fold-change 
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utilizing the following equation (Schmittgen & Livak, 2008):  2-∆∆CT  = (CT [gene of interest] – 
CT [endogenous control]) sample A – (CT [gene of interest] – (CT [endogenous control] sample 
B.  Sample B was considered the untreated group. 
3.1.13 CHART-PCR 
To investigate whether specific viral genes are competent for transcription, their 
accessibility to micrococcal nuclease (MCN) was analyzed by Chromatin Accessibility Real 
Time-(CHART) qPCR (Rao et al., 2001) with modifications. 
3.1.13.1 MCN Digestion and DNA Extraction 
Cells and viruses.  Human induced pluripotent stem cell (iPSC)-derived neurons (iPSC-
neurons) were cultured as previously described (D’Aiuto et al., 2012).  Approximately 1.8 x 107 
iPSC-neurons were harvested from each condition.  The HSV-1 strain was genetically modified 
to express enhanced green fluorescent protein (EGFP) and monomeric red fluorescent protein 
(RFP) under the control of viral promoters ICP0 and gC, respectively (Ramachandran et al., 
2008). 
Viral infection.  To test lytic HSV-1 infection, cell-free virus was adsorbed onto iPSC-
neurons at an MOI = 0.3 for 2 hours.  The inoculum was removed, cells were washed with PBS, 
and the medium was exchanged.  The cells are harvested at 8 hours post infection (hpi) to 
eliminate the risk of confounding secondary or tertiary infections.  For the quiescent infection, 
iPSC-neurons were pretreated with 5BVdU + IFNα (30 µM and 125 u/ml, respectively) for 24 
hours.  HSV-1 was adsorbed onto the cells for 2 hours in the presence of 5BVdU+IFNα at an 
MOI=0.3, the inoculum was removed, the cells were washed with PBS, and fresh neurobasal 
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medium containing 5BVdU + IFNα was added.  Half of the volume of medium was exchanged 
every other day for a total of 7 days and cells were harvested.  iPSC-neurons that were not 
infected were also processed for CHART-PCR. 
MCN digestion and DNA extraction.  The cells for each condition (uninfected, infected, 
or quiescently infected) were gathered into separate 15 ml conical tubes by gentle pipetting with 
a Gilson® PIPETMAN (p1000) and centrifuged at 1,500 rpm for 5 minutes.  The supernatant 
was carefully removed and 4 ml of ice-cold EZ Lysis Buffer was added to lyse the cells while 
leaving the nuclei intact (Nuclei EZ Prep Nuclei Isolation Kit, Sigma Aldrich, catalog NUC-
101).  Samples were vortexed and left on ice for 5 minutes.  The tubes were centrifuged at 1,750 
rpm for 5 minutes at 4°C.  The pellet containing the nuclei was placed on ice after the 
supernatant was removed and discarded. 
The following steps were critical for the experiment.  Because the nuclei could 
aggressively clump at this step, we optimized it by rapidly working on one sample at a time.  In 
each tube (one condition), 250 µl of MCN digestion buffer (10 mM Tris (pH 8), 1 mM CaCl2 in 
autoclaved water) was added, triturated, and quickly distributed evenly into 5 Eppendorf tubes.  
These 5 tubes were kept on ice until all conditions were processed.  One tube per condition was 
kept on ice and not exposed to the MCN.  The other 4 tubes per condition received 0.5 units, 1.0 
units, 3.0 units, or 5.0 units of MCN (Sigma Aldrich, catalog N3755-200UN).  The tubes were 
gently tapped and placed into 39°C for 20 minutes.  The nuclease activity was stopped by adding 
5 mM EGTA (final concentration; pH 8) per tube.  MCN digestion buffer (133 µl) and 17 µl of 
10% SDS were added per sample.  An equal volume of phenol was added and tubes were mixed 
by inversion.  Samples were centrifuged at 14,000 rpm for 10 minutes.  The top layer was 
carefully removed and placed into a new Eppendorf tube.  One-tenth volume of 3M sodium 
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acetate was added and mixed.  Two volumes of ethanol (100%) was added and samples were 
mixed by inversion and placed into -70°C for 30 minutes.  The samples were centrifuged at 
14,000 rpm for 30 minutes and the supernatant was carefully poured off.  The DNA pellet was 
washed twice with ethanol (70%) and allowed to air-dry.  Twenty microliters of PCR-grade 
water was added per tube, except the undigested samples, where 40 µl was added.  Following 
DNA extraction, each sample was quantified using Quant-iT™ PicoGreen® dsDNA Assay Kit 
(ThermoFisher, catalog P11496) per manufacturer’s instruction. 
3.1.13.2 CHART-PCR 
qPCR Conditions.  The qPCR was carried out in 384-well plates (ThermoFisher 
Scientific, catalog 4309849).  For each reaction, 5 ng of DNA was added to a 10 µl master mix 
composed of 2X TaqMan master mix (ThermoFisher Scientific, catalog 4370048), and 1X probe 
master mix (18 µM forward primer, 18 µM reverse primer, and 5 µM internal oligo). 
Samples were analyzed as technical triplicates and loaded on AB Prism 7900HT for the 
following conditions: EGFP:  95°C for 3 min followed by 45 cycles of 95°C for 15 sec and 55°C 
for 30 sec, and finished with 72°C for 30 sec; host genes GAPDH and RHO:  95°C for 3 min 
followed by 45 cycles of 95°C for 15 sec and 60°C for 30 sec, and finished with 72°C for 30 sec; 
and viral genes ICP4, ICP27, gC, and LAT:  95°C for 12 min followed by 45 cycles of 95°C for 
15 sec and 55°C for 1 minute. 
Primers.  Primers were optimized for thermal cycling conditions and the identity of the 
PCR product was verified by Sanger sequencing.  The promoter region of each gene was targeted 
for CHART-PCR (Table 2; Dr. David Bloom, Ph.D. provided the sequences for the LAT 
promoter).  The amplified region of EGFP was downstream of the ICP0 promoter region. 
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Table 2. Primer sequences for the promoter regions of control host loci and viral loci. 
 
3.1.14 Other Assays for Viral Titers in the Latency Model 
RNA FISH (Prieto et al., 2007) and PCR in situ (Bagasra, 2007) assays were attempted. 
We reasoned that an RNA FISH probe specific for the viral latency associated transcript (LAT) 
would provide a method to quantify latently infected cells, especially if it could be paired with 
flow cytometry.  Similarly, PCR in situ that amplified a viral gene may provide a method to 
detect the viral genome in latently infected neurons.  However, in the results were variable and 
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Induced pluripotent stem cell (iPSC)-based technologies offer an unprecedented 
opportunity to perform high- throughput screening of novel drugs for neurological and 
neurodegenerative diseases. Such screenings require a robust and scalable method for generating 
large numbers of mature, differentiated neuronal cells. Currently available methods based on 
differentiation of embryoid bodies (EBs) or directed differentiation of adherent culture systems 
are either expensive or are not scalable. We developed a protocol for large-scale generation of 
neuronal stem cells (NSCs)/early neural progenitor cells (eNPCs) and their differentiation into 
neurons. Our scalable protocol allows robust and cost-effective generation of NSCs/eNPCs from 
iPSCs. Following culture in neurobasal medium supplemented with B27 and BDNF, NSCs/ 
eNPCs differentiate predominantly into vesicular glutamate transporter 1 (VGLUT1) positive 
neurons. Targeted mass spectrometry analysis demonstrates that iPSC-derived neurons express 
ligand-gated channels and other synaptic proteins and whole-cell patch-clamp experiments 
indicate that these channels are functional. The robust and cost-effective differentiation protocol 
described here for large-scale generation of NSCs/eNPCs and their differentiation into neurons 
paves the way for automated high-throughput screening of drugs for neurological and 
neurodegenerative diseases. 
3.2.2 Introduction 
Research in neuropsychiatry and neurodevelopmental disorders has been hampered by 
difficulty in obtaining neuronal cells from affected individuals that can be cultured and amplified 
in vitro. Human embryonic stem (hES) cells and human iPSCs (Takahashi & Yamanaka, 2013) 
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have revolutionized such research, as they can be differentiated into neurons in vitro from 
specific individuals (Beevers et al., 2013; D'Aiuto et al., 2012; Eigentler et al., 2013), potentially 
enabling personalized medicine by overriding the problems of allogenic recognition. Compelling 
evidence now indicates that iPSC-based models can be used to model selected aspects of 
neurological and neurodegenerative disorders (Brennand et al., 2011; Liu et al., 2012; Kaye & 
Finkbeiner, 2013). Besides their potential to provide important molecular insights into 
pathogenic mechanisms, iPSC-based cellular platforms can also be used for drug discovery in 
specific differentiated cell types (Boissart et al., 2013). Such platforms require replicable, 
efficient, and cost effective protocols to generate uniform cultures of neurons in sufficient 
numbers to enable screening of potentially thousands of different compounds. For high-
throughput screening, NSCs or NPCs from hES cells or iPSCs are currently transferred into 
multi-well culture plates for neuronal differentiation (Zhao et al., 2012; Charbord et al., 2013; 
Efthymiou et al., 2014). Different strategies are employed to derive the NSCs or NPCs, such as 
generation of EB followed by differentiation into neural rosettes (Dhara & Stice, 2008; Muratore 
et al., 2014; Velasco et al., 2014). EBs are 3-dimensional spherical aggregates that recapitulate 
several aspects of early embryogenesis. EBs generated from hES cells and human iPSCs 
efficiently differentiate into neural rosettes when cultured in specific selective culture media with 
growth factor supplements (Kurosawa, 2007), but EBs can have variable differentiation 
outcomes based on factors such as their initial size (Bauwens et al., 2008). To enable more 
homogenous differentiation, microwell arrays have been specifically developed to allow the 
formation of EBs with uniform size (StemCell Technologies, Inc. Inc.). 
The drawbacks related to EBs motivated differentiation protocols based on adherent 
culture systems that eliminate the EB generation step. Another advantage of adherent culture 
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systems is that more uniform exposure to morphogens and growth/differentiation factors is 
achieved (Dhara & Stice, 2008). Neural rosettes (which represent a distinct class of NSCs; 
Elkabetz & Studer, 2008) generated in these adherent culture systems are isolated mechanically, 
then transferred and cultured into low attachment plates, where they form spherical cell 
aggregates called neurospheres that can be propagated as 3-dimensional structures (Cho, et al., 
2008), or expanded as monolayer cultures of NSCs/ NPCs (Zhao et al., 2012) However, 
neurospheres are not ideal for large-scale production of neurons in multi-well plates for high-
throughput screening because of technical difficulties in loading uniform numbers of spheres 
with uniform size into individual wells. Thus, monolayer cultures of NSCs/NPCs would be 
advantageous. Several protocols to derive NSCs/NPCs efficiently from hES cells or iPSCs 
currently utilize Noggin to induce neuronal differentiation (Baharvand et al., 2007; Kirkeby et 
al., 2012), but the need for Noggin significantly increases the cost of the differentiation process. 
We have recently developed a method for efficient differentiation of human iPSCs into 
neurons (D'Aiuto, et al., 2012) that does not involve generation of EBs. Using an adherent 
culture system that does not require Noggin, we generate NSCs/eNPCs in a scalable manner. 
This process takes about 4 weeks and approximately 4 additional weeks are required for 
differentiation mainly into VGLUT1 positive neurons. Here, we describe a detailed step-by-step 
protocol that allows efficient, robust, cost effective and large-scale generation of neurons. This 
differentiation protocol has been successfully applied to 6 different iPSC lines. 
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3.2.3 Results 
3.2.3.1 Outline of differentiation protocol and nomenclature 
The steps of large-scale generation of NSCs/eNPCs from iPSCs and their differentiation 
into neurons are schematically described in FIGURE 7. Human iPSC cultures are exposed for 5 d 
to Neural Precursor (NP) Selection medium, and successively for 7 d in NP expansion medium. 
Following this phase, differentiating iPSC cultures are characterized by the presence of cellular 
aggregates that include emerging neural rosettes. These cells express NSCs markers, such as 
NESTIN (Elkabetz & Studer, 2008), SOX1 (Venere et al., 2012), and MUSASHI (Kim et al., 
2012; FIGURE 8). The expression of PAX6 (Elkabetz & Studer, 2008) is limited to the areas 
forming neural rosettes (FIGURE 8). This observation is in line with data by Suter et al. (Suter et 
al., 2009) showing that PAX6 expression follows the expression of SOX1. The cellular 
aggregates progressively develop into increasing numbers of neural rosettes. 
To facilitate further differentiation into NSCs/eNPCs, cellular aggregates are manually 
fragmented and cultured in ultra-low attachment plates where they round up, forming spherical 
cellular aggregates (FIGURES 7 and 9). Microscopic and immunocytochemical analyses of the 
spherical cellular aggregates show features of neurospheres similar to those generated by 
culturing human sub-ventricular zone from postmortem brains (Gonzalez-Perez, 2012; 
FIGURES 9a, 9b and 49). Because it is unclear whether these spherical cellular aggregates 
possess all the characteristics of neurospheres, they are termed neurosphere-like structures 
(NLSs) in this report. Note that most of the NLSs contain multiple neural rosettes. The NLSs are 
further purified by transferring them into matrigel-coated plates (FIGURE 7). When the NLSs 
are thus flattened, it is possible to clearly observe the neural rosettes (FIGURE 9) that are 
subsequently dissected and transferred into new ultra-low attachment plates where they round up 
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overnight to form new purified NLSs (FIGURE 7). Purified NLSs can then be expanded as 
monolayer cultures of NSCs/eNPCs (FIGURE 10) and further differentiated into neurons 
(FIGURES 11 and 12). 
3.2.3.2 Characterization of iPSC-derived NSCs/eNPCs and neurons 
Western blotting analysis of NSCs/eNPCs showed a relatively low expression level of 
NeuroD1, indicating the absence of, or the presence of only a minor fraction of late NPCs (Gao 
et al., 2009) (FIGURE 10a). Hence, NPCs were denoted as “early” (eNPCs). Expression of NCS 
markers MUSASHI, PAX6, NESTIN, and SOX1 is depicted in FIGURE 10b.  Analysis of PAX6 
expression in NSCs/ eNPCs by high-content imaging in individual wells of a 96-well plate 
showed that greater than 99% of the cells have PAX6 FITC levels above background (FIGURE 
10c). 
Following culture in neurobasal medium supplemented with B27 and BDNF for 4 weeks 
(see Reagents setup), more than 90% of differentiating cells were TUJ1 positive (FIGURE 11). 
Immunocytochemical analysis showed that in our culture conditions, neuronal cells are also 
prevalently VGLUT1 positive (FIGURE 11). Expression of the NR1 subunit of NMDA receptors 
was detected in a substantial fraction of neurons (FIGURE 11). A small fraction of neurons were 
GAD1 positive (D'Aiuto et al., 2012). No dopaminergic neurons were observed following 
immunocytochemistry. A subpopulation of neurons stained for CALBINDIN (FIGURE 12), a 
cytosolic calcium-binding protein with increased expression in layer 3 of pyramidal cells in the 
dorsolateral prefrontal cortex (DLPFC) compared with layer 5 pyramidal cells in the same region 
(Hayes & Lewis, 1992). In addition, expression of the neuropeptide CART, which is increased 
layer 3 versus layer 5 pyramidal cells (Dr. David Lewis, unpublished), was observed only in 
discrete areas of the neuronal cultures (FIGURE 12). Conversely, low-level staining was 
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observed for the layer markers FEZ2 and HS3ST2, which have higher expression in layer 5 
pyramidal cells vs. layer 3 cells (Dr. David Lewis, unpublished; FIGURE 12). Taken together, 
these results indicate that neurons obtained with our differentiation procedure possess features of 
DLPFC layer 3 pyramidal neurons. 
In whole-cell patch-clamp experiments, currents were recorded from ligand-gated 
channels after 2 months of neuronal differentiation of NSCs/eNPCs in neurobasal medium. 
Glutamate receptor-mediated currents were recorded at a holding potential of -85 mV in 
response to application of 100 µM glutamate + 100 µM glycine (6 of 10 cells; in responding 
cells peak current range was -88.5 to -771.1 pA, average -376.6 pA; FIGURE 13a), 100 µM 
AMPA (8 of 13 cells; in responding cells peak current range was -15.5 to -481.8 pA, average -
186.6 pA; FIGURE 12 and 13b) and 100 µM N-methyl-D-aspartate (NMDA) + 100 µM glycine 
(4 of 7 cells; in responding cells peak current range was -80.0 to -320.0 pA, average -233.5 pA; 
FIGURE 13c). GABA receptor-mediated currents were recorded at a holding potential of 15 mV 
in response to application of 1 mM GABA (11 of 12 cells; in responding cells peak current range 
was 75.5 to 3958.8 pA, average 736.9 pA; FIGURE 13d). 
We observed robust expression of numerous neuronal proteins, both pre- and post-
synaptic in iPSC-derived neurons (FIGURES 14a and 14b). In general, synaptic protein 
expression was higher in human cortex tissue compared to iPSC-derived neurons per mg total 
protein (FIGURE 14c). This is unsurprising, as the cellular composition of human cortex and 
neuronal cultures generated from iPSCs is very different. It does indicate, however, that the 
iPSC-derived neurons express many neuron-specific genes. 
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Figure 7. Schematic flow diagram to depict the stages of differentiation into neurons from induced 
pluripotent stem cells (iPSCs). 
3.2.4 Discussion 
The relatively simple culture media described in this protocol allows a large-scale 
generation of NSCs/eNPCs. Variability in the yield of NCSs migrating away from neural rosettes 
has been noticed among iPSC lines from different individuals. Furthermore, fibroblast-like cells 
are observed during the expansion of NSCs/eNPCs, but these cells are manually eliminated. One 
6-well plate of confluent NSCs/eNPCs is sufficient to generate approximately 15 (384-well) 
  NSCs: neural stem cells; eNPCs: early neural progenitor cells; NLSs: neurosphere-like structures. 
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plates of highly enriched neuronal cultures (more than 90% of TUJ1 positive cells). High content 
analysis has shown a uniform distribution of NSCs/eNPCs over the different wells in 384-well 
plates. The relative proportions of astrocytes and oligodendrocytes have not been investigated 
because the goal of this study was to provide a generalizable method for large-scale generation 
of NSCs/eNPCs that can be further differentiate into neurons in microtiter well format for high 
throughput analyses. The cost to generate a neuronal culture in a 384-well plate (where 
NSCs/eNPCs have been cultured in neurobasal medium for 4 weeks) starting from iPSCs is 
approximately $190. 
The protocol detailed here enables a scalable and cost-effective derivation of 
NSCs/eNPCs that can be further differentiated into VGLUT1 positive neurons displaying 
features of layer 3 pyramidal cells. Synaptic protein expression was, on average, less in iPSC-
derived neurons compared to human cortex tissue. This finding is to be expected considering the 
numerous differences between cell culture and tissue. Further studies are needed to evaluate 




Figure 8.  Expression of neural stem cell markers in cellular aggregates developing into neural rosettes 
observed in differentiating iPSCs cultured in NP expansion medium. 
Forming neuronal rosettes are more clearly distinguishable in Hoechst staining where nuclei of each neural rosette 
are arranged radially around a central cavity. Scale bar is 50 µm. 
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3.2.5 Materials and Methods 
3.2.5.1 Human iPSC cell lines 
Lines HFF1-S, 73-56010-02, 73-56010-01, 71-500-9000, and 71-500-9001 were 
generated at NIMH funded Rutgers University Cell and DNA Repository (RUCDR) from skin 
fibroblasts. ATR1, another line was derived from T lymphocytes. Cells were reprogrammed with 
Sendai viral vectors expressing the transcription factors Sox2, c-Myc, Klf4, and Oct4. Following 
QC measures described earlier (D'Aiuto et al., 2012),  iPSCs were maintained in 6-well plates 
with the supplemented mTeSR1™ medium (Stem Cell Technologies) changed daily, allowing 
for manual cleaning of differentiated cells. The protocol was approved by the University of 





Figure 9.  Generation of NLSs and neural rosettes. 
 
3.2.5.2 Reagent setup 
NP selection medium.  Dulbecco’s minimum essential medium/F12 medium 
supplemented with 0.5% N2 (GIBCO), 1 mM L-glutamine, 1% nonessential amino acids, 50 
U/ml penicillin G, 50 mg/ml streptomycin, and 0.1 mM 2-mercaptoethanol (Cho et al., 2008). 
(a) NLSs generated from cellular aggregates developing into neural rosettes.  (b) NLSs generated from single cell 
suspension of cellular aggregates in Aggrewell plates.  (c) Microphotograph of neural rosettes observed 12 hours 
after plating purified NLSs. Scale bar is 50 µm. 
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NP expansion medium.  Dulbecco’s minimum essential medium/F12 medium 
supplemented with 1% N2, 20 ng/ml rhFGFb (Invitrogen), 1 mM L- glutamine, 1% nonessential 
amino acids, 50 U/ml penicillin G, 50 mg/ml streptomycin, and 0.1 mM 2-mercaptoethanol (Cho 
et al., 2008). 
Neurobasal medium.  Neurobasal medium supplemented with 2% B27 (GIBCO), 10 
ng/ml BDNF (PeproTech), 50 U/ml penicillin G, and 50 mg/ml streptomycin. 
Matrigel aliquot preparation.  Thaw a 5 ml container of matrigel qualified for use with 
mTeSR1™ medium (BD) on ice.  Alternatively, matrigel can be thawed by placing it on ice and 
leaving it at 4°C overnight.  Prepare aliquots by adding 500 ml matrigel into cryovials on ice. 
Store aliquots at -20°C for use. 
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Figure 10.  Characterization of iPSC- derived NSCs/eNPCs. 
3.2.5.3 Differentiation procedure 
Generation and passaging of feeder-free iPSC cultures 
We recommend using iPSCs at low passage number in order to reduce the probability of 
karyotypic abnormalities (Taapken et al., 2011). We transfer one iPSC colony from feeder-based 
culture into a 6-well matrigel-coated plate as follows. 
i. MATRIGEL PREPARATION. Thaw a matrigel aliquot on ice. Pipette 50 ml PBS into a
disposable falcon 50 ml tube. Add 1 ml of the PBS into the cryotube containing 500 µl matrigel. 
Mix quickly and transfer back to the 50 ml falcon tube. Mix matrigel/PBS mixture by pipetting 
up and down with a 10 ml pipette and dispense into plates. To coat one well of a 6-well plate, use 
1 ml matrigel/PBS mixture.  NOTE: Thawing the matrigel requires approximately 2 hours. Keep 
matrigel aliquot on ice at all times. 
ii. IPSC SEEDING. Examine iPSC culture under a microscope to select undifferentiated
colonies. Using a marking pen, draw a circle around undifferentiated iPSC colonies on the 
(a) Left: Immunoblots showing the expression of markers specific for NSCs (MUSA- SHI, PAX6, NESTIN and 
SOX1), late NPCs (NEUROD1) and neurons (CALRETININ, TUJ1, and MAP2) in iPSC-derived NSCs/eNPCs. 
Right: Normalized expression of NSC markers. The data represent an average of 3 independent experiments. (b) 
Immunocytochemical analysis of iPSC-derived NSCs/ eNPCs. Scale bar is 50 µm. (c) Quantification of PAX6 
expression using High Content Analysis. RFU: relative fluorescence unit. A01-A03 denote biological replicates. 
The distribution of PAX6 labeling among NSCs/eNPCs is shown in the histograms. The histograms indicate 
RFU intensity in the vertical axis and number of cells at that intensity in the horizontal axis. The points outside 
the histograms indicate outliers. The tables below the histograms indicate the number of cells measured in the 
populations (Count), the average (Avg) and standard deviation (StdDev) of the overall PAX6 labeling in the 
population. Greater than 99% of the cells have PAX6 FITC levels above background. The average background 
level in the well is <400 gray levels. The minimum level in the cell is around 1,000 to 2,000. More than 99% of 
the cells show levels greater than 500. 
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bottom of the plate (differentiated iPSC are characterized by non-uniform cell morphology in 
any portion of the colonies). Replace the medium in which iPSCs are cultured with pre-warmed 
(37°C) mTeSR1™ medium. Cut selected colonies into pieces of uniform size using a bent 20-
gauge needle; harvest the iPSC clumps with a 10 ml pipette, and transfer into new culture well 
coated with matrigel, prepared as described in step 1(i). Culture iPSCs in mTeSR1™ medium for 
5–7 d in an incubator under standard conditions (5% CO2, 37°C, and 100% humidity). Change 
culture medium every day. Eliminate unwanted differentiated iPSCs from each well by scraping 
with a pipette tip.  When the iPSC colonies become confluent (colony size approximately 1.5–2 




Figure 11.  Immunostaining of iPSC-derived neurons. 
 
 
TUJ1 (a), MAP2 (b), VGLUT1 (c), and NR1 subunit of the NMDA receptor (d). The percentage of TUJ1 
positive neurons was analyzed by flow cytometry; cells were permeabilized with Cytofix/Cytoperm (Becton 
Dickinson) and dead cells were excluded from the analysis. Filled histogram shows the fraction of TUJ1 stained 
cells compared to secondary antibody staining (e). Scale bar is 50 µm in a-c, and 75 µm in d. 
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Derivation of NSCs/eNPCs from iPSCs. DURATION: 12 d 
Wash iPSC colonies with 2 ml 1X PBS at room temperature twice. Add 2 ml of pre-
warmed NP selection medium and incubate under standard conditions. Change medium every 
other day. At day 5, replace NP selection medium with NP expansion medium and culture for 7 d 
After 3-5 d in NP expansion medium, 50–70% of colonies show the presence of cellular 
aggregates expressing NSCs markers NESTIN (Elkabetz & Studer, 2008), SOX1(Venere et al., 
2012), and MUSASHI (Kim et al., 2012; FIGURE 8). If there is paucity of neural structures after 
7 d culture in NP expansion medium, continue to culture the cells for 5–7 more days. 
 
 
Figure 12.  Immunostaining of iPSC-derived neurons.  
 
 
CALBINDIN (a), CART (b), FEZ2 (c), and HS3ST2 (d). Scale bars are 75 µm. 
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Generation of NLSs. DURATION: 3–4 d 
After 7 d in NP expansion medium, proceed to generate NLSs as follows. 
i. Aspirate the medium, wash the cells twice with 1 ml DMEM/F12 and add 2 ml of pre-
warmed NP expansion medium. With the plate under the microscope (use the 4X 
objective), use a bent 20-gauge needle to dissect cellular aggregates into pieces of 
approximately 40–50  µm diameter. 
ii. Collect the NP expansion medium containing the dissected cell aggregates and transfer 
into an ultra-low attachment 6-well plate. Culture in standard incubator conditions 
overnight. 
iii. On the following day, cell aggregates should round up into floating spherical cellular 
aggregates denoted NLSs (FIGURE 9a). 
iv. Culture NLSs for 2–3 d in NP expansion medium. Change half the culture medium 
every day as follows. Collect NLSs in suspension from the plate and transfer into a 15 ml 
conical tube. Allow NLSs to settle to the bottom of the conical tube for 10 min. Replace 
half of the culture medium with fresh medium. Transfer the NLSs back to the 6-well 
ultra-low attachment plate. To distribute NLSs uniformly on low attachment plates, re- 
suspend NLSs by pipetting up and down 3–4 times with a 5 ml pipette. As the NLSs tend 
to sink to the bottom rapidly, transfer into 2 wells at a time, resuspending each time. 
Continue culturing until the NLSs reach a diameter of approximately 300 µm. 
 
Alternative method for size-controlled formation of NLSs. DURATION: 4–5 d 
Derivation of size-controlled NLSs is more expensive than the method described above. 
However, the percentage of NLSs differentiating into neural cells is higher with this method. To 
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generate size- controlled NLSs, dissect cellular aggregates and transfer them into a 15 ml conical 
tube. Pellet the cells by spinning down for 30 sec at 1,200 rpm. Discard the supernatant and add 
2 ml of StemPro Accutase (Life Technologies). Incubate at 37°C for 10 min (dissociate cells 
thoroughly by pipetting with a P1000 Pipetman every 2– 3 min). Add 8 ml of DMEM/F12 and 
mix by inverting the tube 2– 3 times. Leave the conical tube for 10 min to enable the 
undissociated clumps to settle to the bottom of the tube. Transfer the single cell suspension into a 
new 15 ml conical tube and centrifuge for 5 min at 1,200 rpm. Discard the supernatant and re-
suspend the cells in 5 ml of NP expansion medium. Count viable cells using the trypan blue 
method. Adjust the volume of cell suspension to a density of 2 x 106 cells/ml. Add 2 ml of NP 
expansion medium to each well of an Aggrewell plate (Stem cell Technologies, Vancouver BC). 
Centrifuge the plate for 5 min at 1,200 rpm and discard the medium. Transfer 1 ml of cell 
suspension into each well to be used and centrifuge the plate as described above. Incubate plate 
overnight under standard culture conditions. Following overnight incubation, the cells should 
form spherical cell aggregates of approximately 40– 50 µm (FIGURE 9b). After 24 hours, 
collect the NLSs by using a transfer pipette and transfer to an ultra-low attachment 6-well plate. 
Culture the NLSs as described above until they reach the desired size (approximately 200–250 
µm). To efficiently dislodge NLSs from single micro-wells of the Aggrewell plate, apply mild 
positive pressure on different regions at the bottom of the well, using a transfer pipette bulb. 
After harvesting NLSs, ensure that all the NLSs have been collected by reviewing the donor 
plate under the microscope. Repeat the previous steps if necessary. 
Purification of NLSs. DURATION: 6–7 d 
Transfer the NLSs floating in the NP expansion medium into a 15 ml falcon tube and 
allow them to settle for 10 min. Aspirate the supernatant and re-suspend the NLSs into 12 ml of 
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NP expansion medium. Distribute the NLS suspension (2 ml/well) in a matrigel-coated 6-well 
plate. Incubate in standard conditions. Following overnight incubation, NLSs tend to adhere to 
the bottom of the culture plate and flatten. At this stage, neural rosettes can be observed 
(FIGURE 9c). Place the culture plate under an inverted microscope. Dissect and collect the 
neural rosettes following the same procedure described in steps 3(i) and 3(ii). Incubate in 
standard conditions. On the following day, neural rosettes should round up into NLS. Culture 
NLSs for 2–3 d until the NLSs reach a size of approximately 300 µm. Change half the culture 
medium every other day as described in step 3(iv). 
Generation of monolayer cultures of NSCs/eNPCs. DURATION: 9d 
Collect the NLSs into NP expansion medium and transfer into a matrigel-coated 6-well 
plate. Incubate in standard conditions. After a few hours, NLSs adhere to the surface of the 
culture plate and NSCs migrate away. At this stage, heterogeneous cultures will be generated, 
consisting of NSCs and eNPCs. Fibroblast-like cells may still be observed and should be 
removed under the inverted microscope by scraping them with a pipette tip. 
Passaging NSCs/eNPCs 
Aspirate NP expansion medium and rinse with DMEM/F12. For 6-well cultures, add 1 ml 
of StemPro Accutase per well and incubate for 3 min at 37°C. Add 2 ml of DMEM/F12 medium 
and gently detach cells by pipetting up and down with a p1000 tip. Transfer the cell suspension 
into a 15 ml conical tube. Centrifuge 5 min at 1,200 rpm. Discard the supernatant, re-suspend the 
cells with 12 ml of NP expansion medium, and culture in standard conditions in the appropriate 
plates coated with matrigel. On the next day, replace NP expansion medium with mTeSR1™ 
medium and culture until the cells are confluent (FIGURE 10b). When confluent, the cultures in 
6-well plates should contain approximately 3 x 106 cells/well. From this stage onwards, NSCs/ 
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eNPCs are cultured and passaged in mTeSR1™ medium. The NSCs/eNPCs can be stored at -
135°C or in liquid nitrogen. We do not recommend expanding NSCs/NPCs for more than 12 
passages to reduce the risk of chromosomal aberration (Nguyen, 2013). Freezing and thawing 
procedures of NSCs/ eNPCs are described in Supplementary Information. 
Generating neuronal cultures in 96- and 384-well plates. DURATION: 4 weeks. 
Dissociate NSCs/eNPCs with StemPro Accutase as described above. Count the cells and 
re-suspend them in an appropriate volume of mTeSR1™ medium. Distribute cells in 96-well 
plates at 104 cells/well or in 384-well plate at 2.5 x 103 cells/well. On the next day, change 
mTeSR1™ to neurobasal medium and culture for 4 weeks. Replace half of the culture medium 
with fresh medium every other day by using a multi-channel pipette. Under these conditions, 
highly enriched cultures of neurons are generated (FIGURE 11). 
Immunocytochemistry and Microscopy 
Immunocytochemistry was performed as previously described (D'Aiuto et al., 2008). 
Primary antibodies used were mouse anti-human NESTIN monoclonal antibody (R&D Systems, 
1:200 dilution), rabbit polyclonal anti-SOX1 antibody (Abcam, 1:200 dilution), rabbit polyclonal 
anti-MUSASHI antibody (Abcam, 1:200 dilution), rabbit polyclonal anti-PAX6 antibody 
(Abcam, 1:200 dilution), mouse anti-ß TUBULIN III monoclonal antibody (clone Tuj-1, R&D 
System, 1:50 dilution), mouse monoclonal anti- MAP2 (Millipore, 1:200 dilution), rabbit 
polyclonal anti-VGLUT1 antibody (Synaptic Systems, 1:200 dilution), rabbit anti-NMDAR1 
monoclonal antibody (Abcam, 1:400 dilution), rabbit polyclonal to CALBINDIN antibody 
(Abcam, 1:200 dilution), rabbit polyclonal to FEZ2 antibody (Abcam, 1:200 dilution), rabbit 
polyclonal to HS3ST2 antibody (Novus Biologicals, 1:50 dilution), mouse monoclonal to CART 
antibody (Abcam, 1:100 dilution). Alexa Fluor 488 goat anti-rabbit secondary antibody (Life 
 80 
Technologies, 1:200 dilution) and Alexa Fluor 488 goat anti- mouse secondary antibody (Life 
Technologies, 1:200 dilution) were used for detection. Counterstaining was done with Hoechst 
33342 (Life Technologies, 1:1000 dilution). Images were acquired using a Leica IL MD LED 
inverted fluorescence microscope. 
Western blots 
Cell lysates were prepared with 10 volumes of RIPA buffer (25 mM Tris–HCl pH 7.6, 
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS), denatured by heating at 
95°C and then separated by electrophoresis on 4–12% gradient SDS-polyacrylamide gels, 
transferred onto Immobilon membranes (Millipore). Immunoblots were probed with monoclonal 
antibodies similar to those employed in immunocytochemistry analysis; other antibodies used 
were rabbit anti-CALRETININ monoclonal antibody (Abcam, 1:800 dilution), rabbit anti-
NEUROD1 polyclonal antibody (Abcam, 1:200 dilution). The blots were probed with 
fluorescently labeled secondary antibodies (Li-Cor antibodies) to detect immunoreactivity. 
Fluorescent signal intensities were then quantified using an Odyssey Imaging scanner (Li-Cor). 
Quantification of PAX6 expression using high content analysis 
NSC/eNPCs were fixed with 4% paraformaldehyde and labeled with rabbit polyclonal 
anti- PAX6 antibody followed by Alexa Fluor 488 goat anti-rabbit secondary antibody, and with 
Hoechst 33342 to identify individual cellular nuclei. Cells were imaged on the ImageXpress 
Ultra (IXU) High Content imager with 20x objective using the 405 nm excitation/447 nm 
emission to visualize the Hoechst nuclear stain, and 488 nm excitation/514 nm emission filter to 
visualize the PAX6 Alexa Fluor 488 stain. Images were analyzed using the Multiwavelength Cell 
Scoring application within the MetaXpress software that runs the IXU, and the average 
intracellular intensity of the PAX6 stain was determined for each cell. 
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Electrophysiological recordings 
iPSC-derived NSCs/eNPCs were plated onto matrigel-coated 18 mm coverslips and 
cultured for 8 weeks in neurobasal medium for neuronal differentiation. Neuronal cells were 
visualized on 18 mm coverslips with a Zeiss inverted microscope. The external recording 
solution contained 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl2, 0.01 mM EDTA (to eliminate 
contaminating Zn2+, which inhibits some NMDA receptor subtypes), 10 mM HEPES, pH 7.2 ± 
0.05 adjusted with NaOH, osmolality 290 ± 10 mmol/kg adjusted with sucrose, and agonists 
added at indicated concentrations. The pipette solution contained 130 mM K- gluconate, 10 mM 
NaCl, 1 mM CaCl2, 1.1 mM EGTA, 10 mM HEPES, 2 mM ATP-Na2, 2 mM MgCl2, pH 7.2 ± 
0.05 adjusted with KOH, osmolality 275 ± 10 mmol/kg. 
Whole-cell recordings from iPSC-derived neurons were performed using pipettes pulled 
from borosilicate glass and fire-polished (5–8 MΩ). Membrane currents were recorded with an 
Axopatch 200B amplifier (Molecular Devices) in voltage-clamp mode, low-pass filtered at 5 
kHz, and digitized at 10 kHz with a Digidata 1322a (Molecular Devices). Series resistance was 
compensated at 75–85%. For data presented here, recordings were rejected if holding current at -
85 mV exceeded -600 pA (Molecular Devices). Rapid solution exchange was achieved using an 
in-house-fabricated fast perfusion system (Qian et al., 2002) connected to gravity-fed reservoirs. 
All experiments were performed at room temperature. Peak currents are measured relative to 




Figure 13.  Electrophysiological recordings of iPSC-derived neurons.  
 
Targeted Proteomics 
Cell lysates were prepared as described above and total protein quantified by micro BCA 
(Pierce). Human postmortem cortex gray matter homogenates previously prepared from 3 normal 
subjects were obtained (Deo et al., 2013). Twenty micrograms of protein from iPSC-derived 
neurons or human cortex gray matter tissue homogenate were mixed with 20 µg of a stable 
isotope labeled neuronal proteome standard, separated by electrophoresis on a 4–12% gradient 
SDS-polyacrylamide gel, and subject to on-gel digestion as previously described (MacDonald et 
al., 2012). Liquid Chromatograph – Selected Reaction Monitoring analyses were conducted on a 
Example traces of whole-cell voltage-clamp recordings from HFF1-S cells in response to application of the 
indicated agonists. Currents were recorded in a Mg+-free extracellular solution at a holding potential of -85 mV 
(a–c) or 15 mV (d) during approximately 5 s applications (indicated by horizontal bar above each trace) of 100 
µM glutamate + 100 µM glycine (a, peak current -494.3 pA), 100 µM AMPA (b, peak current = -261.8 pA), 100 
µM NMDA + 100 µM glycine (c, peak current = -324.4 pA), or 1 mM GABA (d, peak current = 851.8 pA). 
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TSQ Quantum triple stage quadrupole mass spectrometer (ThermoFisher Scientific) with an 
Ultimate 3000 HPLC (Dionex) and a PicoChip Column (New Objective). Two µl (»1 µg protein) 
sample was loaded onto the column at 1 µl/min for 12 min, and eluted at 300 nl/min over a 25 
min gradient from 3–35% mobile phase B (Acetonitrile containing 0.1% formic acid). SRM 
transitions were timed using 1 min retention windows, depending on the number of SRMs to be 
assayed. Transitions were monitored, allowing for a cycle time of 1 sec, resulting in a dynamic 
dwell time never falling below 10 msec. The MS instrument parameters were as follows: 
capillary temperature 275°C, spray voltage 1100 V, and a collision gas of 1.4 mTorr (argon). The 
resolving power of the instrument was set to 0.7 Da (Full Width Half Maximum) for the first and 
third quadrupole. Data were acquired using a Chrom Filter peak width of 4.0 sec. Peak areas and 
area ratios were calculated within Skyline (Lista et al., 1988). Raw files were loaded into Skyline 
files containing target proteins/peptides/transitions. All individual SRM transitions and 
integration areas were manually inspected. Transitions for which the signal-to-noise ratio was 
below 3 were excluded from analysis. The ratios of the integrated areas for “light” endogenous 
peptides and “heavy” 13C6STD peptides were calculated to obtain peptide measures using 




Figure 14.  Targeted proteomic comparison of iPSC-derived neurons and human cortex gray matter.  
Expression of representative presynaptic (A) and post-synaptic (B) proteins in iPSC-derived neurons 
(NSCs/eNPCs cultured in neurobasal medium for 6 weeks) and human cortex gray matter. (C). Distribution of 
the averaged difference between the 2 groups expressed as a ratio of iPSC-derived neurons: Cortex gray matter. 
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Background:  Herpes simplex virus, type 1 (HSV-1) commonly produces lytic mucosal 
lesions. It invariably initiates latent infection in sensory ganglia enabling persistent, lifelong 
infection. Acute HSV-1 encephalitis is rare and definitive evidence of latent infection in the 
brain is lacking. However, exposure untraceable to encephalitis has been repeatedly associated 
with impaired working memory and executive functions, particularly among schizophrenia 
patients. Methods: Patterns of HSV-1 infection and gene expression changes were examined in 
human induced pluripotent stem cell (iPSC)-derived neurons. Separately, differences in blood 
oxygenation level-dependent (BOLD) responses to working memory challenges using letter n-
back tests were investigated using functional magnetic resonance imaging (fMRI) among 
schizophrenia cases/ controls. Results: HSV-1 induced lytic changes in iPSC-derived 
glutamatergic neurons and neuroprogenitor cells. In neurons, HSV-1 also entered a quiescent 
state following co-incubation with antiviral drugs, with distinctive changes in gene expression 
related to functions such as glutamatergic signaling. In the fMRI studies, main effects of 
schizophrenia (P = .001) and HSV-1 exposure (1-back, P = 1.76 × 10−4; 2-back, P = 1.39 × 
10−5) on BOLD responses were observed. We also noted increased BOLD responses in the 
frontoparietal, thalamus, and midbrain regions among HSV-1 exposed schizophrenia cases and 
controls, compared with unexposed persons. Conclusions: The lytic/quiescent cycles in iPSC-
derived neurons indicate that persistent neuronal infection can occur, altering cellular function. 
The fMRI studies affirm the associations between non-encephalitic HSV-1 infection and 
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functional brain changes linked with working memory impairment. The fMRI and iPSC studies 
together provide putative mechanisms for the cognitive impairments linked to HSV-1 exposure. 
3.3.2 Introduction 
Herpes simplex virus, type 1 (HSV-1) causes human specific infections in the majority of 
US adults (http:// www.cdc.gov/nchs/nhanes.htm) and increasing numbers of neonates (Gupta et 
al., 2007; Flagg & Weinstock, 2011). Mucosal lesions such as cold sores occur after primary 
infection, and recurrent infections can induce blinding stromal keratitis. HSV-1 causes fulminant 
lytic infection in all human cells except sensory ganglia, where latent infection can be 
established in neurons that serve as reservoirs for lifelong recurrent infections. Persistent 
infection is thus marked by sporadic productive, lytic infections alternating with latency, when 
gene expression is largely silenced and only the untranslated latency-associated transcripts 
(LAT) are abundantly expressed (Steiner et al., 2007). 
Periodic reactivation can cause HSV-1 encephalitis, with extensive cognitive impairment, 
and postencephalitic sequelae (Steiner et al., 2007). Its rarity (~0.04%) suggests that HSV-1 
infection does not ordinarily affect the brain, but viral DNA has been detected in 35% of 
nonencephalitic postmortem brain tissues (Baringer & Pisani, 1994; Karatas et al., 2008), 
suggesting spread to the brain during persistent infection. Mild/moderate impairments in 
attention, working, and verbal memory untraceable to prior encephalitis or socioeconomic status 
(SES; Baringer et al., 1994) were reported repeatedly among HSV-1 exposed schizophrenia 
patients and even healthy individuals (Dickerson et al., 2003; Dickerson et al., 2004; Dickerson, 
et al., 2008; Shirts et al., 2008; Schretlen et al., 2010; Yolken et al., 2011; Prasad et al., 2012; 
Dickerson et al., 2012; Watson et al., 2013), with only one discrepant report (Aiello et al., 2008). 
89 
The estimated ORs for cognitive dysfunction among HSV-1–exposed young adults are 1.25–3.2 
(Dickerson et al., 2008; Watson et al., 2013), indicating population attributable risks between 
15.2%– 59.3%. Reduced prefrontal cortical gray matter volume was also reported among HSV-
1–exposed schizophrenia patients (Prasad et al., 2007; Prasad et al., 2011), with progressive 
cognitive impairments and gray matter loss (Prasad et al., 2011). The cognitive impairments 
were alleviated with an antiviral agent in a randomized placebo-controlled trial (Prasad et al., 
2012). These studies together affirm the majority of Bradford-Hill criteria, suggesting causal 
links (Prasad et al., 2012). 
To generate testable mechanisms for the associations, we investigated cellular models 
using human induced pluripotent stem cells (iPSCs), because existing HSV-1 models utilize 
nonhuman tissues or transformed cell lines; such models may not recapitulate human specific 
infection (Giordani et al., 2008; Bloom et al., 2010; Nicoll et al., 2012). With functional 
magnetic resonance imaging (fMRI), we separately evaluated brain activation patterns while 
participants performed the n-back task, a well-established working memory task that identifies 
consistent patterns of brain activation differences among schizophrenia cases (Friedman & 
Goldman-Rakic, 1994; Carter et al., 1998). 
3.3.3 Methods 
3.3.3.1 iPSC-Based Studies 
iPSCs.  iPSCs were generated from human skin biopsies. Line 5404 from a schizophrenia 
patient was used for all experiments. Line HFF1-S, from neonatal foreskin of an anonymous 
donor was used for confirmatory studies. Neural progenitor cells (NPCs) and glutamatergic 
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neurons (D'Aiuto et al., 2012) were derived from iPSCs (D'Aiuto et al., 2012) (FIGURES 50 and 
51 and supplementary information described in Appendix B). 
HSV-1 Infection. We used a genetically engineered HSV-1 construct incorporating 
enhanced green fluorescent protein (EGFP) and monomeric red fluorescent protein (RFP) as 
reporter genes whose expression is driven by the viral promoters ICP0 and glycoprotein C, 
respectively (Ramachandran et al., 2008). EGFP expression in infected cells indicates that HSV-
1 has entered lytic cycles, while RFP expression indicates commitment to viral DNA replication. 
Cells were incubated with HSV-1 for 2 h at specified multiplicity of infection (MOI). To inhibit 
viral replication, cells were pre-incubated with antivirals used in animal models: acyclovir (50 
μM), or (E)-5-(2-bromovinyl)-2′-deoxyuridine (5BVdU, 30 μM) along with interferon-alpha 
(IFN-α, 125 U/ml; Carter et al., 1998). The proportion of cells expressing EGFP and RFP was 
determined by flow cytometry (FC). Images were acquired using a Leica IL MD LED inverted 
fluorescence microscope and a Leica DM5500B fluorescence microscope. 
Viral Gene Expression. RNA was extracted using Qiagen kits. Complementary DNA was 
synthesized using total RNA with SuperScript III recommended protocol (Invitrogen) and 
quantitative PCR (qPCR) performed using the target and reference (beta actin) Taqman probes 
with Applied Biosystems-recommended protocols (ABI). All experiments were conducted in 
triplicate and the comparative Ct method used for quantification (Talkowski et al., 2010). 
Three-Dimensional Fluorescence In Situ Hybridization. Three-dimensional fluorescence 
in situ hybridization (3D-FISH) was performed using the HSV-1 genome as a probe (Cremer et 
al., 2007). To visualize viral DNA in host cellular nuclei, iPSC-derived neurons were infected 
after 60 days of differentiation in neurobasal medium on matrigel-coated chamber slides. 
Neurons were infected with HSV-1 in the presence or absence of 5BVdU+IFN-α at MOI 0.3. On 
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average, 50 nuclei from each cellular preparation were scanned. Digital images were generated 
using Leica LAS AF, 3D Visualization Module. Hybridization signals were subjected to uniform 
thresholding to demarcate the signals. 
Oligonucleotide Microarray Analyses. Cy3-labeled cRNA was used for hybridization to 
Agilent Human GE 8x60K V2 Gene Expression microarrays (Agilent Technologies), the 
microarrays scanned using the Agilent Microarray Scanner and data analyzed with Agilent 
Feature Extraction software (A 9.1.3; D'Aiuto et al., 2012). Differentially expressed genes were 
determined using unpaired t tests and Benjamini-Hochberg correction with P ≤ .05 and the fold 
change of 2 as thresholds. The data were deposited in NCBI’s Gene Expression Omnibus 
database (http://www. ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46043). 
fMRI Studies 
Clinical Evaluations. Participants (schizophrenia = 19, controls = 23) completed the 
Structured Clinical Interview for DSM-IV (First et al., 1995) followed by consensus diagnoses 
(Prasad et al., 2007). SES was evaluated using the Hollingshead Index (Hollingshead, 1975). 
Exclusion criteria included substance abuse in the past month or dependence in the last 6 months, 
history of medical/neurological disorders, mental retardation (DSM-IV), illness duration over 8 
years or participation in prior HSV-1 studies. The controls were screened for absence of 
psychosis and substance abuse (Prasad et al., 2007). After complete description of the study, 
written informed consent was obtained. 
HSV-1 Exposure. IgG antibodies to HSV-1 were assayed using solid-phase enzyme 
immunoassays (Prasad et al., 2012). 
MRI Studies. Structural MRI was acquired on a Siemens 3T Tim Trio whole-body 
scanner using the MPRAGE sequence to co-register fMRI data, overlay the blood oxygenation 
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level-dependent (BOLD) responses and identify regions-of-interest. Scanning parameters were: 
echo time (TE) = 3.52 ms, repetition time (TR) = 2300 ms, flip angle = 9°, thickness = 0.8mm, 
and number of slices = 192 (Stolz et al., 2012). In the same session, subjects performed a letter n-
back task and whole-brain BOLD responses were collected using gradient-echo echo-planar 
imaging (EPI). Scanning parameters for the fMRI were: TE = 31ms, TR = 2000 ms, 36 
axial/oblique slices of 4-mm thickness, field of view = 240 mm, flip angle = 80°, and matrix size 
= 64 × 64. The letter n-back task consisted of 6 blocks (2 blocks each of 0-back, 1-back, and 2-
back) of English upper case letters as stimuli. Each stimulus was presented for 500ms. The 
interstimulus interval (ISI) was jittered randomly between 1.5 and 5.5 s with an average ISI of 
3.5 s. Each block was followed by 20 s rest. The first block presented was always 0-back to 
acclimatize the subjects in the scanner, followed by a randomized order of presentation. Stimuli 
were presented using E-prime through back projection on a white screen. Subjects responded 
through a fiber-optic button system by pressing the assigned button every time they saw X on the 
screen for the 0-back, if they saw the same letter preceding the one presented earlier for the 1-
back and if they saw a letter shown 2 letters before the one they were seeing for the 2-back. The 
responses were collected for both accuracy and response time. 
Image Processing. fMRI data were analyzed using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Images were realigned and normalized to a 
standard EPI template and smoothed with 8 × 8 × 8 Gaussian kernel. A full-factorial random 
effects model was implemented within SPM8 with age, sex, and SES as covariates. We preferred 
to compare groups across each task level since the behavioral data between-group showed 
significant differences across each task level rather than between levels of performance. A priori 
combined intensity and spatial extent threshold significance was determined by running 10,000 
 93 
Monte Carlo simulations on AlphaSim (Maldjian et al., 2003) for the whole brain. The 
simulation showed that the BOLD differences within a cluster of 1385 contiguous voxels with a 
minimum voxel-wise difference of P < .05, would provide a P < .05 corrected for both the 
intensity and the spatial extent of the clusters. Task performance data were analyzed using 
generalized linear models for mean response time and the Mann-Whitney U tests for accuracy. 
Percent signal changes were extracted from the regional masks of Brodmann areas (BA) defined 
by the WFU PickAtlas (Ward, 2000) that contained the peak intensity voxel and were analyzed 
using ANOVA on SPSS 21. 
3.3.4 Results 
3.3.4.1 iPSC-Based Studies 
HSV-1 Infection in NPCs and Neurons. At 24h postinfection (p.i.), FC analysis showed 
~30% and ~15% of EGFP-positive (EGFP+) cells in infected NPCs and neurons respectively, 
indicating lytic infection (FIGURE 15). A ~2-fold reduction of EGFP+ cells was observed in 
NPCs and ~3-fold reduction in neurons when HSV1infected cells were co-incubated with 
acyclovir, compared with vehicle-treated controls. Separately, NPCs and neuronal cultures co-
incubated with 5BVdU and IFNα showed a greater reduction in EGFP+ cells (percentage of 
EGFP+ cells were ~8% and ~2%, respectively), compared with untreated control cells or 
acyclovir-treated cells, suggesting that the antiviral agents suppressed viral gene expression. 
Even in the presence of 5BVdU+IFN-α, the majority of infected NPCs detached from 
culture plates without a concomitant increase in the frequency of EGFP+ and RFP+ cells, 
suggesting that HSV-1 quiescent infection cannot be established consistently in NPCs (FIGURE 
16, top panel). 
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In contrast, when neuronal cultures were infected at MOI of 0.3 with 5BVdU+IFN-α and 
maintained from day −1 to day +7 p.i., only 9% of cells expressed EGFP, suggesting that viral 
gene expression was suppressed in the majority of cells and lytic infection was present in a 
minority (FIGURE 16, middle panel). Infectious viral particles were undetectable in the 
supernatant for 7 days of infected neuronal cultures treated with inhibitors, based on subsequent 
Vero cell plaque assays (FIGURE 16, bottom panel, left). Culture supernatants from these 
neuronal cultures tested against new neuronal cultures (1/20 of the volumes of the culture 
supernatants were applied to neuronal cultures) failed to yield EGFP+ or EGFP+/RFP+ cells in 
all cultures up to 48 h p.i., consistent with the plaque assays (FIGURE 16, bottom panel, right). 
Though the green fluorescence in the initial neuronal cultures indicates activation of the ICP0 
promoter, productive infection was thus fully suppressed and quiescent infection may be present 
(FIGURE 16, middle panel). 
Withdrawal of 5BVdU+IFN-α was followed by ~3-fold increase of EGFP+ cells and ~5-
fold increase of EGFP+/RFP+ cells (FIGURE 16, middle panel). Infectious viral particles were 
undetected in most cultures, although a relatively low level of infectious virus (~3 log(10) pfu/ 
ml) was detected in 3 out of 9 cultures (data not shown). Culture supernatants were also tested 
for presence of virions by application to additional neuronal cultures. Only sporadic EGFP+ and 
EGFP+/RFP+ cells were observed when neuronal cultures were infected with up to 1/20 of the 
volume of the culture supernatants (FIGURE 16, bottom panel, right). Thus, withdrawal of 





Figure 15.  Comparative efficiency of antiviral drugs to reduce acute infection in induced pluripotent stem-
derived neural progenitor cells (NPCs) and neurons.  
 
Reactivation of Quiescent Infection with Sodium Butyrate.  Neurons were cultured for 5 
days with sodium butyrate (NaB) (5mM), a histone deacetylase inhibitor, after initial 7-day 
treatment with 5BVdU+IFN-α. FC showed ~2-fold increase of EGFP+ cells and ~6-fold increase 
of EGFP+/RFP+ cells, (FIGURE 16, middle panel). Productive infection was confirmed by 
applying NaB-treated culture supernatants to fresh neuronal cultures, yielding a high proportion 
Top panel: microphotographs of NPCs and neuronal cultures infected with herpes simplex virus, type 1 (HSV-1) 
(multiplicity of infection of 0.1 and 0.3, respectively) in the presence or absence of viral replication inhibitors 
acyclovir or 5-(E)-5-(2bromovinyl)-2-deoxyuridine along with interferon-α. Bottom panel: fluorescence-
activated cell sorting analysis of uninfected and HSV-1 infected NPC and neuronal cultures. Scale bar is 50 μm. 
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of EGFP+ and EGFP+/RFP+ cells (FIGURE 16, bottom panel, right). The viral titer of culture 
supernatant was ~4 log(10) pfu/ml (FIGURE 16, bottom panel, left). Thus, HSV-1 can be 
recovered from quiescently infected neurons with NaB. 
Nuclear Localization of the HSV-1 Genome During Neuronal Infection. Lytic or 
quiescent infection was induced in iPSC-derived neurons as described and HSV-1 genomes 
visualized using 3D-FISH. In acutely infected cultures, numerous FISH signals corresponding to 
HSV-1 genomes were found in the central region of the nucleus, and the host chromatin showed 
displacement toward the nuclear periphery (FIGURE 52a). In neurons with quiescent infection, 
only a weak signal was detected at the nuclear periphery (FIGURE 52b). 
Viral and Neuronal Gene Expression. Using qPCR assays, viral LAT, ICP4, and DNA 
polymerase genes were expressed at higher levels during lytic vs quiescent infection (fold-
changes: LAT: 54, ICP4: 63, DNA polymerase: 51). Microarray analysis of host neuronal gene 
expression indicated that 10,087 genes were altered significantly during lytic infection (P < .05, 
corrected for multiple comparisons, mean fold changes <0.5 or >2), but during quiescent 
infection, only 1,525 genes changed significantly; the latter included glutamate receptor and 
voltage-gated ion channel genes (FIGURE 17). During lytic infection, Ingenuity Pathways 
Analysis (IPA) indicated enrichment of glutamate receptor signaling, mitochondrial dysfunction, 
axonal guidance signaling, chondroitin and dermatan sulfate degradation pathways; an 





Figure 16. Quiescent infection established in neurons but not in neural progenitor cells (NPCs). 
Top panel: microphotographs of induced pluripotent stem-derived NPCs infected with herpes simplex virus, type 
1 (HSV-1) in the presence of 5-(E)-5-(2-bromovinyl)-2 deoxyuridine (5BVdU) and interferon (IFN)-α 
(5BVdU+IFN-α). Middle and bottom panels: neuronal cultures were incubated under the following conditions: 
(1) uninfected, (2) infected with HSV-1 and 5BVdU + IFN-α for 7 days (“HSV-1+5BVdU+IFN-α”), (3) infected 
with HSV-1 and cultured with 5BVdU+IFN-α for 7 days, then drugs were removed from culture medium, and 
infected cells were further cultured for 5 days in neurobasal medium alone (“withdrawal of 5BVdU+IFN-α”), (4) 
infected with HSV-1 and cultured with 5BVdU+IFN-α for 7 days, then drugs were removed from culture 
medium, and infected cells were further cultured for 5 days in neurobasal medium with sodium butyrate (NaB) 
(“reactivation with NaB”). The relative fraction of enhanced green fluorescent protein+/ red fluorescent protein+ 
cells in each condition is shown (middle panel, right). Viral titer in the supernatants from the culture plates was 
measured using Vero plaque assays (bottom panel, left). Microphotographs in the bottom panel, right, show the 
effects of adding supernatants from the original cultures to fresh neuronal cultures (label to left of each 




Participants. HSV-1 exposure was significantly more prevalent among schizophrenia 
cases (HSV1+ = 13, HSV1− = 6) than healthy controls (HC; HSV1+ = 6, HSV1− = 17; χ2 = 
7.53, df = 3, P = .006), but the mean age (schizophrenia, 27.44 ± 9.87 years; HC, 26.38 ± 6.78 
years, t = 0.41, P = .4) and gender (schizophrenia, M/F 10/9; HC, M/F 8/15, χ2 = 1.35, df = 3, P 
= .25) distribution did not differ significantly across diagnostic groups or by serological status 
(all P > .4). Although the SES of schizophrenia patients (27.03 ± 8.76) was significantly lower 
than the HC (41.59 ± 9.01) (χ2 = 5.28, P < .001), it did not differ by HSV-1 status in the 
case/control groups. 
Letter n-Back Task. The overall sensitivity of performance (d′) was 2.95, with no 
significant differences across diagnostic or serostatus groups. The response time of 0-back 
(schizophrenia, 676.94 ± 121.25 ms; HC, 627.38 ± 192.77 ms; Wald χ2 = 4.01, df = 1, P = .045) 
and 1-back (schizophrenia, 795.31 ± 181.15 ms; HC, 712.57 ± 275.82 ms; Wald χ2 = 5.94, df = 
1, P = .015) showed diagnosis effect but not HSV-1 status or diagnosis-by-serostatus interaction 
effects. The 2-back task response time showed a trend for the main effect of diagnosis 
(schizophrenia, 895.29 ± 504.43 ms; HC, 825.64 ± 276.44 ms; Wald χ2 = 2.9, df = 1, P = .088) 
and HSV-1 status (HSV1+ = 986.74 ± 527.78 ms; HSV1− = 712.39 ± 438.30 ms, Wald χ2 = 
3.45, df 1, P = 0.06) and diagnosis-by-HSV1 status interaction (Wald χ2 = 3.6, df = 1, P = .058). 
There were no significant main effects of diagnosis, HSV-1 status or diagnosisby-HSV1 status 
interaction on accuracy of performance. Besides, we did not observe either diagnosis or HSV1 
status effect on mean response times or accuracy between each level of task across the groups. 




Figure 17.  Gene expression analysis in acutely and quiescently infected neurons. 
 
BOLD Response Differences (FIGURE 18) 
Main Effect of Task, Diagnostic Status, and HSV-1 Status. Task Main Effect The task 
main effect was noted in the prefrontal (BA 10, 45 and anterior cingulate gyrus,), posterior 
The heat map represents statistically significant (P ≤ .05), differentially expressed genes after one-way ANOVA 
analysis and Benjamini-Hochberg correction applied. Columns represent individual samples (each group n = 3); 
selected genes are represented in rows. Upregulated genes are shown in yellow, and downregulated genes are 
shown in purple. Right: Ingenuity Pathways Analysis of acutely and quiescently infected neuronal cultures. 
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parietal cortex (BA 40), occipital and insular cortices for the 1-back, and the prefrontal (BA 8 
and 10), posterior parietal (BA 40), occipital and inferior temporal cortices for the 2-back, but 
not for the 0-back task where only the occipital cortex (BA 17 and 18) showed increased 
activations. 
HSV-1 Main Effect A significant effect of HSV-1 exposure was noted in the prefrontal 
and subcortical regions for the 1-back (BA 8) and 2-back (BA 6, 8, left thalamus, substantia 
nigra, and red nucleus), but not for the 0-back. 
Diagnosis Main Effect 0-back did not show diagnosis main effect. We observed 
diagnosis main effect for 1-back in the inferior parietal lobule (BA 40), and for the 2-back task in 
the superior temporal gyrus (STG, BA 42, 22), and the right cuneus, but not in the prefrontal 
regions at the combined intensity and spatial extent threshold used here. 
Diagnosis-by-HSV-1 Interactions A significant interaction was noted in the left superior 
parietal lobule (BA 7, F = 16.30, P = 3.02 × 10−4) for the 0-back, but not for the 1-back and 2-
back tasks. 
Associations with HSV-1 Status. The t tests to investigate directionality of effects showed 







Table 3.  fMRI Results with Contrasts. 
 
Note: BA, Brodmann area; fMRI, functional magnetic resonance imaging; HC, healthy control; 
HSV1, herpes simplex virus, type 1;SZ, schizophrenia. 
 
aBA 9 and 10 was significant when the cluster size was reduced to 1343 voxels that 
corresponded to corrected P < .06. All other regions were examined at cluster size of 1385 that 











(A) Combined schizophrenia and healthy control sample. Herpes simplex virus, type 1 (HSV1)+ show greater 
activation compared with HSV-1− subjects in the substantia nigra, the red nucleus, and thalamus.  (B) HSV1+ 
schizophrenia subjects show increased activation in bilateral red nucleus and substantia nigra compared with 
HSV1− schizophrenia subjects. (C) Increased activation in the prefrontal and parietal regions among HSV1+ in 
controls compared with HSV1− controls. (D) HSV1+ schizophrenia subjects showed decreased BOLD responses 
in the anterior cingulate regions compared with HSV1+ HC. (E) HSV1− schizophrenia subjects showing 
increased BOLD responses in bilateral superior temporal gyri. Increased activation in the prefrontal Brodmann 
areas 9 and 46 showed a trend (corrected P = .06). 
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Combined Schizophrenia and HC Controlling for Diagnostic Status HSV-1 exposure was 
associated with increased BOLD responses in the prefrontal and subcortical regions for the 1-
back (BA 6, 8, 32, thalamus) and 2-back (BA 6, thalamus, substantia nigra, and red nucleus) 
tasks, but not for the 0-back task where BOLD responses were increased mainly in the bilateral 
superior temporal gyri (BA 42, 22, and 40) (Table 3). BOLD responses for 1-back task was 
elevated nearly 2.5-fold in the thalamus (t = 2.5, P = .016) among HSV1+ compared with 
HSV1− subjects. For the 2-back task, HSV1+ subjects showed 3-fold increase in BOLD 
responses compared with HSV1− within the substantia nigra, thalamus, and red nucleus cluster (t 
= 3.9, P = .0003; Table 3). 
BOLD Responses Within and Across Schizophrenia/HC Groups, Grouped by Serological 
Status. Within schizophrenia subjects, HSV-1 exposure was associated with increased BOLD 
responses in the BA 6, and the red nucleus, the substantia nigra, the left parahippocampal regions 
for 1-back and 2-back tasks, respectively (Table 3). In contrast, HSV-1–exposed HC showed 
increased BOLD responses in the anterior cingulate gyrus (BA 24 and 32), prefrontal (BA 6, 9), 
and temporal cortices compared with HSV1− HC. The BOLD responses were decreased in the 
anterior cingulate region (BA 24 and 32) and BA 6 among HSV1+ schizophrenia subjects 
compared with HSV1+ HCs for the 2-back task. schizophrenia-HC comparisons among HSV-1–
negative individuals showed increased BOLD responses in schizophrenia subjects in the anterior 




The iPSC-derived neurons recapitulate lytic HSV-1 infection and can be induced into a 
quiescent, persistent, reactivable infection. Like established animal models, quiescent infection is 
accompanied by reduced viral replication, retention of the viral genome in the nucleus, lack of 
infectious virions, expression of LATs (Kosz-Vnenchak et al., 1990; Matthews et al., 1993; Liu 
et al.2000; Kramer et al., 2003; De Clercq, 2005; Margolis et al., 2007; Giordani et al., 2008; 
Bloom et al., 2010; Nicoll et al., 2012) in neurons. Quiescent infection was not observed in 
NPCs. During lytic infection, microarray analyses showed extensive changes in cognition-related 
pathways, such as glutamate and cAMP response element-binding protein (CREB) signaling. 
Fewer changes occurred in quiescent infection, but they too included cognition-relevant 
glutamate receptor and ion channel genes. We therefore propose a model in which persistent 
infection occurs in brain neurons similar to that in sensory ganglia, and over time impairs 
neuronal function (suggested by altered gene expression) without producing florid encephalitis; 
the altered function may underlie observed cognitive deficits. The relatively high sensitivity of 
NPCs to HSV-1 infection also suggests that individuals infected in childhood can experience 
cognitive impairment secondary to altered NPC proliferation and differentiation (Regnell et al., 
2012) suggesting the neurodevelopmental implications of HSV-1 exposure. This model needs to 
be tested and immunological/ glial responses explored; simultaneous in vitro and MRI studies in 
the same persons may also be worthwhile. 
The fMRI results suggest increased processing time for working memory performance 
associated with schizophrenia and HSV-1 exposure. The 2-back mean response time showed a 
trend toward significance for the diagnosis, HSV-1 status, and diagnosis-by-HSV-1 exposure 
interaction, with nonsignificant differences in accuracy of performance. fMRI data mainly 
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showed increased BOLD responses among both schizophrenia and HSV-1–exposed individuals 
suggesting that an increased neurobiological effort in the prefrontal cortex (PFC), posterior 
parietal cortex, hippocampus/parahippocampus, thalamus, substantia nigra, and superior 
temporal lobes is needed to achieve accuracy of working memory performance comparable to 
unexposed participants. Notably, the HSV-1-exposed individuals showed BOLD responses in the 
midbrain regions and thalamus. The trigeminal nucleus that receives neuronal inputs from the 
trigeminal ganglion is situated close to the red nucleus and substantia nigra, and projects to the 
thalamus. Increased BOLD response in these regions raises the possibility of altered dopamine 
transmission among HSV-1–exposed subjects. The increased activation in the STG is notable 
since this region is markedly affected during HSV-1 encephalitis (Steiner et al., 2007). HSV-1–
exposed HC showed activation differences in the classical working memory network that include 
prefrontal cortex and posterior parietal cortex, whereas HSV-1–exposed schizophrenia subjects 
recruited regions outside this network (substantia nigra where dopamine neurons are situated, red 
nucleus, thalamus, and superior temporal gyrus) to perform at the same level as HC. Besides, 
HSV-1-exposed schizophrenia subjects showed similar prefrontal activations compared to HSV-
1 unexposed schizophrenia subjects while performing on par with them, possibly by recruiting 
other networks involving STG and subcortical structures. 
Some shortcomings should be noted. Though functional (D'Aiuto et al., 2012), the iPS-
derived neurons cannot completely recapitulate the milieu interior of the human brain. The fMRI 
studies did not show diagnosis effects at the PFC; possibly reflecting inadequate power since 
lowering the statistical threshold to P < .06 corrected for intensity and spatial extent shows 
diagnosis effect. Because HSV-1 virions are usually undetectable in serum (Steiner et al., 2007), 
HSV-1 exposure was indexed through serum antibody assays in the fMRI studies. 
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In conclusion, HSV-1 induces quiescent infection in human iPSC-derived neurons that 
resembles animal models of latent infection. The fMRI studies indicate increased hemodynamic 
responses during working memory challenge among HSV-1–exposed individuals without prior 
encephalitis. We propose specific testable cellular and other models for the published HSV-1–
associated cognitive dysfunction. 
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3.4 ADDITIONAL VIROLOGICAL ASSAYS 
In order to further characterize our model of HSV-1 latency, additional experiments were 
performed for Aim 1a: (i) to assess the time course of change in viral DNA copy number in host 
cells and viral titers in the supernatant; (ii) to evaluate nuclear localization of viral genomes 
during lytic and quiescent infections. 
In addition, to further characterize our model of HSV-1 latency, additional experiments 
were performed for Aim 1b: (iii) to investigate viral DNA chromatin accessibility to MCN at 
viral gene promoters during lytic and quiescent HSV-1 infections; and (iv) evaluate the 
association of heterochromatin protein-1 (HP1) to the viral genome in lytically infected cells. 
3.4.1 Rationale of proposed experiments 
3.4.1.1 Rationale of Experiment 1:  qPCR assay to determine viral copy number 
Viral DNA copy number was estimated by qPCR in acutely and latently infected iPSC-
neurons and during viral reactivation.  Furthermore, productive infection for the aforementioned 
conditions was analyzed.  To rule out the possibility that the antiviral compounds 
(5BVdU+IFNα) used to establish quiescence in iPSC-neurons could have adverse effects on the 
earliest events of infection, two additional conditions were evaluated:  i) human iPSC-neurons 
were pretreated with 5BVdU+IFNα for 24 hours and then infected with HSV-1 for 2 hours in the 
presence of these antivirals; and ii) human iPSC-neurons were infected with HSV-1 for 2 hours 
in the absence of 5BVdU+IFNα.  The cells infected with a viral construct carrying the reporter 
genes EGFP and RFP under the control of viral promoters (Ramachandran et al., 2008).  The 
HSV-1 viral DNA copy number was quantified as described in section 3.1.7 (FIGURE 19). 
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3.4.1.2  Rationale of Experiment 2:  Fluorescent in situ hybridization (FISH) to evaluate the 
sub-nuclear compartments containing viral DNA during models of HSV-1 infection in 
iPSC-neurons 
We employed 2D FISH to further evaluate our models of HSV-1 infection.  In a time-
course experiment, we evaluated the progression of viral infection in Vero cells (FIGURE 20).  
The cells were infected at an MOI=1 and blocked for FISH at the indicated time points.  In iPSC-
neurons, the same FISH technique was performed on a 24-hour lytic infection, quiescently-
infected cells, and cells that were induced for viral reactivation.  Given our inability to detect 
quiescent viral genomes by the original FISH protocol (FIGURE 21), we adopted a three-
dimensional (3D) FISH technique (Cremer et al., 2007) with modifications (FIGURE 22).   
A FISH procedure was optimized for infected cells that were not affixed to microscope 
slides.  The original FISH procedure was carried out on cells that were in suspension (FIGURE 
23).  We evaluated the efficiency of this protocol to provide alternate methods of viral readout. 
3.4.1.3  Rationale of Experiment 3:  Evaluating the association of heterochromatin protein-
1 (HP1) with the viral genome in lytically infected cells using Co-ICC/FISH 
HSV-1 infected cells were evaluated for patterns of heterochromatin by utilizing 3D 
FISH paired with immunocytochemistry (Co-ICC/FISH; FIGURE 24).  FISH was performed on 
Vero cells (MOI=1) and human iPSC-neurons (MOI=0.3) that were infected with HSV-1 for 24 
hours with a probe that is complementary to the HSV-1 genome.  Next, ICC was performed on 
the same cell preparations using an anti-HP1α mouse monoclonal antibody (heterochromatin 
protein-1 alpha).  HP1α binds with H3K9me3, an indicator of transcriptional gene silencing, and 
is associated with heterochromatic structures (Jacobs et al., 2001). 
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3.4.1.4 Rationale of Experiment 4:  CHART-qPCR to investigate chromatin accessibility of 
viral gene promoters to MCN during lytic and quiescent HSV-1 infections 
This technique quantifies nuclease accessibility across the genome, by digesting DNA not 
bound to histone complexes and then amplifying with locus-specific promoters. Briefly, the cells 
were harvested, the nuclei were extracted, and then distributed evenly into 5 tubes.  MCN was 
added to each tube in increasing concentrations (0.5, 1.0, 3.0, and 5.0 units).  One sample was 
treated only with nuclease digestion buffer.  Samples were incubated for 20 minutes at 39° C.  
DNA was then extracted from the samples and identical amount of DNA (5ng) were used for 
quantitative PCR assays. 
The host loci encoding rhodopsin (RHO) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were chosen for controls.  RHO served as a locus that is less accessible to the 
micrococcal nuclease (MCN), as it is expressed primarily in ocular tissues.  GAPDH, a 
housekeeping gene, served as a locus that is accessible to MCN.  If the underlying DNA is 
protected from MCN digestion, more intact DNA will be available to be amplified in the qPCR 
(RHO); however, if the DNA is not protected, the nuclease will digest and result in poor qPCR 
amplification (GAPDH; FIGURE 25).  By taking the difference of Ct values of the digested and 
undigested, the ∆Cq value (quantification cycle) can be determined (∆Cq= Ct(-MCN) – 
Ct(+MCN)).  The viral loci include amplifying a region of the promoter for i) immediate early 
gene ICP4, ii) immediate early gene ICP27, iii) late gene glycoprotein C, and iv) the latency 
associated transcript (LAT).  In iPSC-neurons, the promoters for the control and viral genes were 
analyzed at 8-hour lytic infection and a 7-day quiescent infection (FIGURE 26).  The 8-hour 
time point was chosen to eliminate analyzing secondary or tertiary infections that occur during a 
full 24-hour cycle. 
 110 
3.4.2 Results of proposed experiments 
3.4.2.1  Results for Experiment 1:  qPCR assay to determine viral copy number 
Viral copy number was assessed in iPSC-neurons under several experimental conditions 
(FIGURE 19, left panel).  Following the 2 hour adsorption time, we observed no statistical 
difference in viral copy number when infecting in the absence or the presence of 5BVdU+IFNα 
(p=0.2092).  The mean viral copy number for HSV-1 at 24 hours post infection was 212,163 
copies in 5 ng of total DNA extracted from the neurons.  After exposing the infected cultures to 
5BVdU+IFNα for 7 days, the mean viral copy number was 1,743 copies.  After sodium butyrate 
was applied to induce reactivation on quiescent cultures, the mean viral copy number increased 
to 81,039 (p=0.00506).  The number of infectious viral particles released from these cells was 
later estimated using the plaque assay on Vero cells (FIGURE 19, right panel).  No plaques were 
observed in any condition, with the exception of HSV-1 incubated for 24 H (mean plaque 
forming units per milliliter was 48,667) and Reactivation (5D; mean plaque forming units per 
milliliter was 27,333).  Each group was tested for homogeneity of variance using Levene’s test 
and found they had unequal variance, thus we tested for differences in group means using an 




Figure 19.  Viral DNA copy number in iPSC-neurons (left) and corresponding plaque assays of virions 
produced in the supernatant titrated on Vero cells, shown in PFU/ml (right). 
3.4.2.2  Results for Experiment 2:  Fluorescent in situ hybridization (FISH) to evaluate the 
sub-nuclear compartments containing viral DNA during models of HSV-1 infection in 
iPSC-neurons 
The 2D FISH protocol was able to detect signals for HSV-1 gDNA in the lytic infection 
in Vero cells (FIGURE 20) and iPSC-neurons (FIGURE 21).  Following a lytic HSV-1 infection 
in Vero cells, the viral genome was observed to replicate in distinct compartments in the nucleus 
as indicated by FISH probes (12 hours post infection, FIGURE 20).  As infection proceeds, these 
replication compartments merge and completely occupy the interior of the nucleus (24 + hours 
post infection, FIGURE 20). 
When using the 2D FISH protocol, numerous FISH hybridization signals were observed 
in the nuclei of acutely infected iPSC-neurons (MOI=0.3); conversely, no FISH signals were 
The following groups of human iPSC-neurons were assayed:  i) uninfected cells; ii) cells infected for 2 hours 
(“HSV-1_2H”); iii) cells infected for 24 hours (“HSV-1_24H”); iv) cells infected in the presence of 
5BVdU+IFNα for 2 hours (“quiescence_2H”); v) infected cells cultured in the presence of 5BVdU+IFNα for 7 
days (“quiescence_7D”); vi) infected cells cultured in the presence of 5BVdU+IFNα for 7 days followed by 
treatment with sodium butyrate to induce viral reactivation for 5 days (“Reactivation_5D”). 
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observed in quiescently infected iPSC-neurons. (FIGURE 21).  Upon treatment with sodium 
butyrate for 5 days the hybridization pattern was similar to what was observed in the acutely 
infected cells (FIGURE 21).  To circumvent our inability to detect quiescent HSV-1 genomes 
using our 2D FISH procedure, we used 3-dimensional (3D) FISH.  With this protocol, we were 
able to detect viral genomes in our model of latent HSV-1 infection in iPSC-neurons, as well as a 
24-hour lytic infection (FIGURE 22). 
Additionally, we performed FISH in suspension on Vero cells following a 24-hour 
infection (MOI=1.0; FIGURE 23).  The protocol provided the groundwork to utilize FISH for 




Figure 20.  FISH on HSV-1 (strain KOS) infected Vero cells. 
 
Cells were infected at MOI=1 and analyzed by 2D FISH at the indicated time points. The probe signal is shown 
in red.  Nuclei are counterstained with Hoechst 33342 (blue).  Scale bar is 5 µm. 
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Figure 21.  Location of HSV-1 genomes (strain KOS) in iPSC-neurons with lytic infection, quiescent infection, 
and reactivation by FISH analysis. 
 
 
The probe signal is shown in red. Nuclei were counterstained with Hoechst 33342 (blue).  Scale bar is 5 µm. 
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Figure 22.  Location of HSV-1 genomes in lytically (left) and quiescently (right) infected neurons (strain KOS) 




Figure 23.  FISH in suspension performed on HSV-1 infected Vero cells. 
 
A 3D FISH analysis was performed on iPSC-derived neurons that were acutely infected for 24 hours (left) or a 7-
day quiescent infection (MOI=0.3). The probe signal is shown in green in the merged images. Nuclei were 
counterstained with Hoechst 33342.  The scale bar is 5 µm. 
FISH in suspension that was performed on Vero cells following a 24-hour infection with HSV-1 (strain KOS; 
MOI=1) utilizing the viral gDNA as a probe (green).  Nuclei are counterstained with Hoechst 33342 (blue).  The 
scale bar is 5 µm. 
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3.4.2.3 Results for Experiment 3:  Evaluating the association of heterochromatin protein-1 
(HP1) with the viral genome in lytically infected cells using Co-ICC/FISH 
FISH (using a probe that was complementary to the viral genome) was combined with 
immunocytochemistry (Co-ICC/FISH) using an anti-heterochromatin protein-1 (HP1α) mouse 
monoclonal antibody.  HP1α binds with H3K9me3, an indicator of transcriptional gene 
silencing, and is associated with heterochromatic structures (Jacobs et al., 2001).  Co-localization 
of these signals may indicate the heterochromatizined viral genomes.  In Vero cells, substantial 
overlap of HP1 was not observed with the viral DNA (FIGURE 24, left).  However, acutely 
infected iPSC-neurons showed differing overlapping signals (yellow) from HP1 (green) and the 
viral DNA (red; FIGURE 24, right).  Although the presence of overlapping signals may indicate 
binding of HP1 protein with some viral genomes, this needs careful evaluation using confocal 
microscopy, which will provide 3-dimensional resolution that is not evident in this thesis. 
 
 
Figure 24.  Co-ICC/FISH on HSV-1 infected cells. 
Vero cells (left) and human iPSC-neurons (right) were infected with HSV-1 (strain KOS) for 24 hours at 
MOI=1.0 and 0.3, respectively.  FISH was performed using HSV-1 gDNA as a probe (shown in red) and ICC 
was performed using an anti-HP1α mouse monoclonal antibody (shown in green; Millipore, catalog 05-689).  
Nuclei are counterstained with Hoechst 33342 (shown in blue).  The scale bar is 5 µm. 
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3.4.2.4 Results for Experiment 4:  CHART-qPCR to investigate chromatin accessibility of 
viral gene promoters to MCN during lytic and quiescent HSV-1 infections 
In iPSC-neurons, CHART-PCR was performed following an 8-hour HSV-1 infection and 
a 7-day quiescent infection (MOI=0.3).  Control genes showed different levels of MCN 
accessibility: the RHO promoter was less accessible than the GAPDH promoter (∆Cq was 
estimated at 0.63 and 7.37, respectively; FIGURE 25).  The viral gene promoters of ICP27, 
glycoprotein C, and EGFP (that is under the control of ICP0 promoter) showed higher 
accessibility to MCN during acute HSV-1 infections (∆Cq was estimated at 2.18, 1.80, and 2.63, 
respectively) when compared to quiescent infections (∆Cq= 0.94, 0.90, and 1.17, respectively; 
FIGURE 26).  LAT and ICP4 promoters showed higher MCN accessibility in quiescent 
infections (∆Cq was estimated at 1.93 and 2.05, respectively) when compared to acute infection 






Figure 25.  CHART-PCR performed on lytically infected human iPSC-neurons.  
 
iPSC-neurons were infected with HSV-1 viral construct expressing reporter genes EGFP and RFP under the 
control of viral promoters for 8 hours (MOI=0.3).  Following MCN digestion and DNA extraction, real-time 
qPCR was conducted using primers specific to promoter regions of host genes.  Left, RHO, as a control for a 
transcriptionally silent gene in iPSC-neurons, is minimally susceptible to nuclease degradation (∆Cq was 
estimated at 0.63), compared with Right, housekeeping gene GAPDH (∆Cq was estimated at 7.37). 
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Figure 26.  CHART-PCR performed on human iPSC-neurons amplifying viral gene promoters. 
iPSC-neurons were acutely infected with HSV-1 viral construct expressing reporter genes EGFP and RFP under 
the control of viral promoters for 8 hours (MOI=0.3) and quiescently infected with HSV-1 for 7 days (MOI=0.3).  
Following MCN digestion and DNA extraction, real-time qPCR was conducted using primers specific to 
promoter regions of viral genes.  MCN accessibility was determined by calculating the difference of the 
undigested DNA and the digested DNA (∆Cq).  Error bars represent the standard deviation of the ∆Cq values. 
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4.0  AIM 2.  ANTIVIRAL SCREENING AND GROUNDWORK FOR MODERATE 
THROUGHPUT DRUG SCREENING 
The primary goal is to identify drugs that potentially have a different mechanism of 
action than currently available antivirals for HSV-1 infections.  The matter is acquiring urgency 
as viral resistance toward antivirals that target viral genes, such as viral DNA polymerase, viral 
DNA replication, or the helicase has been repeatedly documented (Burrel et al., 2013; Dropulic 
& Cohen, 2010; Malvy et al., 2005; Stránská et al., 2005).  In immunocompromised individuals 
or organ transplant recipients, the frequency of viral reactivation of an antiviral-resistant virus is 
significantly higher compared with immunocompetent individuals, and can lead to devastating 
outcomes.  Therefore, identifying small molecules with a novel mechanism of action will be part 
of our goal.  Additionally, there is no drug directed toward the latent form of HSV-1.  By using 
iPSC-neurons and the HSV-1 models of infection previously outlined, we tested molecules for 
antiviral effects and inhibition of reactivation from latency. 
In order to enable a moderate throughput screening campaign for anti-HSV-1 compounds 
we propose scaling-up our efforts to generate a robust and cost-effective cellular platform.  Drug 
screening campaigns require: (i) generation of large numbers of neurons in a multi-well culture 
system and (ii) meaningful readouts to test drug efficacy. 
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Sections 4.1 and 4.2 will cover two peer-reviewed manuscripts that detail our initial 
efforts to screen small compound libraries in HSV-1 infected human iPSC-neurons for antiviral 
effects i) using molecules that were previously reported to have lysosomotropic activities and ii) 
using novel, naturally occurring alkaloids derived from the Amaryllidaceae plant family.  Section 
4.3 follows these studies and details the groundwork required to culturing iPSC-neurons in 96- 
and 384-well culture plates and viral readout methods, which may be used in future studies to 
agnostically screen compounds for antiviral effects. 
 
Aim 2a.  Generation of culture plates containing homogeneously distributed human 
iPSC-neurons in monolayer fashion. 
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Herpesvirus infections cause considerable morbidity and mortality through lifelong 
recurrent cycles of lytic and latent infection in several tissues, including the human nervous 
system. Acyclovir (ACV) and its prodrug, the current antivirals of choice for herpes simplex 
virus (HSV) and, to some extent, varicella zoster virus (VZV) infections are nucleoside 
analogues that inhibit viral DNA replication. Rising viral resistance and the need for more 
effective second-line drugs have motivated searches for additional antiviral agents, particularly 
non-nucleoside based agents. We evaluated the antiviral activity of five compounds with 
predicted lysosomotropic activity using conventional and human induced pluripotent stem cell-
derived neuronal (iPSC-neurons) cultures. Their potency and toxicity were compared with ACV 
and the lysosomotropic agents chloroquine and bafilomycin A1. Out of five compounds tested, 
micromolar concentrations of 30N12, 16F19, and 4F17 showed antiviral activity comparable to 
ACV (50 μM) during lytic herpes simplex virus type 1 (HSV-1) infections, reduced viral DNA 
copy number, and reduced selected HSV-1 protein levels. These compounds also inhibited the 
reactivation of ‘quiescent’ HSV-1 infection established in iPSC-neurons, but did not inhibit viral 
entry into host cells. The same compounds had greater potency than ACV against lytic VZV 
infection; they also inhibited replication of human cytomegalovirus. The anti-herpetic effects of 
these nonnucleoside agents merit further evaluation in vivo. 
4.1.2 Introduction 
Herpesvirus infections affect the vast majority of adults world-wide, with rates exceeding 
95% for human cytomegalovirus (HCMV) and varicella zoster virus (VZV), and up to 60% for 
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herpes simplex virus type I (HSV-1; Xu et al., 2006; Cannon et al., 2010). These viruses can 
infect an array of human tissues including the peripheral and/or central nervous system (CNS), 
causing severe CNS disease (Schmutzhard, 2001; Steiner et al., 2007). Currently, the list of FDA 
approved antiviral drugs is limited, particularly for HCMV or VZV (Strasfeld & Chou, 2010), 
moreover, the available drugs can produce serious adverse effects. Acyclovir (ACV) or its 
prodrug valacyclovir (VACV) are the most widely used agents for HSV-1 and VZV. Both drugs 
are processed to nucleoside analogues that are selectively activated in virus-infected cells and 
then block viral DNA replication. Resistance to ACV can develop from mutations in the viral 
thymidine kinase and/or DNA polymerase (Burrel et al., 2013), with incidence rates of 0.3–7.1% 
(Malvy et al., 2005; Stránská et al., 2005). Though some new antiherpetic drugs target the viral 
helicase and primase, viral resistance to these agents has also been reported (Kleymann et al., 
2002; Sukla et al., 2010). In addition, nephrotoxicity can occur following prolonged ACV 
treatment (Izzedine et al., 2005). Moreover, ACV is not clinically effective against HCMV. 
There is thus a compelling need to search for additional drugs to treat herpesvirus infections. 
Here, we report on novel anti-herpetic compounds that are based on non-nucleoside 
agents initially proposed to have lysosomotropic activities. Our studies were motivated by earlier 
reports indicating the efficacy of lysosomotropic drugs like chloroquine (CQ) and bafilomycin 
A1 (BFLA) in inhibiting HSV-1 infections (Harley et al., 2001). Lysosomotropic agents increase 
intracellular pH and presumably inhibit viral packaging and maturation through the trans-Golgi 
network, although their precise mechanisms of action against herpesviruses remain unclear 
(Nieland et al., 2004). In the present study, the in vitro efficacy of selected agents for HSV-1, 
VZV, and CMV infections was tested. We focused particularly on HSV-1, including analyses of 
lytic infection, as well as a model of ‘quiescent’ infection in human iPSC-derived neuronal cells 
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that mimics several aspects of HSV-1 latent infections (D'Aiuto et al., 2014). We report on three 
promising agents that appear to have a broader spectrum of activity compared with ACV. 
4.1.3 Materials and Methods 
4.1.3.1 Drugs 
Compounds 30N12, 16F19, 4F17 (95% purity), 16D20, and 17G7 (90% purity) were 
purchased from ChemBridge. CQ (≥98% purity), phosphonoacetic acid (PAA; ≥98% purity), and 
BFLA (≥90% purity) were purchased from Sigma. ACV (≥98% purity) was purchased from 





Figure 27.  Structure of compounds tested against herpesviruses. 
 
4.1.3.2 Cell lines and viral constructs 
Vero cells were maintained in Eagle’s minimum essential medium (EMEM) 
supplemented with 10% fetal bovine serum (FBS; HyClone) and 5% antibiotic/antimycotic 
(HyClone). VZV permissive human retinal pigmented epithelial cells (ARPE-19) were 
maintained in Dulbecco’s modified Eagle medium/F12 (DMEM/12) supplemented with 10% 
FBS (HyClone) and 5% antibiotic/antimycotic (HyClone). Human foreskin fibroblasts (HFF; 
ATCC, CRL-2088) were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 
10% FBS (HyClone). Human iPSC lines 73-56010-02 and HFF1-S were differentiated into 
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functional neurons (iPSC-neurons) as described (D'Aiuto et al., 2012). All cells were grown at 
37°C, 5% CO2, and 100% humidity. 
The HSV-1 strain was based on the KOS virus (VR-1493; ATCC). This recombinant 
virus expresses the enhanced green fluorescent protein (EGFP) from the ICP0 promoter, and the 
monomeric red fluorescent protein (RFP) from the glycoprotein C promoter (Ramachandran et 
al., 2008). The VZV construct, derived from an infectious Bacterial Artificial Chromosome of 
the whole VZV genome of the Parent of Oka strain, was engineered to express the luciferase 
reporter as a fusion to the VZV ORF9 protein, as described recently (Bayer et al., 2015). The 
human cytomegalovirus (HCMV) recombinant virus, derived from the Towne strain, was 
engineered to express the luciferase under the control of the viral pp28 gene promoter (He et al., 
2011). 
4.1.3.3 Viral infections 
To test the effects of the compounds during acute HSV-1 infection, cell-free virus was 
adsorbed onto cells for 2 hours (h) at a multiplicity of infection (MOI) of 1.0 for Vero cells and 
0.3 for iPSC-neurons. The inocula were removed, cells were washed with PBS, and medium was 
exchanged. Compounds 30N12, 16F19, 4F17, 16D20, and 17G7 (Nieland et al., 2004) were 
added 2 h post infection (hpi) at the concentrations indicated. Parallel cultures were pretreated 
for 24 h with CQ (50 μM) or BFLA (0.1 μM; (Joubert et al., 2009). As positive controls, cultures 
were pretreated with ACV (50 μM; (D'Aiuto et al., 2014) for 24 h or pretreated with PAA, a 
HSV-1 DNA polymerase inhibitor (300 μg/ml; (Blaho et al., 1993) for 1 h prior to the infection. 
We tested effects on HSV-1 attachment to the host cell membrane and host cell entry 
using a published protocol (Krepstakies et al., 2012); FIGURE 58). 
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To test the effect of the compounds on the HSV-1 reactivation, quiescence was 
established using (E)-5-(2-bromovinyl)-20-deoxyuridine + interferon alpha (5BVdU+IFN-α ; 30 
μM, 125 U/ml, respectively) for 7 days as reported (D'Aiuto et al., 2014). After this period, the 
quiescence-inducers were withdrawn, and iPSC-neurons were cultured for 48 h in the presence 
or absence of the test compounds. HSV-1 infection was then reactivated by treatment with 
sodium butyrate (NaB; 5 mM) for 5 days (D'Aiuto et al., 2014). The number of cells expressing 
EGFP and RFP was determined by flow cytometry (FC) on Fortessa FACS analyzer (Becton 
Dickinson). 
Inhibition of VZV was assessed on ARPE-19 cells, inoculated with 1000 PFU/well of a 
cell-associated high titer VZV stock for 2 h at 37 °C, in which >70% of cells were infected and 
infectious. Small molecules were added in the same manner as just detailed, and luciferase 
activities were assayed 48 hpi. 
Inhibition of HCMV was evaluated by cell-free virus infection adsorbed on HFF cells for 
90 min at MOI of 1.0, at which point, small molecule inhibitors were added in a manner as just 
detailed. Ganciclovir (5 μM) was used as control in all experiments. Luciferase activities were 
assayed 72 hpi. 
4.1.3.4  qPCR assays for viral DNA 
The EGFP sequence from the genetically engineered HSV-1 was utilized as the target for 
copy number analysis. Copy number qPCR was performed as previously reported (Kaufman et 
al., 2005), employing an EGFP plasmid standard curve, using 5 ng total DNA with biological 
and technical triplicates, along with corresponding non-template controls. The probe master mix 
had final concentrations of 18 μM EGFP forward primer (5’-ccacatgaagcagcacgactt-3’), 
18 μM EGFP reverse primer (5’-ggtgcgctcctggacgta-3’), and 5 μM                                
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probe (5’-6FAM-ttcaagtccgccatgcccgaa-TAMRA-3’). The reaction conditions were 
95°C for 3 min followed by 45 cycles of 95°C for 15s and 55°C for 30s, and finished with 72°C 
for 30s. All qPCRs were conducted on a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) and analyzed with manufacturer’s software SDS 2.4. 
4.1.3.5 Cytotoxicity assay 
The viability of iPSC-neurons following exposure for 24 h at different concentrations of 
compounds 30N12, 16F19, and 4F17 was assayed by FC using the LIVE/DEAD® Fixable Aqua 
Dead Cell Stain Kit (Life Technologies). The cytotoxicity analysis was also performed in ARPE-
19 cells as described for the iPSC-neurons, but the cells were incubated with the drugs for 48 h 
instead of 24 h. The drug-induced cytotoxicity in HFF cells used for HCMV infection was 
estimated using CellTiter-Glo Assay Kit following incubation with the drugs for 72 h. 
4.1.3.6 Statistical analyses 
Statistical analyses were conducted using the open source software R statistical package 
version 3.0.1, IBM SPSS v21, GraphPad Prism v5.02, and SigmaPlot. The drug concentration 
that reduced the number of fluorescent cells in cultures infected with HSV-1 or VZV by 50% 
(IC50) was estimated using the drc package in R (http://cran.r-
project.org/web/packages/drc/drc.pdf; version 2.3– 96); briefly, model fit was first assessed by 
comparison to an ANOVA model using an F-test. Then, a Box-Cox transformation to fit a 4 
parameter, log logistic model provided the best fit to the data (results not shown). The IC50 for 
HCMV was calculated from the dose response curve constructed by using SigmaPlot software. 
Statistical significance was calculated by first testing for equality of variance using Levine’s test, 
where two-tailed Student’s t-tests (where variances were not significantly different at a < 0.05) 
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or Welch’s t-tests (where variances were significantly different at a < 0.05) were conducted. Data 
used represent three independent experiments. 
4.1.4 Results 
4.1.4.1 Antiviral activity of new drugs on HSV-1 infection 
Vero cells 
Vero (green monkey kidney epithelial) cells were infected with HSV-1 at MOI of 1 for 
24 h in the presence or absence of the test compounds, as well as CQ, BFLA, and ACV 
(FIGURE 28a). FC analysis indicated that at 50 μM, compounds 30N12 and 16F19 displayed a 
90- and 73-fold reduction of EGFP+ cells, respectively, compared with a 22-fold reduction at the 
same concentration of ACV. Compound 4F17 (50 μM) produced a more modest 2.7-fold 
decrease, while 16D20 and 17G7 did not reduce HSV-1 infection substantially. The presence of 
infectious particles in supernatant of treated infected cultures was analyzed by a conventional 
plaque assay using Vero cells. Consistent with the FC analysis, infectious particles were 
undetectable in the supernatants of the cultures incubated with 30N12, 16F19, 4F17, CQ, BFLA, 
or ACV (FIGURE 28b), while infectious particles were detected in the supernatants from 
cultures treated with compounds 16D20 and 17G7. Thus, at 50 μM concentrations, 30N12 and 
16F19 showed greater potency than ACV. 
For both viral attachment and entry, no statistically significant reduction in viral DNA 
copy number was observed in cells treated with the test compounds compared to the untreated 




In view of the toxic effects of HSV-1 on neuronal cells, we employed iPSC-derived 
neurons (iPSC-neurons) to test the antiviral effect of the aforementioned compounds. iPSC-
neurons were infected with the HSV-1 construct at MOI of 0.3 and assayed at 24 hpi. FC 
analysis indicated that compounds 30N12 and 16F19 reduced fluorescent cells approximately 
20-fold (approximately 1% of EGFP+ cells in drug-treated cultures, versus over 20% in the 
control, drug-free cultures), similar to the inhibition caused by ACV, CQ or BFLA (FIGURE 
28c; all drugs at 50 μM except BFLA, which was 0.1 μM). Compound 4F17 resulted in a 6.3-
fold reduction of EGFP+ cells (3.3%; FIGURE 28c). Compound 17G7 resulted in a modest 2-
fold reduction of EGFP+ cells (9.9%; FIGURE 28c). Unlike CQ or BFLA, however, 
supernatants from cell cultures treated with 4F17, 30N12, or 16F19 produced no detectable 
infectious virus (FIGURE 28d). The patterns of effects produced by 4F17, 30N12, or 16F19 
were moderately correlated in Vero cells and iPSC-neurons, motivating further analyses of these 




Figure 28.  Comparison of inhibitory effects of test compounds on lytic HSV-1 infection. 
 
(a) Flow cytometry (FC) analysis of uninfected and HSV-1 infected Vero cells in the presence or absence of test 
compounds using HSV-1 expressing EGFP from an IE gene promoter and RFP from a late gene promoter. The 
fractions of cells showing fluorescence of the appropriate color are indicated. *p≤0.0019. (b) Plaque assays of 
virus produced in the supernatant of HSV-1 infected Vero cells titrated on Vero cells, shown as plaque forming 
units per milliliter (pfu/ml). *p≤0.0017. (c) FC analysis of uninfected and HSV-1 infected iPSC-neurons in the 
presence or absence of test compounds. *p≤0.026. (d) Plaque assays of virus produced in the supernatant of 
HSV-1 infected iPSC-neurons titrated on Vero cells, shown as pfu/ml. *p≤0.045. The data represent an average 
of three independent experiments. CQ: chloroquine (50 μM); BFLA: bafilomycin A1 (0.1 μM); ACV: acyclovir 





The IC50 concentration of 30N12, 16F19, and 4F17 in iPSC-neurons was 9.27, 0.42 and 
41.35 μM, respectively (FIGURE 29a). The IC50 of ACV in iPSC-neurons is 0.27 μM (FIGURE 
56). 
4.1.4.2 Cellular toxicity 
At concentrations up to 50 μM, 30N12, 16F19, or 4F17 caused less than 50% reduction 
in iPSC-neuron viability, precluding estimation of their therapeutic index (FIGURE 29b). At 
higher concentrations, compound 30N12 showed mild cytotoxicity at 100 and 500 μM (viable 
cells: 74.5% ± 4.95% and 67.1% ± 0.808%, respectively). Compound 16F19 produced relatively 
mild cytotoxicity at 100 μM (viable cells: 75.7% ± 2.05%), but substantially higher effects at 500 
μM (viable cells: 38.6% ± 0.723%). Compound 4F17 did not show significant cytotoxicity at 




Figure 29.  Antiviral efficacy and cytotoxicity of 30N12, 16F19, and 4F17 against HSV-1. 
4.1.4.3 Effects on HSV-1 DNA copy number in iPSC-neurons 
Next, we analyzed HSV-1 copy number using quantitative PCR (qPCR) to investigate 
whether these compounds alter HSV-1 DNA replication. HSV-1 DNA copy number was 
estimated in acutely infected iPSC-neurons 24 hpi, using the EGFP sequence in the HSV-1 viral 
construct as a probe. In 5 ng of total DNA, the number of copies of viral DNA were as follows: 
HSV-1 infected, untreated iPSC-neurons (3,461,970), 30N12 (1,664), 16F19 (48,530), 4F17 
(561,665), PAA (924), and ACV (483; FIGURE 30). Fluorescence in situ hybridization (FISH) 
analyses were consistent with the qPCR results: similar to ACV or PAA, a substantial reduction 
in viral DNA copy number was observed in infected cells treated with 30N12, or 16F19, and to a 
(a) Efficacy of varying drugs concentrations against HSV-1 lytic infection; FC performed 24 hpi. (b) 
Neurotoxicity of 30N12, 16F19, and 4F17 without HSV-1 infection was assessed by FC using fixable viability 
dye. The data represent an average of three independent experiments. Error bars represent (a) model-based 
standard error and (b) standard deviations. 
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lesser extent with 4F17, (FIGURE 53). Further, markedly reduced expression of the HSV-1 
immediate early genes ICP0 and ICP4 was observed in separate immunocytochemistry 





Figure 30.  qPCR assays for HSV-1 genome copy number in iPSC-neurons. 
 
4.1.4.4 Effects on reactivation of HSV-1 quiescent infection 
Based on protocols for rodent models of HSV-1 latent infection, we have proposed a 
model of quiescent HSV-1 infection in iPSC-neurons (D'Aiuto et al., 2014). Treatment with 
5BVdU + IFN-α causes a sustained reduction in the percentage of EGFP+ cells and 
EFGP+/RFP+ cells in HSV-1 infected iPSC-neurons; furthermore, HSV-1 can be reactivated 
Cells were infected with HSV-1 for 24 h in the presence or absence of test compounds (all at 50 μM). HSV-1 
copy number calculated in 5 ng total DNA. ACV: acyclovir, PAA: phosphonoacetic acid. *p≤0.015. Error bars 
represent standard deviations. 
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subsequently by incubation with sodium butyrate (NaB, 5 mM), a histone deacetylase inhibitor 
for 5 days (D'Aiuto et al., 2014). The pattern of infection, denoted ‘‘quiescent infection,’’ 
mimics several features of rodent latent infection models. In the present experiments, quiescent 
infection was induced with 5BVdU + IFN-α, the drugs were withdrawn, and cells were incubated 
for 48 h in the presence of the vehicle (DMSO) or test compounds. Subsequently, the infection 
was reactivated with NaB (5 days). FC analysis showed a 16-fold increase of EGFP+ cells and 
850-fold increase of EGFP+/RFP+ cells in vehicle treated cells (FIGURE 31a). Following 
incubation with 30N12, 16F19, 4F17, or ACV for 48 h, a more modest reactivation was 
indicated by lower levels of EGFP+ cells (8-, 6-, 6-, and 2-fold, respectively) or EGFP+/RFP+ 
cells (201-, 97-, 26-, and 17-fold, respectively; FIGURE 31a).  Compared to vehicle, treatment 
with ACV or test compounds also lowered the mean intensity of fluorescence (MFI; FIGURE 
31b). 
Consistent with these results, the supernatant culture medium from neuronal cultures 
treated with 5BVdU + IFN-α, followed by ACV or 4F17 had no detectable infectious viral 
particles, while treatment with 30N12 and 16F19 resulted in a 7.3- and 4-fold decrease in 
infectious virion production as compared to treatment with vehicle for 48 h (FIGURE 31c). 






Figure 31.  Effects of test compounds on reactivation of quiescent HSV-1 infection in iPSC-neurons.  
4.1.4.5  Effects on VZV and HCMV infection 
In the VZV permissive ARP19 line, infection with the VZV construct was monitored 
using luciferase activity. PAA effectively inhibited VZV infection, while ACV treatment caused 
a more modest 1.8-fold reduction at 50 μM. Incubation with 30N12, 16F19, and 4F17 resulted in 
60.3-, 548.2-, and 2.7-fold reduction in luciferase activity, respectively, at 50 μM (FIGURE 32a). 
At these concentrations, none of the drugs were cytotoxic for ARPE-19 cells (FIGURE 32b). The 
IC50 values for 30N12 and 16F19 were estimated to be 11.52 and 2.43 μM (FIGURE 32c). At 
the highest concentration tested, 4F17 and ACV produced less than 50% inhibition. 
FC was performed after reactivation of quiescently infected iPSC-neuronal cultures as described. (a) Percentage 
of fluorescent cells. *p≤0.027. (b) Mean fluorescence intensity (MFI). *p≤0.016. (c) Plaque assays of virus 
produced in the supernatant of reactivated cells titrated on Vero cells, shown as plaque forming units per 
milliliter (pfu/ml). *p≤0.002. The data represent an average of three independent experiments. 5BVdU: (E)-5-(2-
bromovinyl)-20-deoxyuridine, IFN-α: interferon alpha, NaB: sodium butyrate, vehicle: DMSO. Error bars 
represent standard deviations. ‘‘Qsc’’: Quiescent HSV-1 infection established by infecting iPSC-neurons with 
HSV-1 and then culturing in neurobasal medium containing 5BVdU + IFN-α for 7 days (See methods). ‘‘Qsc + 
vehicle or compounds (ACV, 4F17, 16F19, or 30N12); HSV-1 reactivation’’: 5BVdU + IFN-α were withdrawn 
and cells were cultured in the presence of vehicle or compounds for 48 h; HSV-1 was then reactivated by 




Figure 32.  Analysis of VZV infection. 
 
In permissive HFF cells infected with HCMV (MOI of 1), the IC50 and the concentration 
that reduced the HFF cell viability by 50% (CC50) for 4F17 were estimated at 8.85 and 123.68 
μM, respectively (selectivity index: 13.98; FIGURE 33). IC50 and CC50 were estimated for 
compounds 30N12 (10.4, 37.8 μM; selectivity index: 3.63) and 16F19 (4.1 μM, 12.3 μM; 
selectivity index: 3). However, both compounds exhibited a low selectivity index. 
 
(a) ARPE-19 cell lysates were assayed for luciferase activity following infection with VZV-ORF63fluc in the 
presence or absence of drugs for 48 hpi. LCPS: luciferase counts per second. *p≤0.013. (b) Cytotoxicity of the 
compounds in the absence of VZV in ARPE-19 cells. (c) Efficacy of 30N12, 16F19, and 4F17 at different 
concentrations; with the luciferase assay performed at 48 hpi. The data represent an average of three independent 
experiments. Error bars represent standard deviations. 
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Figure 33.  Anti-HCMV activity of 4F17. 
4.1.5  Discussion 
We assessed the potency and cytotoxicity of five novel non-nucleoside drugs for 
inhibiting infections with HSV-1, VZV, and CMV. Of these, compounds 30N12, 16F19, and 
4F17 inhibited lytic HSV-1 with potencies similar to ACV, CQ, and BFLA. Like ACV, these 
compounds also inhibited viral reactivation in iPSC-neurons with prior quiescent HSV-1 
infection. Furthermore, they were efficacious against VZV and compound 4F17 was also 
effective in vitro for HCMV infection. To our knowledge, these antiviral effects have not been 
reported before. 
(a) Dose response of HCMV inhibition based on luciferase expression. (b) Cellular toxicity in non-infected HFF 
cells as determined by Cell- titer GLo assay. The data represent an average of three independent experiments. 
Error bars represent standard deviations. 
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The mechanism of action of these drugs is unknown. The present investigations were 
motivated by the reported efficacy of lysosomotropic agents like CQ and BFLA against lytic 
HSV-1 infection (Harley et al., 2001). It was hypothesized that the antiviral activity of CQ and 
BFLA is due to increase in the pH of the trans-Golgi network (TGN) and endosomes–organelles 
that are critical for HSV-1 egress (Johnson & Baines, 2011). As the test compounds were 
previously reported to interfere with Golgi-to-cell surface traffic (Nieland et al., 2004), we 
predicted that they would inhibit productive HSV-1 infection. Productive infection was indeed 
reduced by 30N12, 16F19, and 4F17. In addition, these agents also reduced the proportion of IE-
expressed EGFP+ cells, with concomitant reduction in MFI. Further, FISH analyses also 
indicated a substantial reduction in viral DNA load (FIGURE 53). Several recent reports have 
strongly implied that, at least for HSV-1, viral entry may utilize the endosomes in some cell 
types (Döhner et al., 2002; Nicola, et al., 2005; Harkness, et al., 2014). It is unlikely these 
lysosomotropic compounds may affect HSV-1 entry in Vero cells and neurons, as all the drugs 
were added to cell cultures 2 h after HSV-1 infection, when most of the nucleocapsids are 
expected to be transported to the nuclear membrane; further, viral entry was previously reported 
to be pH-independent in neurons (Nicola et al., 2005). These compounds do not appear to affect 
viral attachment and entry (FIGURE 58). Taken together, these results indicate that 30N12, 
16F19, and 4F17 exert their antiviral effects by influencing one or more stages of the early phase 
of the HSV-1 lytic cycle and late stages of infection. Although our data clearly indicate that 
30N12, 16F19, and 4F17 efficiently block events at or before DNA replication, the exact stage of 
the block remains to be determined. While our analyses suggest that these compounds reduce IE 
gene expression consistent with earlier reports, the repression may be a secondary effect of 
multiple rounds of replication (Park et al., 2013; Pierce et al., 2005; Zambrano et al., 2008). 
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The patterns of the effects on HSV-1 infection may differ between the compounds. For 
example, the IC50 for 1619 is 10- to 100-fold lower than the other compounds, the slope of the 
dose response curve is more gradual, and the values are more variable. This suggests a different 
mechanism of action compared with 30N12 and 4F17. Indeed, 16F19 may have multiple targets 
in Vero cells, although it is not possible to identify them at present. 
The spectrum of antiviral activity of these compounds is also noteworthy. 30N12, 16F19, 
and 4F17 inhibited lytic VZV infection with greater potency than ACV (FIGURE 32a). These 
compounds also effectively inhibited HCMV infection; however, 30N12 and 16F19 showed a 
low selectivity index. It is not known whether the mechanisms of action against VZV and 
HCMV are similar to their effects against HSV-1 infection. It is likely to be different at least for 
16F19, as the IC50 curve for this compound is typical, in contrast to a more complex effect 
against HSV-1 (FIGURE 32). 
In summary, we identified three non-nucleoside compounds with potent antiviral effect 
comparable to that of ACV against HSV-1. Consistent with prior reports of relatively low 
efficacy of ACV against VZV vis a vis HSV-1 infection (Iwayama et al., 1998), the test 
compounds showed a higher potency than ACV against VZV, at concentrations that produced 
relatively low cellular toxicity. In addition, HCMV infection was inhibited effectively. The 
selective activities for individual herpesviruses suggest the agents have different mechanisms of 
activity, or influence cellular processes that are more important for one herpesvirus over another. 
Further studies are needed to investigate the underlying mechanism/s accounting for the antiviral 
activity of these compounds. 
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The Amaryllidaceae alkaloid trans-dihydrolycoricidine 7 and three analogues 8−10 were 
produced via asymmetric chemical synthesis. Alkaloid 7 proved superior to acyclovir, the 
current standard for herpes simplex virus, type 1 (HSV-1) infection. Compound 7 potently 
inhibited lytic HSV- 1 infection, significantly reduced HSV-1 reactivation, and more potently 
inhibited varicella zoster virus (VZV) lytic infection. A configurationally defined (3R)-
secondary alcohol at C3 proved crucial for efficacious inhibition of lytic HSV-1 infection. 
Herpes simplex virus, type 1 (HSV-1) is a ubiquitous DNA virus from the Herpesviridae 
family that causes substantial human morbidity and mortality (Kinchington et al., 2012). With 
seropositivity rates exceeding 70% in elders, it causes recurrent cold sores, corneal infection, 
blindness, and, rarely, encephalitis (Kinchington et al., 2012). It establishes latent infection in 
sensory neurons that is refractory to clearance, producing an intractable lifelong reservoir that 
cycles with lytic infections. Though acute HSV-1 infection is readily treatable with nontoxic 
nucleoside analogues such as acyclovir (ACV), no drug successfully eliminates the latent 
infection. In addition, growing ACV drug resistance has further fueled the search for novel 
antivirals (Burrel et al., 2013).  
Plants of the Amaryllidaceae family produce numerous structurally diverse, biologically 
active alkaloids (Evidente et al., 2009; Jin 2013). In particular, alkaloids of the lycorane subclass 
including lycorine 1, pseudolycorine 2, pancratistatin 3, its 7-deoxy analogue 4, and the 
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unsaturated derivatives narciclasine 5 and deoxy analogue 6 have demonstrated a variety of 
antiviral activities (FIGURE 34) (Gabrielsen et al., 1992; Hwang et al., 2008; Ieven et al., 1982; 
Li et al., 2005; McNulty & Zepeda-Velázquez, 2014; Renard-Nozaki et al., 1989; Vrijsen et al., 
1986; Zou et al., 2009). The restricted availability of other natural lycorane-type alkaloids and 
the absence of a rapid synthetic route toward structural analogues has impeded further 
development of the antiviral pharmacophore. 
 
 
Figure 34.  Structure of antiviral Amaryllidaceae alkaloids. 
 
The development of synthetic strategies that allow rapid access to functionally dense, 
stereochemically defined cores not only enables the asymmetric synthesis of biologically active 
natural products, but opens synthetic entry to non-natural analogues. These analogues expand the 
structural diversity available for biological assessment facilitating the discovery of previously 
unknown effects, improving our understanding of the structural requirements for such biological 
activity.  
Alkaloids 1−7 are natural products. Compounds 7−10 were accessed via total synthesis. Lycorine 1, 
pseudolycorine 2, pancratistatin 3, 7- deoxypancratistatin 4, narciclasine 5, 7-deoxynarciclasine 6, trans- 
dihydrolycoricidine 7, 3-epi-trans-dihydrolycoricidine 8, and 3-deoxy- trans-dihydrolycoricidine 9. 
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We recently reported the total asymmetric synthesis of trans- dihydrolycoricidine 7 
employing a convergent, stepwise organocatalytic [3 + 3]-Michael-aldol annulation of 
substituted acetone derivative 13a onto functionalized cinnamaldehyde 12 (McNulty & Zepeda-
Velázquez, 2014), catalyzed by diarylprolinol ether 11 (TMS = trimethyl- silyl). This crucial step 
allows for the asymmetric entry to functionalized, nitrogen-substituted cyclohexanes, in one step, 
and could be conducted at gram scale. In this case (McNulty & Zepeda-Velázquez, 2014),
compound 14a was converted to alkaloid 7 in a short sequence of subsequent transformations 
involving epoxidation and 2,3- diaxial diol installation, FIGURE 35).  
Figure 35.  Scheme 1a. 
In order to extend the [3 + 3]-Michael-aldol methodology to obtain more oxygenated 
cyclohexane derivatives directly, we have now investigated the reaction of 12 with the 
nonsymmetrical 1,3-disubstituted benzoyloxy-azidoacetone derivative 13b (FIGURE 35). To our 
delight, this reaction was found to proceed in a highly regioselective fashion with the initial 
Asymmetric organocatalytic Michael-aldol [3 + 3]-cycloaddition reaction of cinnamaldehyde derivative 12 and 
azido-acetone derivatives 13a allows a one-step access to stereochemically defined cyclohexanol 14a permitting 
rapid asymmetric entry to natural alkaloid 7, while reaction of 13b leads to 14b, permitting access to C3-
epimeric and deoxy analogues 8, 9, and 10. 
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Michael-addition being fully directed by the azido group, allowing a direct entry to cyclohexanol 
14b. The complex cyclohexane product 14b was obtained directly as a precipitate that formed 
during the reaction in 73% isolated yield and did not require chromatographic purification. The 
reaction also proved to be highly diastereoselective (dr = 96%) with the major diastereomer 
being essentially homochiral (>99% ee). The relative and absolute stereochemistry of this major 
cycloadduct was determined as α-benzyloxy at C3 as shown in 14b. This data was confirmed by 
single crystal X-ray analysis of the 4-bromobenzoate analogue 15 (see FIGURE 36 and 
Supporting Information in Appendix D). 
With rapid access to compounds of the C3-epimeric series now available (in comparison 
to natural products 3−7), we converted 14b to compound 8, the C3-epimer of natural product 7, 
as shown in FIGURE 36. Catalytic hydrogenation of the azido group and in situ protection as the 
methoxycarbonylamino ketone 16 was successfully achieved from 14b using 
dimethoxydicarbonate (DMDC). The ketone 16 was subjected to axial hydride reduction and the 
desired C4-equatorial alcohol protected alongside the C2-axial hydroxyl group to give the 
orthogonally protected triol 18. Cyclization of 18 was achieved using the Banwell modification 
of the Bischler−Napieralski reaction to give 19 with high regioselectivity (no minor diastereomer 
detected), which was now deprotected to give the target molecule 8. 
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Figure 36.  Scheme 2a. 
Access to compound 8 was exceedingly efficient given the one-pot asymmetric entry to 
the azido-cyclitol 14b and high yields obtained in conversion to 8 as shown in FIGURE 36. The 
C3-deoxy analogue 9 and the acyclic intermediate 10 were now prepared via a similar [3 + 3]-
Michael-aldol annulation of azidoacetone 13 and cinnamaldehyde derivative 12, as outlined in 
Supplemental Schemes 1 and 3 in Appendix D. 
Reagents and conditions: Yields of isolated products (%) are indicated. (a) 13b (1.00 equiv), 12 (1.05 equiv), 11 
(10 mol %), quinidine (10 mol %), CH2Cl2, −10 °C → RT, 73%. (b) DMDC (3.0 equiv), H2, 10% Pd/C (0.075 
equiv), EtOAc, 50 psi, RT, 79%. (c) Me4NHB(OAc)3 (4.0 equiv), AcOH (10.0 equiv), MeCN, RT, 90%. (d) 
AcCl (100 equiv). (e) Tf2O (5.0 equiv), DMAP (3.0 equiv), CH2Cl2, 0 °C → RT, 73%. (f) K2CO3 (0.10 equiv), 
H2O/MeOH 9:1, RT, 81%. DMDC = dimethyl dicarbonate, Tf = triflic, DMAP = 4- dimethylaminopyridine, 
Moc = methyloxycarbonyl. 
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With synthetic access to the natural alkaloid 7, C-3-epimer 8, C-3-deoxy analogue 9, and 
acyclic compound 10 now on-hand and, in conjunction with natural products 3 and 5, we 
proceeded with their antiviral assessment. 
Based on an earlier report showing the anti-HSV-1 activity of alkaloids derived from 
Amaryllidacea (Renard-Nozaki et al., 1989), we initially evaluated the efficacy of compounds 3, 
5, 7, 8, 9, and 10 against HSV-1 infection. We employed a genetically engineered HSV-1 
construct, incorporating enhanced green fluorescent protein (EGFP) and red fluorescent protein 
(RFP) as reporter genes, whose expression is driven by the viral promoters ICP0 and 
glycoprotein C (gC), respectively (Ramachandran et al., 2008). ICP0 is an HSV-1 immediate 
early (IE) gene, while gC is expressed only after onset of viral DNA replication. Vero cells 
initially infected with HSV-1 at multiplicity of infection (MOI) 1 were cultured at 2 h 
postinfection (hpi) in media containing compounds 3, 5, 7, 8, 9, or 10 (10 μM) or ACV (50 μM). 
Flow cytometry analysis (FC) showed that the percentage of EGFP positive (EGFP+) cells in 
infected cultures exposed to 3, 5, and 7 was reduced 8.3-, 10.6-, and 19.6-fold, respectively, 
compared with un- treated, HSV-1 infected cultures 24 hpi (FIGURE 37a), while ACV caused 
4.3-fold reduction of EGFP+ cells. Productive infection, estimated in the culture supernatant by 
virus yield reduction assay using Vero cells 48 hpi was also suppressed in cell cultures treated 
with 3, 5, and 7 (10 μM), similar to ACV (50 μM) (FIGURE 37b). Conversely, compounds 8, 9, 
and 10 (10 μM) did not inhibit HSV-1 infection (FIGURE 37a); furthermore, these compounds 
did not suppress productive infection (FIGURE 37b). These results reveal a critical role played 




Figure 37.  Natural and synthetic Amaryllidaceae alkaloids selectively inhibit HSV-1 infection in Vero cells 
and iPSC-neurons.  
 
As humans are the natural hosts for HSV-1, and human neurons are the only known 
reservoir of HSV-1 infection, compounds 3, 5, and 7 were also tested in neurons derived from 
(a) Flow cytometry (FC) analysis of uninfected and HSV-1 infected Vero cells (MOI 1) 24 hpi. (b) Viral titer in 
Vero cell culture supernatants estimated with virus yield reduction assay using Vero cells 48 hpi. Plaques were 
not observed in cultures treated with compounds 3, 5, and 7. A very low titer was observed for ACV (33.3 
pfu/mL). (c) FC analysis of uninfected and HSV-1 infected iPSC-neurons (MOI 0.3) 24 h postinfection (hpi). (d) 
Viral titer in iPSC-neuronal culture supernatants estimated with virus yield reduction assay using Vero cells 48 
hpi. Plaques were observed only in cultures infected with supernatants deriving from untreated, infected neurons. 
Dimethyl sulfoxide (DMSO) is the vehicle. The data represent an average of three independent experiments. 
Error bars represent standard deviations. 
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human induced pluripotent stem cell (iPSCs) (D'Aiuto et al., 2012; D'Aiuto et al., 2014). iPSC- 
neuronal cultures were infected with the genetically engineered HSV-1 construct (MOI 0.3) and 
subsequently treated with 3, 5, 7, or ACV 2 hpi. FC analysis showed ∼62-, 69-, and 28-fold 
reduction in the percentage of EGFP+ cells in iPSC-neuronal cultures treated with 3, 5, and 7 (10 
μM) 24 hpi, respectively, while ACV caused more modest inhibition (∼8.5-fold at 50 μM; 
FIGURE 37c). Suppression of productive infection in iPSC- neurons treated with compounds 3, 
5, and 7 (10 μM) was also noted (FIGURE 37d).  
Next, using fluorescent in situ hybridization (FISH) we investigated whether the test 
compounds affected HSV-1 DNA replication in iPSC-neurons similar to ACV. FISH analysis of 
HSV-1 infected iPSC-neurons treated with 3, 5, 7 (10 μM), or ACV (50 μM) indicated no 
hybridization with HSV-1 DNA, whereas infected cells treated with 8, 9, or 10 (10 μM) showed 
numerous hybridizing signals, suggesting ongoing viral replication (FIGURE 59). Thus, 
compounds 3, 5, and 7 appear to exert an inhibitory effect on HSV-1 DNA replication like ACV. 
Since compound 7 is the simplest analogue from a functional and stereochemical perspective to 
exhibit these novel antiviral effects and is readily available through our total synthetic strategy, 
we selected it for further analyses (McNulty & Zepeda-Velázquez, 2014).  
iPSC-neurons were infected with HSV-1 as described above, and DNA was extracted 24 
hpi. Quantitative PCR (qPCR) analysis indicated dramatic reduction in viral DNA copy number 
in cells treated with 7 (over 1,800-fold reduction at 10 μM) and ACV (2,300-fold reduction at 50 
μM), compared with infected, untreated cells (FIGURE 59b). The HSV-1 immediate early gene 
ICP4 is essential for viral replication (Bates & DeLuca, 1998); therefore, we utilized RT-qPCR 
to test the expression of ICP4 and viral DNA polymerase 24 hpi in infected iPSC-neurons treated 
with 7 or ACV.  
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A substantial reduction in the expression of ICP4 and viral DNA polymerase was 
observed in iPSC-neurons treated with 7 (10 μM) and ACV (50 μM; FIGURE 59c). The 
reduction of ICP4 expression level was further confirmed by Western blotting (FIGURE 59d). 
Taken together, these results indicate that 7 influences one or more stages of HSV-1 lytic cycles 
at or before DNA replication. Alternatively, the reduced expression of IE genes and viral DNA 
polymerase with both drugs may result from the inhibition of multiple rounds of viral replication. 
As the drugs were added 2 hpi, it was unnecessary to test effects on viral entry. The 
concentration of 7 that caused a decrease in the percentage of EGFP+ cells by 50% (EC50) was 
estimated to be 0.10 μM, similar to ACV (EC50 = 0.07 μM; FIGURE 60a). At concentrations 
from 100 nM to 50 μM, 7 or ACV did not significantly affect iPSC-neuronal viability (FIGURE 
60b). 
Given the remarkable anti-HSV-1 activity of 7, we next investigated its effect on nonlytic 
HSV-1 infection. By adapting conventional rodent latency protocols, we have previously used an 
antiviral cocktail of (E)-5-(2-bromovinyl)-2′-deoxyuridine (5BVdU, 30 μM) + interferon-α (IFN-
α, 125 U/mL) for 7 days to induce “quiescent” infection in iPSC-neurons that mimics several 
aspects of HSV-1 latency (D'Aiuto et al., 2014).
  
As reported before, up to 5 days after 5BVdU + 
IFN-α were withdrawn, only low levels of productive infection were noted (FIGURE 38c), but 
HSV- 1 could be reactivated using sodium butyrate (NaB, 5 mM), a histone deacetylase inhibitor 
(D'Aiuto et al., 2014). Cells treated with 7 (10 μM) or 7 + IFN-α showed 2.9- and 2.1-fold 
greater increase, respectively, in the percentage of EGFP+ cells compared with 5BVdU + IFN-α 
treated cells after withdrawal of agents for 5 days (FIGURE 38a), but infectious viral particles 
were nevertheless undetectable in the supernatant harvested from any of the cells (FIGURE 38c). 
Unexpectedly, the EGFP mean fluorescence intensity (MFI) in cells treated with 7 or 7 + IFN-α 
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was approximately 1.6- and 2.5-fold lower than the 5BVdU + IFN-α treated cells, 5 days after 
the drugs were withdrawn (FIGURE 38b). Cells treated with 7 or 7 + IFN-α also differed from 
the 5BVdU + IFN-α treated cells following incubation with NaB; whereas the latter showed 
robust reactivation with respect to percentage of EGFP+ cells or EGFP MFI, cells treated with 7 
or 7 + IFN-α did not show significant reactivation (FIGURE 38a,b). Similarly, the proportion of 
EGFP-RFP+ cells and EGFP-RFP MFI were significantly reduced in cells treated with 7 or 7 + 
IFN-α after treatment with NaB when compared to the cells treated with 5BVdU + IFN-α 
(FIGURE 38a,b). Taken together, these experiments suggest that the repression induced by 7 or 





Figure 38.  Compound 7 significantly reduces HSV-1 reactivation and inhibits VZV lytic infection (a−c).  
To explore whether the antiviral effects of 7 extend beyond HSV-1, we compared 7 and 
ACV against varicella zoster virus (VZV), another common herpes virus that causes chicken 
pox, shingles, and neuralgia (Smith et al., 2011). We used a VZV construct expressing luciferase 
Sodium butyrate (NaB) induces HSV-1 reactivation in quiescent neuronal cultures (QCs) but not in infected 
cultures treated with 7 or 7 + IFN-α. Quiescent neuronal cultures were produced by incubating iPSC-neurons 
with HSV-1 in the presence of 5-bromodeoxyuridine (5BVdU) and interferon-α (IFN-α). Cells were also 
infected with HSV-1 in the presence of 7 or 7 + IFN-α. After 7 days, drugs were withdrawn (wd) and cells were 
either cultured in the presence of NaB to induce HSV-1 reactivation or vehicle for an additional 5 days. (a) 
Percentage of EGFP+ and EGFP- RFP+ cells. (b) Mean fluorescence intensity (MFI) of EGFP+ cells and EGFP-
RFP+ cells. (c) Viral titer in culture supernatants estimated with virus yield reduction assay using Vero cells 48 
hpi. Indicated p- values for comparisons in panel b involving EGFP and EGFP-RFP are depicted in green and 
red, respectively. The data represent an average of three independent experiments. Error bars represent standard 
deviations. 
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from the late ORF9 promoter (Bayer et al., 2015). ARPE-19 retinal pigment epithelial cells were 
infected with VZV at 1000 PFU/ well. Compound 7 or ACV were added 2 hpi and assayed 48 
hpi. Compound 7 caused ∼220-fold reduction at 10 μM in luciferase counts per second and 
showed an EC50 of 0.15 μM, while ACV (50 μM) caused only 1.8-fold reduction (FIGURE 60c). 
No significant changes in cell viability were observed at tested concentrations for 7 and ACV 
(FIGURE 60d). 
Various antiviral activities of Amaryllidaceae alkaloids have been reported over the last 
three decades (Ieven et al., 1982). A comprehensive evaluation on the antiviral activity of several 
of these alkaloids revealed that pancratistatin 3, narciclasine 5, trans-dihydrolycoricidine 7, and 
its 7-hydroxy analogue were active against Japanese encephalitis, yellow fever, and dengue 
viruses (Gabrielsen et al., 1992). Antiviral activity of lycorine 1 against the avian influenza virus 
was recently reported (He et al., 2013). Lycorine can also inhibit other RNA-viruses, including 
severe acute respiratory syndrome (SARS)-associated coronavirus (Li et al., 2005), poliovirus 
(Hwang et al., 2008), and West Nile virus. The present work significantly expands knowledge on 
the antiviral activity of these alkaloids by identifying derivatives that exhibit novel, distinctive, 
and diverse inhibitory effects against HSV-1 and VZV infection that are superior to ACV. The 
facile method reported here for the rapid asymmetric synthesis of natural and non-natural 
lycorine-type alkaloids permitted discovery of a clear structure−activity pattern, demonstrating 
that a crucial role is played by the (3R)-hydroxy substituent in these alkaloids as a requirement 
for this antiviral activity. Only compounds 3, 5, and 7 containing the (3R)-stereochemistry 
demonstrate potent antiviral activity, the C3-epimeric compound 8 and C3-deoxy derivative 9 
are significantly less active. 
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This allowed identification of alkaloid 7 as a functionally minimum antiviral 
pharmacophore. Further applications on harnessing the iPSC-neuron based platform with 
additional pathogens with the current and additional analogues prepared through refinements on 
the synthetic protocol are under active investigation. Most importantly, as latent HSV-1 infection 
is lifelong and drug-refractory, the multiple effects of compound 7 on HSV-1 infection, 
including its ability to significantly reduce HSV-1 reactivation from quiescence, motivate 
additional studies of viral entry and viral heterochromatinization. Additional studies are needed 
to evaluate whether compound 7 alone or in combination with currently known antiherpetic 
drugs can repress HSV-1 irreversibly to confer protection of immunocompromised individuals 
who may be at risk for ACV-resistance (Antoine et al., 2013) or patients with renal failure. 
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4.3 GROUNDWORK FOR MODERATE THROUGHPUT DRUG SCREENING 
Generation of neuronal cultures in 384-well plates is condicio sine qua non start for a 
moderate or high throughput drug screening campaign aiming to identify novel compounds 
exhibiting antiviral activity able to inhibit HSV-1 lytic infection or inhibit viral reactivation from 
latency; therefore, we propose to i) generate human iPSC-neuron cultures in 384-well plates and 
ii) develop a sensitive and cost-effective read-out method for HSV-1 infections.  This section 
will describe these methods. 
4.3.1 IPSC-Neuronal Cultures for 384-Well Plates 
In Aim 1 (Section 3.2), we described a method for large-scale generation of neural stem 
cells/early neural progenitor cells (NSCs/eNPCs) from induced pluripotent stem cells (iPSCs) 
and their differentiation into neurons (iPSC-neurons; D’Aiuto et al., 2015).  Cultures displaying a 
high percentage of flat, non-neuronal cells were purified by a rapid and easy method as 
previously described (Azari et al., 2014) with modifications. 
4.3.1.1 Purification of NSCs/eNPCs 
In each well of a 6- well plate, the medium was aspirated and 500 µl accutase was added.  
Cells were observed under the microscope for a rounded-up morphology (approximately 90 
seconds).  One milliliter of DMEM/F12 (Lonza, catalog 12-719F) was added very slowly to the 
side of the wells, and then all the medium was carefully removed and discarded.  One milliliter 
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of mTeSR1™ cell culture medium was dispensed into each well, the edges were sealed with 
parafilm, and the plate was wrapped in aluminum foil to protect from light.  The plate was placed 
on a VWR OS-500 orbital shaker for 30 minutes on speed 4. 
The cells that detached during the 30-minute shake were collected and dispensed onto a 
new 6-well matrigel-coated plate.  The cells were propagated and mTeSR1™ medium changed 
daily.  Once the cells reached 80% confluency, cells were treated with accutase for propagation 
into a new matrigel-coated 6-well plate, or the medium was exchanged with neurobasal for 
neuronal differentiation (FIGURE 39). 
 
 
Figure 39. Schematic flow diagram to depict the stages of differentiation into neurons from induced 
pluripotent stem cells (iPSC). 
NSC: neural stem cells; eNPC: early neural progenitor cells.  Adapted from “Large-scale generation of human 
iPSC-derived neural stem cells/early neural progenitor cells and their neuronal differentiation,” by D’Aiuto et 
al., 2014, Organogenesis, p. 365-77. Copyright © 2014 Taylor & Francis Group, LLC. Adapted with permission. 
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4.3.1.2 Cell seeding 
Human iPSC-derived NSCs were cultured as reported (D’Aiuto et al., 2015) with 
modifications for NSC purification.  Purified NSCs were plated onto matrigel-coated 6-well 
plates and grown to approximately 80% confluency with mTeSR1™ cell culture medium.  The 
medium was exchanged to neurobasal medium for 4-6 weeks to enable neuronal differentiation.  
iPSC-neurons cultured in 6-well plates were dissociated using 1 ml accutase (ThermoFisher, 
catalog a11105-01) for 2-3 minutes.   The accutase was diluted by adding 1 ml of DMEM/F12 
and cells were very gently triturated by pipetting with a p1000 Pipetman.  The cell suspension 
was transferred into a 15 ml conical and centrifuged at 1,200 rpm for 5 minutes.  The supernatant 
was carefully removed and the cell pellet was gently disturbed by flicking the tube. The cells 
were re-suspended in neurobasal medium.  An aliquot of cells was removed for determining the 
cell count using a haemocytometer following trypan blue stain.  Cells were then seeded into a 
matrigel-coated 384-well plate at a density of 5,000 cells/well for lytic infections (FIGURE 40) 
or 20,000 cells/well for quiescent infections (FIGURES 47 and 48).  The plates were then 
centrifuged at 500 rpm for 30 seconds to deposit the cells to the bottom of the wells.  The plate 
was incubated in standard cell culture conditions. 
 
NOTE.  Since 384-well culture medium in cell culture plates tends to evaporate 
relatively quickly along the wells on the periphery of 384-well culture plates, the stack of plates 
were placed in a second, smaller water bath that was positioned on the bottom shelf close to the 
main water reservoir dish. 
 
 161 
The cells were cultured for a minimum of 7 days to recover from the transferring process 
and half-volume of neurobasal medium was replaced every other day using a multichannel 
pipette or Hydra 96-well liquid transfer machine.  The iPSC-neurons plated at a density of 5,000 
cells per well were immunostained for neuronal markers TUJ1 and MAP2 (FIGURE 41 and 42). 
4.3.2 384-Well Plate Infection 
4.3.2.1 Lytic Infections 
Lytic HSV-1 infections were performed at MOI = 5 for 2 hours using the HSV-1 viral 
construct incorporating reporter genes EGFP and RFP under the control of the promoters for 
ICP0 and gC, respectively (FIGURE 43).  Increased cell seeding densities used in the quiescent 
infection were also able to be acutely infected with HSV-1 (FIGURE 47 left). The antiviral 
compounds acyclovir (ACV 50 µM) or phosphonoacetic acid (PAA 300 µg/ml) were included as 
controls, and cells were pretreated as previously described (McClain et al., 2015). At 2 hours 
post infection (hpi), the inoculum was removed and replaced with either neurobasal or 
neurobasal with drug.  At 48 hpi, the medium was removed, the cells were washed with PBS, 
and fixed with 4% paraformaldehyde for 20 minutes.  Hoescht 33342 solution (1:1,000 in PBS) 
was added to the wells for 2 minutes to counterstain the nuclei.  Cells were washed twice with 
PBS, followed by addition of PBS (80 µl).  Plates were wrapped in aluminum foil to protect from 
light prior to analysis.  Fluorescent cells were analyzed using the ImageXpress Ultra (IXU) High 
Content imager with 20x objective.  Imaged cells were analyzed with Multiwavelength Cell 
Scoring application within the MetaXpress software at the University of Pittsburgh Drug 
Discovery Institute in collaboration with Dr. Mark Schurdak, Ph.D. 
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A parallel experiment was performed using a different virus (KOS, wild-type) at 
MOI=5.0 and imaged 48 hours post infection to evaluate reproducibility.  HSV-1 positive cells 
were detected by ICC utilizing an anti-HSV-1 ICP4 monoclonal antibody (Abcam, catalog 
ab6514; FIGURE 44). 
Small molecules that were previously tested for antiviral activity against HSV-1 by flow 
cytometry (McClain et. al., 2015; McNulty et. al., 2016) were also tested for anti-lytic activity 
using the high content imaging at the DDI.  Human iPSC-neurons were infected with KOS strain 
at MOI=5.0 and imaged 48 hours post infection.  Mode of detection was ICC utilizing an anti-
HSV-1 ICP4 monoclonal antibody (Abcam, catalog ab6514; FIGURE 45). 
4.3.2.2 Quiescent Infections 
The iPSC-neurons were pretreated with 5BVdU+IFNα (30 µM and 125 u/ml, 
respectively) for 24 hours.  The following day, cells were infected with an HSV-1 viral construct 
that expresses fluorescent reporter genes EGFP and RFP under the control of viral promoters 
ICP0 and glycoprotein C, respectively in neurobasal medium containing 5BVdU+IFNα 
(MOI=5.0).  The plate was centrifuged for 30 seconds at 500 rpm and the plate was returned to 
the incubator for 2 hours.  At 2 hours post infection, the infectious medium was removed and 
replaced with neurobasal medium supplemented with 5BVdU+IFNα.  Half the volume of 
medium was exchanged every other day for a total of 7 days.  The quiescent wells were 
monitored on a daily basis for indication of spontaneous reactivation, indicated by EGFP/RFP 
expression (FIGURES 46 AND 47 right). 
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4.3.2.3 HSV-1 Reactivation 
Following the induction of a 7-day quiescent infection, the quiescent inducing medium 
was removed, the cells were washed with DMEM/F12, and the reactivation was induced by 
culturing cells in the presence of sodium butyrate (NaB; 5 mM; an HDAC inhibitor) for 5 days. 
Alternative means of reactivation were investigated, which included the substitution of NaB with 
trichostatin A (TSA; 1 µM; an HDAC inhibitor) or LY294002 (PI3Ki; 20 µM; phosphoinositide 
3-kinase inhibitor; FIGURE 48).  To evaluate spontaneous reactivation in the absence of 5BVdU 
+ IFNα, withdrawal of these compounds was followed by culturing cells in regular neurobasal 
medium for 7 days (FIGURE 48). The cells were monitored on a daily basis for induced 
reactivation, indicated by EGFP/RFP expression and cytopathic effect. 
4.4 RESULTS FOR AIM 2 
4.4.1 Cell Seeding in 384-Well Plates 
Cells were titrated to obtain a monolayer culture of cells.  Seeding 5,000 cells per well 
yielded a monolayer culture of cells that recovered well and was able to be analyzed with the 
Multiwavelength Cell Scoring application within the MetaXpress software (FIGURE 40). 
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Figure 40.  iPSC-neurons plated in 384-well culture plates. 
4.4.2 Immunocytochemistry Analysis of iPSC-Neurons 
Immunocytochemisry (ICC) was performed on cells seeded in the 96- and 384-well 
plates for neuronal markers beta tubulin III (TUJ1) and microtubule associated protein-2 (MAP2) 
using an inverted fluorescent microscope (FIGURE 41), and using the ImageXpress Ultra (IXU) 
High Content imager at the DDI (FIGURE 42).  ICC analyses indicate expression of both 
proteins in cells plated on 96- and 384-well culture plates. 
 
iPSC-neurons were differentiated in 6-well matrigel-coated plates.  Following accutase treatment, cells were 
seeded into matrigel-coated 384-well plates at the following densities per well: 1,000; 3,000; and 5,000. 
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Figure 41.  Human iPSC-neurons cultured in a 96-well plate for 4 weeks’ differentiation. 
Cells were immunostained with neuronal markers beta tubulin III (TUJ1, left) and microtubule-associated 
protein-2 (MAP2, right).  Nuclei were counterstained with Hoechst 33342.  Images were acquired using Leica 
LAS AF.  Scale bar is 50 µm. 
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Figure 42.  Immunostaining of iPSC-neurons in 384-well plates with TUJ1 and MAP2.  
 
Cells were imaged using the ImageXpress Ultra (IXU) High Content imager with 20x objective.  Imaged cells 
were analyzed with Multiwavelength Cell Scoring application within the MetaXpress software at the University 
of Pittsburgh Drug Discovery Institute. 
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4.4.3 HSV-1 Infections in 96- or 384-Well Plates 
To test the robustness of the DDI analysis program to detect viral inhibition and to 
evaluate the readout method, iPSC-neurons were infected with either the HSV-1 viral construct 
that expresses EGFP and RFP reporter genes or with KOS wild-type virus in 384-well culture 
plates at MOI=5 for 48 hours (FIGURES 43 AND 44).  Immunocytochemistry was used to 
detect virally infected cells using an anti-HSV-1 ICP4 monoclonal antibody.  FIGURES 44 and 
45 show the effects of antiviral, acyclovir and viral DNA inhibitor, phosphonoacetic acid on a 
lytic HSV-1 infection.  Compounds that were previously tested for antiviral effects (McClain et 
al., 2015; McNulty et al., 2016) showed an anti-HSV-1 effect in the 384-well culture plates 
following a 48-hour infection (FIGURE 45). 
Next, the models of HSV-1 quiescence and viral reactivation were evaluated in human 
iPSC-neurons seeded in 96- or 384-well culture plates.  In 96-well plates, HSV-1 infected cells 
that were treated with 5BVdU+IFNα for quiescence resulted in an absence of EGFP and RFP 
expression; conversely, viral reactivation of HSV-1 in iPSC-neurons was evident following a 5-
day exposure to sodium butyrate, trichostatin A, or PI3K inhibitor (FIGURE 46).  In the 384-
well plates analyzed with the high content imaging at the DDI, lytic HSV-1 infection and 
quiescently-infected cells were observed (FIGURE 47) and quantified in addition to the 
aforementioned methods of viral reaction (FIGURE 48).  Compounds that function as histone 
deacetylase inhibitors (trichostatin A and sodium butyrate) produced more robust viral 
reactivation (FIGURE 48).  These findings were consistent with our previously reported data that 
used flow cytometry to detect EGFP-positive HSV-1 infected iPSC-neurons that were cultured in 
12-well plates (D’Aiuto et al., 2015). 
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Figure 43.  Inhibition of lytic infection with antiviral drugs using HSV-1 viral construct. 
 
Acyclovir (ACV; 50 µM; yellow) and phosphonoacetic acid (PAA; 300 µg/ml; blue) inhibit HSV-1 lytic 
infection (brown) at MOI = 5.0 on 384-well plates.  Cells were imaged 48 hours post infection for EGFP 
expression.  Untreated, uninfected neurons (gray) provide the basis of inhibition detection in 384-well plates, 
which is 3 standard deviations above its mean (gray dotted line).  The distribution of EGFP-positive cells is 
shown in the histograms.  The table below the histograms indicate the number of cells measured in each 
population (Count), the average (Ave), the median (Median) and the standard deviation (StdDev) of overall 
EGFP expression in the population. 
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Figure 44. Inhibition of lytic infection with antiviral drugs using HSV-1 KOS strain and 
immunocytochemistry. 
 
Cells were imaged 48 hours post infection.  Inhibitors Acyclovir (ACV; 50 µM; yellow) and phosphonoacetic 
acid (PAA; 300 µg/ml; blue) were used to inhibit HSV-1 lytic infection (KOS; MOI=5.0; brown).   Untreated, 
uninfected neurons (gray) provide the basis of inhibition detection in 384-well plates, which is 3 standard 
deviations above its mean (gray dotted line).  ICC was performed to detect HSV-1 positive cells using an anti-
HSV-1 ICP4 monoclonal antibody.  The distribution of ICP4-positive cells is shown in the histograms.  The 
table below the histograms indicate the number of cells measured in each population (Count), the average (Ave), 
the median (Median) and the standard deviation (StdDev) of overall ICP4 expression in the population. 
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Figure 45.  Novel compounds inhibit HSV-1 lytic infection. 
 
Human iPSC-neurons were infected with KOS strain at MOI=5.0 and imaged 48 hours post infection.  
Untreated, uninfected neurons (gray) provide the basis of inhibition detection in 384-well plates, which is 3 
standard deviations above its mean (gray dotted line).   ICC was performed to detect HSV-1 positive cells using 
an anti-HSV-1 ICP4 monoclonal antibody.  The distribution of ICP4-positive cells is shown in the histograms.  
The table below the histograms indicate the number of cells measured in each population (Count), the average 
(Ave), the median (Median) and the standard deviation (StdDev) of overall ICP4 expression in the population. 
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Figure 46.  Induced reactivation models of HSV-1 quiescently infected iPSC-neurons in a 96-well plate.   
 
 
Following the 7-day quiescent infection (HSV-1 expressing reporter genes for EGFP and RFP; MOI 5.0), the 
cells were exposed to sodium butyrate (NaB), trichostatin A (TSA), and PI3K-inhibitor (PI3Ki) for 5 days.  Cells 
were imaged on a Leica DM IL LED inverted, fluorescence microscope.  Scale bar is 50 µm. 
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Figure 47.  HSV-1 models of lytic and latent infection on iPSC-neurons seeded into 384-well culture plates.   
 
Human iPSC-neurons were infected (MOI=5) with HSV-1 viral construct that expresses reporter genes EGFP 
and RFP under the control of viral promoters ICP0 and glycoprotein C, respectively for 48 hours (left).  Human 
iPSC-neurons were quiescently infected for 7 days with HSV-1 (MOI=5; right). 
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Figure 48.  Alternate modes of HSV-1 reactivation analyzed with high content imaging.  
 
HSV-1 quiescence was induced in iPSC-neurons for 7 days and then removed.  The reactivation compounds 
were added for 5 days.  TOP. Histograms depicting the EGFP intensity in lytically infected cultures (black 
histogram), quiescently infected cultures (green histogram), HSV-1 reactivation from quiescence (blue 
histograms; NaB, PI3Ki, TSA, or withdrawal of quiescent-inducing compounds), and uninfected/untreated iPSC-
neurons (orange histogram).  BOTTOM:  Percentage of EGFP-positive cells (black) and EGFP-negative cells 
(gray).   The distribution of EGFP-positive cells is shown in the histograms.  The table below the histograms 
indicate the number of cells measured in each population (Count), the average (Ave), the median (Median) and 
the standard deviation (StdDev) of overall EGFP expression in the population. 
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5.0  DISCUSSION 
Research on human neurological diseases, neurodegenerative diseases, or neuroinvasive 
infections has previously been hampered by the inability to obtain sufficient amounts of human 
neurons to investigate pathogenesis or conduct drug screens in cultured cells.  Therefore, many 
groups relied either on animal models or on human post-mortem brain tissues.  Even such 
sources do not conveniently provide substantial quantity of neural tissue needed for drug screens.  
iPSC technologies have revolutionized this field of research by enabling virtually limitless 
supplies of iPSC-neurons that resemble human neuronal cells and related non-neuronal tissues.  
The utility of iPSC neurons for modeling and drug screens related to human HSV-1 infections 
was explored in the present thesis. 
In Aim 1a, I have described the generation of neural stem cells/early neural progenitor 
cells (NSCs/eNPCs) from human iPSCs using a method that is scalable, cost effective, and 
relevant for studying human-specific neurotropic viruses.  NSCs/eNPCs are mitotically active, 
multipotent stem cells that can be differentiated into large-scale quantities of neuronal cells.  The 
method eliminated previously reported steps of embryoid body generation, saving time and cost.  
The adherent cultures of NSCs/eNPCs was also favored over embryoid bodies as it enabled more 
uniform contact of each cell with the cell culture medium.  The use of B27 and BDNF in the cell 
culture medium resulted in a cell population that had 90% TUJ1 positive cells.  The neurons also 
expressed other neuronal markers like MAP2, VGLUT1, and NR1 (subunit of the glutamate 
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receptor).  A modest proportion of the cell population also expressed proteins that are found in 
layer 3 of pyramidal cells in the dorsolateral prefrontal cortex (DLPFC) in the human brain.  
These ‘iPSC-neurons’ express proteins found in human cortex tissues and have functional 
ligand-gated channels (D’Aiuto et al., 2014).  Furthermore, the iPSC-neurons express glutamate 
receptors (D’Aiuto et al., 2014), which are also found on neurons from the trigeminal ganglia 
and the CNS, the site of HSV-1 latent reservoirs (Lazarov, 2002). 
Further on in Aim 1a, the neuronal cells derived from human iPSCs were used to model 
lytic and latent HSV-1 infections with an HSV-1 viral construct that expresses two fluorescent 
reporter genes.  Neural progenitor cells (NPCs) and iPSC-neurons were permissive to HSV-1 
lytic infection.  HSV-1 quiescence was established in human iPSC-neurons with the use of 
antivirals (E)-5-(2-bromovinyl)-2-deoxyuridine and interferon-alpha (5BVdU+IFNα).  5BVdU 
is an analog of the nucleoside thymidine that shares a common mechanism of action as acyclovir 
(ACV).  IFNα is a signaling molecule that is secreted in virally-infected cells that promotes an 
‘antiviral state’ (Ivashkiv & Donlin, 2014).  Together, 5BVdU+IFNα act synergistically to 
inhibit HSV-1 infection in vitro and in vivo (van Bijsterveld et al., 1989).  In our models of HSV-
1 infection, these compounds were used to induce quiescence for a 7-day period of time.  The 
quiescently infected cells showed the following features of latent HSV-1 infections that have 
been described in other model systems. 
i) Viral replication is decreased:  Of the total population of cells, 9% expressed 
EGFP.  Upon withdrawal of the antiviral compounds, a ~3-fold increase in EGFP 
expressing cells were detected.  Further, qPCR assays indicated a marked 
reduction in mean viral copy numbers during quiescence when compared with 
lytic infections (1,747 and 212,163, respectively). 
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ii) Productive infection is absent:  The cell culture supernatants from the quiescent 
infections were used to infect fresh Vero cells, which failed to produce any 
plaques, indicating the absence of productive infection.  Withdrawal of the 
antiviral compounds resulted in a significant, continued suppression in infectious 
virions (1 plaque each in 3 wells of 9 examined). 
iii) Viral DNA is retained in the nucleus:  Quiescent viral genomes located in the 
nuclear periphery were detected as distinct foci of hybridization signals using 3D-
FISH; in acutely infected cells, these hybridization signals formed replication 
compartments closer to the interior of the host nuclei, which eventually merged to 
completely occupy the host nucleus. 
iv) Expression of LAT during infection:  The quiescently-infected neurons expressed 
LAT.  Interestingly, consistent with prior publications, LAT was also expressed at 
higher levels during lytic infection. 
v) Quiescent viral infections can be reactivated.  HSV-1 quiescent cultures were 
exposed to the histone deacetylase inhibitor sodium butyrate (Davie, 2003) to 
induce viral reactivation.  This resulted in a 2-fold and 6-fold increase of EGFP- 
and EGFP/RFP-positive cells, respectively.  Additionally, viral copy numbers are 
increased when compared with quiescent infections (81,039 and 1,747, 
respectively). 
vi) Quiescent genomes exist as a heterochromatinized fragment of DNA within host 
nuclei.  In acutely infected Vero cells, we did not observe co-localization of a 
protein associated with heterochromatin (HP1) with viral genomes, indicating that 
a substantial fraction of viral DNA does undergo heterochromatization.  The 
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pattern in acutely-infected iPSC neurons may show some co-localization.  
However, it could not be determined at this time for quiescently-infected iPSC 
neurons.  Fine-grain analyses of nuclease accessibility on promoter regions of the 
viral genome were performed with CHART-PCR.  Viral lytic gene promoters 
were more accessible to nuclease degradation during lytic infections, with the 
exception of ICP4.  LAT was more accessible to nuclease degradation during 
quiescent infections. 
 
During latency, LAT expression is commonly reported.  Mouse explant cultures that were 
latently infected showed LAT promoter genomic regions associated with H3K9 and H3K14 
acetylation, indicative of gene transcription (Kubat et al., 2004); however, LAT has been 
reported to be expressed late during infection cycles, in addition to latency (Spivack & Fraser, 
1988; Roehm et al., 2011; Ma et al., 2014).  In the iPSC-neuron cultures, we have reported LAT 
expression during both the quiescent infections, as well as a 24-hour acute infection.  During 
viral quiescence, there may be subpopulations of cells that show quiescent infection, others that 
are resistant to viral infection, or still others with lytic infection.  As our RT-qPCR assays used to 
derive LAT expression were performed on pools of cells, this question could be resolved through 
single-cell analysis.  In 2008, Umbach and colleagues described viral miRNAs originating from 
latently-infected mouse trigeminal ganglia that were antisense to viral genes ICP0 and ICP34.5 
(Umbach et al., 2008).  It would be instructive to see if the same miRNAs can be detected in this 
model of HSV-1 latency. 
The iPSC-neuron model of HSV-1 latency was further analyzed using copy number 
qPCR.  In Aim 1 of this thesis, we used several methods to evaluate viral infections.  Our 
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primary readout method using qPCR was to quantify the EGFP locus expressed in the genomes 
of the viral construct.  The standard curve was generated using an EGFP plasmid that was 
serially diluted.  The resulting standard curve had an R2 of 0.991, indicating the data points were 
a good fit with minor variation to the regression line.  The standard curve was similar to 
previously reported assays using qPCR-based means to estimate viral copy number (Cohrs et al., 
2000).  The uninfected Vero cells had a mean Ct of 38.407 (SD 0.306), which corresponded to a 
mean copy number of 15.41 (SD 7.54).  Thus, the lower detection limit of this assay was set to 
approximately 100 copies per 5 ng total DNA. 
To induce quiescence, the iPSC-neurons are pretreated with 5BVdU+IFNα for 24 hours 
prior to infection.  There was no significant difference in viral copy number when infecting 
iPSC-neurons in the presence or absence of 5BVdU+IFNα during the 2-hour adsorption period, 
indicating the compounds did not interfere with the earliest events of the viral lifecycle (p=0.21).  
A 7-day quiescent infection resulted in a decrease in viral copy number compared with a lytic, 
24-hour infection (1,743 and 212,163 in 5 ng of total DNA, respectively).  A moderate increase 
of viral copy numbers was observed when sodium butyrate was used to induce reactivation for 5 
days (81,038 copies in 5 ng of total DNA).  There was a statistically significant difference in the 
mean copy numbers of the lytic infection and in cells that experienced viral reactivation 
(p=0.005).  This may indicate i) some viral genomes are persisting in the quiescent state, even in 
the presence of sodium butyrate, ii) loss of cells that harbor quiescent genomes, or iii) aborted 
reactivation.  The corresponding plaque assay that quantified the presence of infectious viral 
particles was consistent with the copy number assays.  After the 2-hour adsorption period, 
acutely infected neurons (in the presence or absence of 5BVdU+IFNα) did not release infectious 
virions, but infectious particles were observed in a 24-hour lytic infection and viral reactivation 
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(48,667 PFU/ml and 27,333 PFU/ml, respectively).  The use of sodium butyrate has been 
previously used to induce viral reactivation in quiescently infected PC-12 cells (Danaher et al., 
2005); as well as in vivo mouse models of reactivation, where upwards of 75% of latently 
infected mice experienced viral reactivation (Neumann et al., 2007). 
Fluorescent in situ hybridization (FISH) was used as an additional method to evaluate the 
latency model.  Acutely infected Vero cells were blocked for FISH in a time course experiment, 
which showed the first reported hybridization signals at 12 hours post infection.  By 24+ hours, 
the viral genome occupied the majority of the interior of the nuclei whilst the host chromatin was 
displaced to the periphery.  Like acutely infected Vero cells, acute HSV-1 infections in neurons 
resulted in similar patterns of FISH probes at 24 hours post infection.  However, the method was 
not sensitive enough to detect quiescent viral genomes, even though the same inoculum was used 
to infect both the quiescently infected cells and the cells that experienced viral reactivation in 
that particular experiment.  Therefore, a 3D FISH method was optimized and used to detect viral 
genomes during quiescence.  During quiescence, the hybridization signals were observed as 
discrete foci at the host nuclear periphery, where transcription may be repressed, similar to a 28-
day latently-infected mouse model following TG sectioning (Catez et al., 2014).  The nuclear 
periphery is mostly considered a region of repressed transcription, however there is evidence 
some loci do transcribe if localized at the periphery (Deniaud & Bickmore, 2009).  This method 
may be applied to provide quantitative data if paired with flow cytometry, but must be optimized 
for cost-effectiveness and efficacy. 
Withdrawing the quiescence-inducing drugs resulted in low-level viral replication, 
possibly due to a few number of spontaneous reactivation events that spread to neighboring cells. 
The flow cytometry data indicate that ~25% of cells are expressing EGFP from the viral 
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immediate early promoter, but only a third of those are expressing RFP from a late gene 
promoter.  The plaque assays showed 1 each in 3 of 9 wells.  Together, these data suggest the 
viral remains latent in the majority of infected cells in the absence of 5BVdU+IFNα. 
A quiescent HSV-1 infection was not observed in NPCs, nor was it observed when 
infecting iPSC-neurons with the replication-defective virus, indicating both cell-type and virus-
strain specificities.  Using a replication defective virus (provided by Dr. Fred Homa), we hoped 
to avoid infecting neighboring cells (and thus potentially leading to lytic infection in other cells); 
however, quiescence could not be established using the same protocols.  Following the day of 
infection and in the presence of 5BVdU+IFNα, the cell cultures showed widespread necrosis and 
further culture of live cells was not possible.  The reasons for the toxic effects are uncertain.  
Further studies may be able to optimize the quiescent inducing conditions for this virus. 
In iPSC-neurons, microarray analyses show both the acute infection and viral reactivation 
caused altered gene expression, but consistent with other models of latency, the quiescently-
infected neurons show less extensive gene changes.  Pathway analyses show the top significantly 
functions affected during quiescent infection are axonal guidance signaling (p=5.21 x 10-4), 
complement system (p=8.74 x 10-4), and NFκB signaling (p=4.9 x 10-3).  Additional studies are 
needed to tease out the effects of a quiescent HSV-1 infection on neuronal function and survival. 
In latent infections, HSV-1 exists as an extrachromosomal fragment that is silenced, in 
part, by the formation of heterochromatin.  This was initially described by Deshmane and Fraser, 
who showed latent viral genomes are coupled with histones in a manner similar to host DNA 
(Deshmane & Fraser, 1989).  Therefore, in Aim 1b, I sought to analyze patterns of 
heterochromatin by utilizing 3D FISH paired with immunocytochemistry (Co-ICC/FISH) and 
performing CHART-PCR on viral gene promoters.  The ICC was specific for an anti-HP1α 
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monoclonal antibody and FISH probes were complementary to viral genomic DNA.  HP1α binds 
to trimethylated H3K9, an indicator of transcriptional repression (Jacobs et al., 2001).  In acutely 
infected Vero cells, substantial overlapping signals were not observed, indicating that a 
considerable fraction of viral DNA is not heterochromatinized.  In acutely infected iPSC-
neurons, overlapping signals were not as clear.  Co-localization of HP1 protein on viral genomes 
in quiescently infected cultures also proved to be technically challenging (data not shown).  The 
co-ICC/FISH protocol needs to be optimizing using confocal microscopy. 
CHART-PCR analyses indicated that host control gene promoters that are 
transcriptionally active (GAPDH) or transcriptionally repressed (RHO) were more and less 
susceptible to digestion by MCN, respectively.  In the qPCR assays of the digested samples, this 
resulted in low level amplification of GAPDH and when compared with the undigested sample, 
there was a mean difference in Ct values (∆Cq) of 7.37.  On the other hand, RHO was protected 
from the digestion of the nuclease and amplified similar to its undigested counterpart (∆Cq = 
0.63).  The difference in the resulting cycle threshold values was as expected for these control 
genes (Cruickshank et al., 2008).  In iPSC-neurons that were infected with HSV-1 for 8 hours, 
viral gene promoter regions that are active during acute infections were more accessible to MCN 
digestion during lytic infections than during quiescent infections, with the exception of ICP4.  
The EGFP locus (downstream of the promoter) was digested the most during lytic infections, 
indicating more permissive regions for MCN digestion (∆Cq was 2.63).  The promoter region for 
LAT and ICP4 were more accessible to MCN during quiescent infection (∆Cq was estimated at 
1.93 and 2.05, respectively) than during lytic infection (∆Cq was estimated at 1.07 and 0.88, 
respectively).  The HSV-1 genome incorporates seven clusters of sequences that are bound by 
CTCF (CCCTC-binding factor, a chromatin insulator protein) and partitions the genome into 
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distinct compartments of transcriptional permissiveness or repression (Bloom et al., 2010).  Each 
immediate early gene is bounded by these elements and may be regulated independently (Amelio 
et al., 2006).  In our model of HSV-1 latency, these CTCF proteins may block the spread of 
heterochromatin on the promoter region of ICP4.  In addition, the promoter region may be more 
accessible to MCN during quiescent infections because there may be insulating elements 
organized on the viral genome downstream of the promoter.  Alternatively, ICP4 may be 
transcribed.  Further analysis on this locus is needed.  Estimating levels of ICP4 mRNA by RT-
qPCR, as well as chromatin immunoprecipitation (ChIP) would be useful to gain further 
understanding of ICP4 heterochromatization and transcription during viral latency. 
In Aim 2, we tested novel compounds for antiviral effects and compared them with 
acyclovir.  These initial attempts to screen compounds yielded several promising results.  We 
sought novel compounds to combat viral resistance in individuals who are immunocompromised 
or the recipients of organ transplants.  We used conventional Vero cells, as well as human iPSC-
neurons to evaluate the antiviral effects.  Compounds 30N12, 16F19, 4F17, and R430 
(“compound 7”) inhibited lytic viral infections comparable to or better than acyclovir.  In lytic 
HSV-1 infections, these four compounds i) reduced viral DNA copy numbers, ii) reduced 
selected HSV-1 protein levels, and iii) inhibited productive infection.  Additionally, these 
compounds decreased sodium butyrate-induced HSV-1 reactivation. These compounds were also 
more efficacious against lytic varicella zoster virus (VZV) infections than acyclovir and 4F17 
inhibited lytic human cytomegalovirus infections.  Currently, the mechanism/s of action of these 
novel compounds is unknown. 
Three of these new antiviral compounds were reported in the literature to have 
lysosomotropic activities (Nieland et al., 2004).  Agents that were previously reported to have 
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lysosomotropic activity, like chloroquine (a drug used to treat malaria infections) or bafilomycin 
A1 were also reported to have antiviral activity on HSV-1 infections (Harley et al., 2001).  
Though the precise mechanism has not been elucidated, they may affect viral activities by 
increasing intracellular pH.  Increasing intracellular pH produces an inhibitory effect on the 
trans-Golgi network, and since the trans-Golgi network is critical for HSV-1 egress, these 
compounds may inhibit viral packaging or maturation in the trans-Golgi network (Johnson & 
Baines, 2011).  Compounds 30N12, 16F19, and 4F17 were previously reported to interfere with 
trans-Golgi trafficking, but were not tested for antiviral effects.  The inhibitory concentration of 
30N12, 16F19, and 4F17 that reduced the number of virally-infected iPSC-neurons by 50% was 
9.7 µM, 0.42 µM, and 41.35 µM, respectively.  Of the three compounds, 16F19 has an inhibitory 
concentration curve with a more gradual slope than the others.  It is likely this compound has 
more than one target, but the identity of these target(s) are unknown.  For all three compounds, 
the cytotoxic dose that reduces cellular viability by 50% could not be calculated.  The highest 
concentration of compound added to cells (500 µM) did not significantly reduce viability when 
testing uninfected, treated cells with LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life 
Technologies); however, 16F19 showed the most cytotoxicity at 500 M, where cell viability was 
decreased to 38%.  When testing cell viability with concentrations greater than 500 µM, partial 
product precipitation (data not shown) occurred.  As a result, accurate therapeutic indices could 
not be calculated. 
R430, the fourth compound with antiviral effects is the synthetic version of a naturally 
occurring alkaloid isolated from plants of the Amaryllidaceae family.  R430 (previously 
identified as “compound 7”) was chosen for anti-HSV-1 testing in our model system as prior 
studies report compounds from this family have inhibitory effects against other viruses.  The 
 184 
IC50 for R430 in HSV-1 acutely infected iPSC-neurons was 0.1 µM, which was very similar to 
the IC50 of acyclovir (0.07 µM).  Most interesting is the effect of R430 on viral reactivation.  
When R430 or R430+IFNα  was added to infected cells for 7 days and then withdrawn for 5 
days, it showed a 2.9- and 2.1-fold increased EGFP-positive cells than infected cells treated with 
5BVdU+IFNα for 7 days and then withdrawn for 5 days, however, the mean fluorescence 
intensity of each cell expressing EGFP was lower (p=0.49 for R430+IFNα).  We compared viral 
reactivation induced by sodium butyrate following a 7-day period of time where quiescence was 
induced with 5BVdU+IFNα or viral silencing with R430.  R430 reduced viral reactivation with 
statistically significant mean fluorescence intensity (p<0.0001).  The mechanism of viral 
silencing by R430 is distinct from 5BVdU+IFNα (McNulty et al., 2016). 
The precise mechanism of action for these four compounds is unknown at this time. 
Since the compounds were added two hours post infection, the inhibition reported here is not 
likely due to blocking viral attachment or entry.  I tested for the effects of compounds 30N12, 
16F19, and 4F17 on viral attachment and entry, but did not observe a statistical significance in 
the mean copy numbers of the groups when comparing infected, treated cultures with infected 
cultures alone.  Future studies are needed to determine the mechanism of action.  This work will 
include comparing cells treated or untreated with the aforementioned compounds using RNAseq 
or a proteomics approach (mass spectrometry).  Performing a pathway analysis may reveal 
candidate pathways that are affected by the compound; further fine-grain evaluation of the 
individual molecules in candidate pathways may lead to identifying the mechanism of action.  
Mass spectrometry may indicate intracellular proteins that specificall interact with these 
compounds.  In addition, future studies could include synthesizing pharmacophores based on 
these lead molecule hits and its respective mechanism of action; even minimal molecular 
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modifications may improve efficacy and decrease toxicity.  Broad spectrum compounds that 
operate with mechanism of action different than the current arsenal of antivirals are highly 
desirable, especially for individuals with drug-resistant HSV-1 infections.  Moreover, broad-
spectrum compounds could be very beneficial during acute fulminant infections in individuals 
before precise diagnoses can be established.  Further testing of other viruses and in vivo models 
of infections is warranted. 
To extend the small scale drug screens initiated in Aim 2, additional experiments were 
conducted to lay the groundwork for generating large numbers of neurons in multi-well culture 
plates and methods of readout.  In order to generate 96- or 384-well plates of human iPSC-
neurons, neural stem cells/early neural progenitor cells (NSC/eNPCs) were differentiated from 
iPSCs and purified to eliminate unwanted cell types.  The cells were then expanded and 
differentiated into iPSC-neurons in 6-well plates.  Following a 4- to 6-weeks period of 
differentiation, the cultures were dissociated with accutase and seeded into 96- or 384-well 
culture plates at a density of 20,000 or 5,000 cells per well, respectively.  These cells are TUJ1- 
and MAP2-positive, suggesting neuronal morphology.  We favored 5,000 cells per well since 
seeding less cells compromises the ability of the neurons to reform their complex neurite 
network with neighboring cells and seeding higher cell densities resulted in cell aggregation and 
the formation 3-dimensional structures, which introduced some error for the analysis software 
algorithm. 
The advantage of differentiating the NSC/eNPCs into neurons in the 6-well plates instead 
of directly into the 384-well plates was i) ease of changing cell culture medium; ii) the 6-well 
plates showed less evaporation of cell culture medium in the wells than cells cultured in 384-well 
plates; iii) cells could be counted prior to seeding into the 384-well plates to contain cell counts 
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that were consistent.  Our attempts to differentiate iPSC-neurons directly in 384-well plates 
resulted in greater well-to-well variability; however, the neurons differentiated well in these 
plates (data not shown) and were only limited for use by the software utilized to analyze the data.  
Current analysis algorithms rely on the use of imaging cells on a single, flat plane.  Future 
studies to reduce the well-to-well variability are needed to titrate NSC/eNPCs directly into the 
384-well culture plates and then differentiate them into neurons, as well as investigate new 
methods to analyze these cells. 
 Following the cell titration experiments, we optimized viral infections.  We tested two 
viruses with different methods of readout in virally infected iPSC-neurons.  We compared the 
HSV-1 viral construct that express reporter genes EGFP and RFP under the control of ICP0 and 
glycoprotein C, respectively with HSV-1 KOS wild-type virus.  The detection method for the 
KOS virus was immunocytochemistry (ICC) for the anti-HSV-1 mouse monoclonal ICP4 
primary antibody.  ICP4 is an immediate early viral protein that is abundantly expressed in 
lytically infected cells.  EGFP expression or secondary antibody fluorescence was detected for 
the viral construct and the KOS viruses, respectively.  We found the optimal condition for 
assessing lytic HSV-1 infections in the multi-well plates is a 48-hour infection at an MOI=5.  
Two readout methods for viral inhibition consistently produced similar results. 
The resulting histograms display all of the cell population where the dots represent 
outliers.  (FIGURES 43, 44, and 45). We based the detection of infection to be 3 standard 
deviations of the mean fluorescent intensity of the uninfected population.  In section 4.4.3., we 
found that either infection model is suitable to discriminate uninfected from acutely-infected 
iPSC-neurons.  Furthermore, after adding the antiviral drugs ACV or PAA, the levels of 
fluorescence detected is similar to the uninfected condition (mean nuclear fluorescence is 
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log(2.534), log(2.514), and log(2.533), respectively).  Some of the novel antivirals identified 
earlier in this work inhibited HSV-1 infection and were distinguishable from the acutely-infected 
iPSC-neurons on the 384-well plates; however, compound 4F17 showed some variance 
compared with the flow cytometry readouts (~1-fold and 6.3-fold, respectively).  Quiescent 
HSV-1 infections and viral reactivation was observed in these culture plates, albeit at a higher 
cell density (20,000 cells per well in the 384-well plate).  Inducing reactivation with histone 
deacetylase inhibitors produced the most robust reactivation in both 96-and 384-well plates and 
future studies using adenovirus to supply ICP0 may provide alternate means to reactivate these 
virally infected cultures (Halford et al., 2001). 
Given the need for reproducibly generate cell culture plates with low variability (well-to-
well, plate-to-plate, day-to-day, and assay-to-assay) to screen a large number of compounds for 
antiviral effects, other cell types were considered as follows: 
i. Vero cells.  Vero cells are a lineage of cells isolated from African green monkey 
kidney epithelium that are frequently used in herpesvirus research.  These cells 
form monolayer cultures and have predictable doubling rates; features that would 
be advantageous to high throughput screening campaigns.  However, it is not 
possible to generate viral latency in Vero cells.  Employing a mutant virus 
defective in the immediate early genes may be a solution, however the use of such 
a virus may not recapitulate the native virus and differences in drug effects may 
become pronounced.  Other methods to induce a quiescent herpesvirus infection 
in fibroblast that have been previously described by others is to incubate the cells 
at a higher temperature (42°C) and low multiplicity of infection (MOI=0.003; 
Russell, 1986).  However, these experiments were based on using low MOIs, 
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which could introduce difficulties in data interpretation.  Also, virally-infected 
Vero cells do not synthesize interferon due to a genetic defect, and thus cannot 
intrinsically circumvent viral infection in a manner similar to other cell types 
(Emeny & Morgan, 1979). 
ii. NSC/eNPCs.  These cells are closely related to neurons and are mitotically active, 
enabling us to generate large numbers of cells rapidly, but data must be generated 
to show a positive correlation of antiviral effects with the iPSC-neurons and/or the 
Vero cells.  Still, testing compounds for reducing viral reactivation from latency is 
not possible as HSV-1 latency could not be established in these cells. 
 
If a drug-screening protocol using these cells could identify anti-lytic compounds, it 
would provide a relatively rapid preliminary filter for the next round of screening in iPSC-
neurons.  Furthermore, as latency can be established in the iPSC-neurons, the leading hit 
compounds would be added for 2 days, and then viral reactivation would be induced with sodium 
butyrate.  Compounds that are refractory to viral reactivation would be selected for further 
analyses.  The methods outlined in previous chapters, such as viral copy number qPCRs, 3D-
FISH, and CHART-PCR would provide confirmatory measures of the antiviral activity.  
Additionally, the use of Campenot chambers may be used to assess viral transport in neuronal 
cultures exposed to novel drugs or to assess differences in viral kinetics when infecting neuronal 
projections but not the soma, and vice versa (Curanović et al., 2009). 
What types of compounds should be sought in future drug screens?  Acyclovir and 
valacyclovir are efficacious antiviral compounds for HSV-1 lytic infections that have excellent 
safety profiles.  Other antiviral compounds, such as nucleoside inhibitors, helicase/primase 
 189 
inhibitors, or terminase inhibitor are newly reported potent inhibitors of HSV-1.  However, since 
these antiviral compounds exert their inhibitory effects on viral DNA replication or DNA 
packaging into the capsid, viral resistance could arise through selection pressure.  The use of 
these antivirals in immunocompetent individuals does not frequently result in the development of 
viral resistance.  Conversely, the frequency of antiviral resistance to acyclovir is increased 
among AIDS patients, individuals undergoing chemotherapy, or organ transplant recipients.  The 
development of methods to screen molecules for anti-lytic effects with a different mechanism of 
action would be beneficial for those individuals.  Examples of these types of molecules include 
translation inhibitors or molecules that impair Golgi trafficking.  A second option is to find a 
compound that reduces the frequency of viral reactivation.  Herpes keratitis is the leading cause 
of corneal blindness in the world.  After many cycles of HSV-1 reactivation, infected corneal 
tissue becomes scarred and opaque, resulting in decreased visual acuity and ultimately blindness.  
Additionally, herpes labialis, herpes genitalis, or herpes simplex encephalitis may also be 
exacerbated by reactivation, resulting in decreased quality of life or mortality.  Compounds that 
result in reduced viral reactivation may operate epigenetically to keep the virus in a semi-
permanent state of heterochromatization (Kristie, 2015).  During infection, viral DNA is rapidly 
associated with histones bearing repressive marks (H3K9 and H3K27 methyl; Wang et al., 2005; 
Kwiatkowski et al., 2009).  Modulation of histone repressive marks that can result in gene 
expression, and ultimately viral infection, is carried out by molecules that shape the epigenetic 
landscape (i.e., histone demethylases or methyltransferases; Narayanan et al., 2007).  In fact, 
inhibitors of such molecules (lysine-specific demthylase 1 (LSD1)) and Jumonji C domain-
containing protein 2 (JMJD2)) have potent antiviral effects due to heterochromatic repression, 
resulting in anti-lytic effects, as well as reduced viral reactivation from latency (Liang et al., 
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2013; Hill et al., 2014). Hypotheses focusing on the correlation of cognitive impairment with 
HSV-1 seropositivity may also be tested following use of such a compound.  A third type of 
compound is one that eradicates the virus in its latent form, and thus completely purges HSV-1 
from the human body.  An example of such a molecule could be an HSV-1 meganuclease, i.e., a 
sequence-specific endonuclease could be tailored to target the latent viral genome.  While their 
large target size increases specificity, the mode of delivery of such a molecule must be 
considered.  Currently, adeno-associated virus (AAV) vectors are popular; however, safety 
concerns and nuclease efficiency need to be addressed (Elbadawy et al., 2014).  In addition, 
clustered regularly interspaced short palindromic repeat/ CRISPR associated protein 9 
(CRISPR/Cas9) function to protect bacterial cells from viral infection by nuclease cleavage in a 
sequence-specific manner.  This system has been optimized to be sequence-specific to viruses in 
mammalian cells with the use of guide RNA to induce cleavage of viral DNA by the Cas9 
nuclease (Wang & Quake, 2014; Bi et al., 2014; Kennedy & Cullen, 2015).  Use of the 
CRISPR/Cas9 system to specifically target viral genomes may be a method used in future studies 
to eradicate latent HSV-1 genomes.  A compound that can accomplish a complete viral purge has 
thus far proved elusive, and future studies may shed light on such molecules to accomplish this 
feat. 
Some shortcomings in the present studies should be noted.  The differentiation process to 
generate the NSCs/eNPCs from iPSCs produces unwanted cell types.  Further characterization of 
the iPSC-neurons is desirable.  Additionally, the cells that comprise the brain are a complex, 3-
dimensional structure, and optimization to a 3-dimensioanl culture system may provide a better 
model fit (Zhang et al., 2014).  Our models outlined here do not contain all the aspects of the 
human immune system, which may not be conducive for some studies.  However, other studies 
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investigating host-virus interactions may find its absence to be beneficial.  The CHART-PCR 
method outlined here cannot conclusively demonstrate viral genome heterochromatization during 
quiescent infection, though it can quantify the accessibility of a DNA nuclease (MCN) at specific 
locations in the viral genome.  Since many proteins have the ability to bind directly with DNA, 
chromatin immunoprecipitation (ChIP) or ChIPseq would provide such specificity.  Of interest 
would be to analyze antibodies specific for acetylation or methylation of H3K9, H3K27, and 
H3K4.  These studies have been initiated with our collaborators at the University of Florida (Dr. 
David Bloom).   The antiviral studies are also limited by the absence of in vivo animal data and 
testing for antiviral effects on other viruses in vitro.  Given their potent antiviral activity and 
favorable toxicity profile, such studies are warranted.  To further elucidate their spectrum of 
effect, in vitro testing of these compounds for antiviral activities for other viruses would be 
beneficial. 
In Aim 2, the effect of dissociating the neuronal cells prior to seeding them on 384 well 
plates is a serious limitation.  Treatment with accutase breaks the neurite connections in the 
neuronal network.  The 7-day recovery time does result in the growth and reconnection of these 
structures; however, it is unknown how the accutase treatment affects the neuronal network that 
is re-established.  This may be due to the period of time from the beginning of neuronal 
differentiation to cell seeding into the 384-well plates.  Neuronal cultures that remained in the 6-
well plates for greater than 8 weeks were variable; these cultures were more difficult to 
dissociate, leading to more forceful pipetting to obtain single-cell suspensions.  Additional 
characterization of non-neuronal cells in these cultures will be informative. 
In addition, we are testing how we can make the readout more accurate.  To directly test 
compounds that reduce viral reactivation, an alternative infection method could be utilized.  
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Following HSV-1 infection on iPSC-neurons, novel compounds would be added for a specified 
time (perhaps 2 to 3 days), and then removed.  Fresh, drug-free medium would be added to the 
cells for a specified time (perhaps 5 to 7 days) and then analyzed for reduction in EGFP 
fluorescence.  For this type of experiment, one could use a compound that has known effects on 
reducing viral reactivation, like compound R430. 
Thus, several additional studies are needed to enable an increased throughput for future 
drug screening campaigns.  Such studies are worthwhile not only to identify antiviral drugs for 
HSV-1 infections, but also because the iPSC-neuron based models could be used for drug 
screens against other viruses, to model infections in individuals with specific genomic changes, 
and indeed for patient-specific personalized medicine. 
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6.0  FUTURE DIRECTIONS 
6.1 FURTHER INVESTIGATIONS OF THE LATENCY MODEL 
As noted in the results related to Aim 1, it is difficult to resolve the status of cells in the 
latency model that apparently show fluorescence during the initial days of incubation with the 
antiviral drug cocktail.  Therefore, further clarity could be obtained by single cell analysis, while 
inducing latency in a heterogeneous population of cells that are comprised of both neuronal cells 
and non-neuronal cells.  It should be feasible to identify and analyze single cells in culture 
through laser capture dissection and single cell analysis of the transcriptome and proteome.   
Separately, further analysis of the patterns of heterochromatin and understanding of the 
mechanisms for viral gene silencing in the latency model would be instructive.  Previously, 
investigators who used chromatin immunoprecipitation (ChIP) showed an enrichment of 
trimethylated H3K9 or H3K27 with promoter regions of viral lytic genes during latency.  It 
would be informative to conduct similar ChIP experiments.  Several miRNAs are expressed 
during HSV-1 latency; future work to quantifying such entities in this model of latency would be 
desirable.  Applying this model of latency to 3-dimensional iPSC-neuronal cultures may lead to a 
more superior model, which may also be beneficial for future work in drug discovery. 
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6.2 MODIFICATIONS IN THE DRUG SCREENING PROTOCOL 
We plan to follow up the small scale antiviral studies by developing more efficient 
methods for identifying larger numbers of compounds that target latent infection – including 
derivatives of current lead compounds, as well as small molecule screening libraries.  Further 
modifications in the ‘readout’ for determining efficacy against latent infections are also needed.  
Third, it will be important to use strains resistant to acyclovir in these screens.   
6.2.1 Primary Moderate Throughput Screen For Antiviral Drugs Against HSV-1 in iPSC-
Neurons 
Based on our preliminary data for the initial primary anti-lytic screening, we would infect 
iPSC-neurons in the 384-well plates at an MOI=5.0 for a 2-hours.  The cell culture medium will 
be removed and cells washed with PBS, and then medium containing novel compounds will be 
added.  This can be accomplished using multichannel pipettes or Hydra liquid transfer machines.  
Cells will be analyzed after 48 hours to test HSV-1 anti-lytic effect.  The HSV-1 viral construct 
that we employed in our initial experiments express fluorescent reporter genes, EGFP and RFP, 
under the control of viral promoters.  The primary readout will be reduction in cells expressing 
EGFP as compared to vehicle-treated cells.  We propose an initial compound library such as the 
Library of Pharmacologically Active Compounds collection (LOPAC®1280; Sigma, catalog 
LO1280-1KT), which includes 1,280 small molecules.  We will examine each compound at three 
concentrations (50 µM, 10 µM, and 1 µM) during the primary screen.  Known antiviral acyclovir 
(ACV 50 µM) or viral DNA inhibitor phosphonoacetic acid (PAA 300 µg/ml) will be included 
as controls and pretreated as previously described (McClain et. al., 2015).  Subsequently, we will 
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analyze other compound libraries available through the Drug Discovery Institute of the 
University of Pittsburgh and Dr. James McNulty, Ph.D. from McMaster University. 
The lead compounds that inhibit lytic infection with similar or greater potency than ACV 
will undergo a second screening at a range of concentrations ranging from 100 nM to 250  µM in 
a ten-point IC50 curve (the drug concentration that reduce the number of EGFP-positive cells by 
50%).  Furthermore, the CC50 (the concentration that reduce cell viability by 50%) curve will be 
determined.  Cells will be imaged using the ImageXpress Ultra (IXU) High Content imager and 
analyzed with Multiwavelength Cell Scoring application within the MetaXpress software.  The 
therapeutic index (TI) will be calculated [(CC50/IC50) * 100%].  Compounds with a high 
antiviral effect and low cytotoxicity (TI > 100) will be selected for secondary analyses and 
considered a lead or “hit” molecule. 
6.2.2 Secondary Analysis of Antiviral Effects Following Lead Hit Analyses 
Once a lead hit compound(s) is identified against lytic infection, further analyses will be 
performed to assess the extent of the antiviral effect in a low- or moderate throughput manner.  
We will employ secondary, orthogonal studies to further confirm the antiviral activity, as well as 
provide insights into potential mechanisms of action.  Orthogonal studies (Table 4) will address 
the following questions when comparing vehicle-treated cells with the compound-treated cells: 
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Table 4.  Secondary studies to confirm antiviral activity. 
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7.0  CONCLUSIONS 
Herpes simplex virus, type 1 (HSV-1) is a common human pathogen that causes life-long 
latent infection, with recurrent cycles of reactivation that lead to immense public health burden.  
HSV-1 can cause productive (lytic) infection in virtually any type of cell in humans and other 
mammals; but by definition, latent HSV-1 infections is restricted to human neurons.  The advent 
of induced pluripotent stem cell (iPSC) technologies provides us with the ability to differentiate 
human iPSCs into large numbers of neuron like cells that we call iPSC-neurons.  In this thesis, 
iPSC-neurons were used to model lytic and latent HSV-1 infection, and for drug discovery.   
We generated neural stem cells/early neural progenitor cells (NSC/eNPCs) in 6-well 
culture plates.  The method also produced non-neuronal cells that could be eliminated.  The 
NSC/eNPCs express neural stem cell-specific markers and can be differentiated into iPSC-
neurons that also express functional ligand-gated channels, pre- and post-synaptic proteins, and 
intracellular proteins specific to human neurons.  Thus, we developed relatively homogenous 
cultures of iPSC-neurons that share many properties of human neurons. 
HSV-1 lytic and latent infections were modeled in human iPSC-derived neural precursors 
and neurons, using an HSV-1 construct with dual fluorescent promoter readouts.  HSV-1 caused 
lytic infection in both types of cells.  Only in the human iPSC-neurons were we able to maintain 
‘quiescent’ infection with HSV-1 when co-incubated with an antiviral drug combination.  The 
latency associated transcript (LAT), an indicator of latent infection, was expressed during the 
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quiescent infection.  Even after withdrawal of the antiviral compounds, quiescence was 
maintained in most cells for five days, though some cells continued to show lytic infection from 
the first day. Reactivation of quiescently-infected iPSC-neurons was also induced by co-
incubation with sodium butyrate, a histone deacetylase inhibitor.  In addition, copy number 
analysis and viral genome patterns in the FISH experiments were consistent, as well as levels of 
infectious virions in the cell supernatants.  Quiescence could not be induced in iPSC-neurons 
with a replication defective HSV-1 construct. 
Previous reports indicate heterochromatization of viral DNA during latency; therefore, a 
protein associated with heterochromatin was evaluated during HSV-1 quiescent infection.  Co-
localization was not observed in Vero cells with lytic infection, but the pattern observed in iPSC-
neurons is consistent with predictions of latency; further analysis is needed.  Viral gene 
promoters were quantified for nuclease accessibility during lytic and quiescent infections in 
iPSC-neurons.  Viral genes transcribed during acute infections were more accessible to nuclease 
degradation, with the exception of ICP4.  LATs were more accessible to nuclease degradation 
during quiescent infections, as expected.  These data could indicate transcriptional 
permissiveness with loci that have greater nuclease accessibility.  If lytic genes are found to be 
heterochromatic during the quiescent infection, previously published criteria for HSV-1 latency 
will be satisfied.  Thus, the quiescent infection resembles the majority of classical criteria for 
latent infection, but further optimization of this model is necessary. 
The aforementioned HSV-1 infection models were used to investigate antiviral effects of 
novel compounds.  Four compounds had potent antiviral effects on lytic HSV-1 infections in 
iPSC-neurons, with minimal cytotoxicity. Viral copy number was significantly reduced, and 
FISH experiments provided data consistent with this conclusion.  The compounds decreased 
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viral reactivation induced by HDAC inhibitors in iPSC-neurons.  Further, two compounds (4F17 
and R430) inhibited productive infection during viral reactivation from quiescence.  These 
compounds also inhibited acute varicella zoster virus (VZV) infection with greater potency than 
acyclovir while causing minimal host cell cytotoxicity; 4F17 inhibited human cytomegalovirus 
also.  The mechanism of action is unknown, but it is likely that they have several effects. 
We next scaled up our drug screening efforts.  iPSC-neurons were cultured in 96- and 
384-well culture plates.  The cultured cells showed lytic and quiescent infection with HSV-1; the 
latter could be reactivated.  We evaluated viral infection using two assays.  Further methods for 
each hit compound identification are outlined. 
In summary, iPSC-neurons can be used to model lytic and latent HSV-1 infections.  
These models are suitable for moderate throughput screening of compounds for neurotropic 
viruses or neurological diseases. 
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APPENDIX A: SUPPLEMENTAL INFORMATION FOR “LARGE-SCALE 
GENERATION OF HUMAN IPSC-DERIVED NEURAL STEM CELLS/EARLY 
NEURAL PROGENITOR CELLS AND THEIR NEURONAL DIFFERENTIATION” 
Cryopreservation of iPSCs 
Aspirate mTeSR1™ medium from 50-60% confluent 6-well plate culture wells. Add 1 ml 
of fresh mTeSR1™ and place the plate under the microscope. Eliminate the differentiated areas 
from colonies by scraping with a pipette tip. Aspirate the medium and wash twice with 2 ml of 
DMEM/F12. Add 1 ml/well of mTeSR1™ and cut iPSC colonies as described in 1(ii). Take an 
aliquot, dissociate cell clumps by digestion with accutase, and count viable cells using trypan 
blue. Pellet the cells by centrifugation at 1200 rpm for 5 min. Discard the supernatant and shake 
the pellet gently by flicking. Re-suspend the cells in CryoStore freezing solution to a density of 
4x106 cells/ml. Aliquot 500 µl of cell suspension in cryovials, place in alcohol-free cell freezing 
containers (CoolCell®) and transfer immediately at -80°C. The following day, transfer cryovials 
to a -135°C freezer or into liquid nitrogen containers.  
NOTE:  To improve post-thaw recovery, transfer cryovials to -80°C within 3-5 minutes 
after re-suspending iPSCs in freezing solution.  
Cryopreservation of NSCs/NPCs 
Aspirate NP expansion medium and rinse with DMEM/F12. For 6-well cultures, add 1 ml 
of StemPro Accutase per well and incubate for 3 min at 37°C. Add 2 ml of DMEM/F12 medium 
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and gently detach cells by pipetting up and down with a p1000 tip. Count viable cells using 
trypan blue. Pellet the cells by centrifugation at 1200 rpm for 5 min. Discard the supernatant and 
disturb the pellet by flicking. Re-suspend the cells in CryoStore freezing solution to a density of 
4x106 cells/ml. Aliquot 500µl of cell suspension in cryovials, place in alcohol-free cell freezing 
containers (CoolCell®) and transfer immediately to -80°C. On the following day, transfer 
cryovials to a -135°C freezer or into a liquid nitrogen cylinder.  
Thawing NSCs/NPCs  
Take a cryovial from freezer storage and clean the surface by spraying with 70% ethanol. 
Transfer 5 ml of ice-cold DMEM/F12 medium into a 15 ml conical tube. Remove the cap from 
the cryovial and break the frozen cell suspension by making pressure from the top with 1 ml or 5 
ml plastic pipette (this procedure allows a quick transfer of frozen cells into the culture medium, 
that ensures a high cell recovery). Add 500 μl of cold DMEM/F12 medium and transfer all the 
content of the vial to the 15 ml conical tube. Centrifuge at 1200 rpm for 5 min. Discard the 
supernatant, wash the cells with 2ml of DMEM/F12 medium, re-suspend the cells in 8 ml of 
mTeSR1™ medium, and then seed 2 ml cell suspension/well in a matrigel-coated 6-well plate.  
Culture until the cells are confluent, changing the medium every other day. 
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APPENDIX B: SUPPLEMENTAL INFORMATION FOR “PERSISTENT INFECTION 
BY HSV-1 IS ASSOCIATED WITH CHANGES IN FUNCTIONAL ARCHITECTURE 
OF IPSC-DERIVED NEURONS AND BRAIN ACTIVATION PATTERNS 
UNDERLYING WORKING MEMORY PERFORMANCE” 
Immunocytochemistry and Microscopy 
Immunocytochemistry was performed as previously described (D'Aiuto, et al., 2008). 
Primary antibodies used were mouse anti-β Tubulin III monoclonal antibody (clone Tuj-1, R&D 
System, 1:50 dilution), mouse monoclonal anti-MAP2 (Millipore, dilution 1:200), mouse 
monoclonal anti-human nestin antibody (R&D Systems, 1:1000 dilution), rabbit polyclonal anti-
VGLUT1 antibody (Synaptic Systems, 1:200 dilution), and rabbit polyclonal anti-S100 beta 
antibody (Abcam, 1:200 dilution).  Fluorescently labeled secondary antibodies were used for 
detection.  Counterstaining was done with Hoechst 33342.  Images were acquired using a Leica 







Figure 50.  Top panel: Immunocytochemical analysis of iPS-derived neural progenitor cells (a), neurons (b-d), 
and astrocytes (e).  
 
Bottom panel: Expression of glutamatergic receptors in iPSC-derived neurons. RNA was prepared iPSC-derived 
neurons. Total RNA was converted into cDNA, which was used as a template to PCR-amplify edited regions of 

























Figure 52. Location of HSV-1 genomes in neurons with (a) lytic and (b) quiescent infection. 
iPSC derived neurons underwent lytic or quiescent infection in the absence or presence of 5BVdU +IFN-α as 
described (MOI 0.3).  Cells were fixed to preserve the three-dimensional structure of the nuclei and probed using 
the entire HSV-1 genome.  Signal specificity was assessed through FISH analysis of uninfected neurons (data 
not shown). Cells were probed at 24 h p.i for lytic infection.  The probe signal is pseudo-colored in red in the 
merged images, with DAPI counterstaining. 
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APPENDIX C:  SUPPLEMENTAL INFORMATION FOR “BROAD-SPECTRUM NON-
NUCLEOSIDE INHIBITORS OF HUMAN HERPESVIRUSES” 
 










FISH was performed on iPSC-neurons infected with HSV-1 (KOS strain, MOI 0.3) as previously described 
(D'Aiuto, Antonacci, Marzella, Archidiacono, & Rocchi, 1993), using the HSV-1 genome as a probe. HSV-1 
genome was labeled with red-dUTP (0.2 mM; Abbott), by nick translation (Amersham™ Nick Translation Kit 
(GE Healthcare), both following manufacturer’s instructions. On average, 100 nuclei from each cellular 
preparation were scanned.  Digital images were generated using Leica LAS AF.  Hybridization signals (red) 
were subjected to uniform thresholding to demarcate the signals.  In infected, untreated cells, numerous 
hybridization signals for viral DNA probes were present in the central region of the nuclei, whereas the host 
chromatin (blue) was displaced toward the nuclear periphery.  In contrast, viral DNA could not be detected in 
infected cultures treated with 30N12 and 16F19, similar to ACV or PAA.  Hybridization signals were observed 
in a small fraction of infected neuronal cultures treated with 4F17.  Nuclei were counterstained with DAPI 
(blue).  ACV: acyclovir, PAA: phosphonoacetic acid.   
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Figure 54.  Immunocytochemistry analysis of uninfected and infected iPSC-neurons with ICP0 (green, left 



























Antiviral effects of the aforementioned compounds on acute HSV-1 infection show a moderate correlation when 
comparing the mean percent EGFP+ cells in iPSC-neurons and Vero cells (p=0.044, r=0.72, 95% CI 0.031-
0.945).  Error bars indicate the 95% confidence intervals of mean percent EGFP+ cells for each compound; 
vertical bars in iPSC-neurons and horizontal error bars in Vero cells.  Specified drug concentrations are 50 µM, 
except BFLA, which is 0.1 µM. 
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Efficacy of varying drug concentrations against HSV-1 lytic infection in iPSC-neurons; FC performed 24 hpi.  












Neurotoxicity of 30N12, 16F19, and 4F17 was assessed by FC using fixable viability dye. The data represent an 
average of three independent experiments.  Error bars represent standard deviations. 
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Figure 58.  Analysis of drug inhibition effect on HSV-1 attachment and entry. 
We tested effects on HSV-1 attachment to the host cell membrane, as well host cell entry using a published 
protocol (Krepstakies, et al., 2012, J Infect Dis. 205:1654-64). 
Cell attachment:  Vero cells were pre-treated with each compound or vehicle for 1 hour at 37°C.  Cells were next 
infected with HSV-1 (MOI 1.0) and incubated on ice for 2 hours.  This procedure likely enables attachment, but 
prevents viral entry.    Cells were collected after the 2 hours infection on ice.  DNA was extracted, and viral copy 
number was estimated by qPCR.  We observed no statistically significant reduction in viral DNA copy number 
in cells treated with the different compounds compared to the untreated HSV-1 group. 
Cell entry:  Vero cells were pre-treated with each compound or vehicle for 1 hour at 37°C.  Cells were then 
infected with HSV-1 (MOI 1.0) and incubated on ice for 2 hours. The inocula were removed, the Vero cells were 
washed, and cultured in Vero medium supplemented with compounds/ vehicle for 1 hour at 37°C to enable viral 
particles to enter the cell.  To remove residual viral particles attached to the cell membrane, proteinase K (2 
mg/ml) was added to the culture, and cells were incubated on ice for 1 hour.  Next, protease inhibitor cocktail 
(1mM) was added to the cultures, and cells were harvested.  Total DNA was extracted, and viral copy number 
was estimated by qPCR.  There was no statistically significant reduction in viral DNA copy number observed in 
cells treated with the different compounds compared with the untreated HSV-1 group. 
 215 
APPENDIX D:  SUPPLEMENTAL INFORMATION FOR “IPCS NEURONAL ASSAY 
IDENTIFIES AMARYLLIDACEAE PHARMACOPHORE WITH MULTIPLE 
EFFECTS AGAINST HERPESVIRUS INFECTIONS” 
Biological Assays 
Cell lines and viral constructs 
Human skin fibroblast line 73-56010-02 was reprogrammed into induced pluripotent 
stem cells (iPSC) using Sendai viral vectors, quality control assays were performed, and the 
iPSCs were further differentiated into iPSC-neurons as previously described (D’Aiuto, et al., 
2012; D’Aiuto, et al., 2014).  Vero and human retinal pigmented epithelial cells (ARPE-19) were 
maintained in Dulbecco’s modified essential medium/F12 (DMEM/12) supplemented with 10% 
FBS (Hyclone) and 5% antibiotic/antimycotic (HyClone). HSV-1 strain KOS (VR-1493; ATCC) 
was utilized. A separate strain of KOS was modified to express EGFP and RFP under the control 
of viral promoters ICP0 and glycoprotein C, respectively (Ramachandran, et al., 2008). VZV 
derived from an infectious Bacterial Artificial Chromosome of the whole genome of the Parent 
of Oka strain expressing firefly luciferase as a fusion to the ORF9 promoter at the native locus 
was described previously (Bayer et al., 2015).  
Viral infection 
Vero and iPSC-neurons were infected with the HSV-1 at a multiplicity of infection 
(MOI) of 1.0 or 0.3 PFU/cell, respectively. Two hours post infection (hpi), the inocula were 
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removed, infected Vero cells or iPSC-neurons were washed twice with PBS, and cultured with 
the appropriate media with or without indicated compounds. Control cultures were pretreated 
with ACV (50 uM) for 24 h prior to infection (Joubert et al., 2009).  All assays were conducted 
24 hpi.  
HSV-1 quiescent infection was established in iPSC-neurons using (E)-5-(2-bromovinyl)-
2'- deoxyuridine and interferon alpha (5BVdU+IFNα; 30 μM, 125 U/ml, respectively) for 7 days, 
followed by treatment with sodium butyrate (NaB, 5 mM) for 5 days to induce viral reactivation 
(D’Aiuto, 2014).  Separately, 5BVdU+IFNα were replaced with 7 (10 μM) or 7+IFNα (10 μM, 
125 U/ml, respectively).  
ARPE-19 cells were infected at a density of approximately 1.5x10^5 cells/well with VZV 
at 1000 PFU/well. Following 2 h adsorption, fresh medium containing indicated compounds was 
added. Viral inhibition was determined 48 hpi.  
Flow Cytometry (FC) 
Cells were trypsinized and resuspended in PBS containing Live/Dead® Fixable Aqua 
Dead Cell Stain kit (Life Technologies) 24 hpi with HSV-1/EGFP/RFP construct, following 
manufacturer’s instruction. Cells were fixed in 4% formalin. The proportion of live cells and 
cells expressing EGFP and RFP was determined by FC (Fortessa FACS analyzer, Becton 
Dickinson).  
Cytotoxicity assays 
Human iPSC-neurons or ARPE-19 cells were treated with stated concentrations of 7 or 
ACV for 24 h or 48 h, respectively, and the proportion of live cells was measured by FC using 
Live/Dead® Fixable Aqua Dead Cell Stain kit following manufacturer’s instruction.  
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Fluorescent in situ hybridization (FISH) 
FISH was performed using probes generated from whole genome HSV-1. The HSV-1 
genome (strain KOS) was amplified using Illustra GenomiPhi V2 amplification kit (GE 
Healthcare) and labeled with red-dUTP (0.2 mM; Abbott), by nick translation (AmershamTM 
Nick Translation Kit (GE Healthcare), following manufacturer’s instructions. Human iPSC-
neurons were infected with HSV-1 strain KOS at MOI 0.3 as described above and fixed 24 hpi. 
FISH was performed as previously described (D’Aiuto et al., 1993).  On average, 50 nuclei for 
each cellular preparation were scanned. Digital images were obtained using Leica LAS AF with 
uniformed thresholding.  
Copy number PCR (qPCR) 
Human iPSC-neurons were infected with HSV-1/EGFP/RFP construct for 24 h, followed 
by total DNA extraction (QIAamp DNA Blood Mini Kit; Qiagen) and quantification (Quant-iT 
TM PicoGreen® ds DNA Assay Kit; Life Technologies) following the manufacturer’s 
instructions. Copy number qPCR was performed as previously described (Kaufman et al., 2005)  
using 5 ng total DNA. EGFP forward primer (18 μM; 5′- ccacatgaagcagcacgactt-3’), EGFP 
reverse primer (18 μM; 5′-ggtgcgctcctggacgta-3′), and probe (5 μM; 5′- 6FAM-
ttcaagtccgccatgcccgaa-TAMRA-3′) were used in the probe mix. The reaction conditions were 
95°C for 3 min, followed by 45 cycles of 95° C for 15 sec and 55° C for 30 sec, and finished 
with 72° C for 30 sec. qPCRs were performed on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) and analyzed with manufacturer’s software SDS 2.4.  
Western blotting 
Human iPSC-neurons were infected with HSV-1 (strain KOS), and cells were lysed 24 
hpi with 10 volumes of RIPA (25 mM Tris–HCl pH 7.6,150 mM NaCl, 1% NP-40, 1% sodium 
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deoxycholate, and 0.1% SDS). Cell lysates were denatured by heating at 95°C and then separated 
by electrophoresis on Mini-PROTEAN@ TGXTM Precast gel (BIO-RAD), transferred onto an 
immobilon membrane (Millipore), and probed with mouse monoclonal HSV-1 ICP4 primary 
antibody [10F1] (Abcam (ab6514), 1:500 dilution). The blots were then probed with 
corresponding secondary antibody (Li-Cor) and visualized by using ClarityTM Western ECL 
substrates (BIO-RAD).  
RT-qPCR 
Human iPSC-neurons were infected with HSV-1 (strain KOS). Cells were collected 24 
hpi and RNA was extracted using using RNeasy mini kit (Qiagen) followed by cDNA synthesis 
using QuantiTect Reverse Transcription kit (Qiagen) following manufacturer’s instructions. A 
separate round of cDNA synthesis was made on RNA in a reaction that lacked the enzyme. RT-
qPCR was performed as previously described in triplicate (Liu et al., 2015).   The reaction 
conditions are: 95°C for 12 min, followed by 40 cycles of 95°C for 15 sec and 55°C for 1 min. 
Each reaction analyzed beta actin for normalization and the relative expression of viral 
transcripts ICP4 and viral DNA polymerase was calculated using the 2-ΔCt method (Livak et al., 
1999).  The sequences used for ICP4 are as follows: forward primer 5’-CGA CAC GGA TCC 
ACG ACC C-3’, reverse primer 5’-GAT CCC CCT CCC GCG CTT CGT CCG-3’, and probe 
5’-VIC-ACC GCC AGA GAC AGA CCG TCA GA-MGB-NFQ-3’. The sequences used for 
HSV-1 DNA polymerase are as follows: forward primer 5’- AGA GGG ACA TCC AGG ACT 
TTG T-3’, reverse primer 5’- CAG GCG CTT GTT GGT GTA C-3’, and probe 5’-FAM- ACC 
GCC GAA CTG AGC A-MGB-NFQ- 3’. Human beta actin endogenous control probes are 
TaqMan ready-mix (NM_001101.2) that span exons 2 and 3 (Applied Biosystems).  
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Virus Yield Reduction Assay 
In the HSV-1 infected cultures, supernatant was reserved just prior to cell collection for 
flow cytometry analyses. Confluent Vero cell monolayers in 6-well plates were infected with 10 
microliters of the aforementioned supernatant in 1 mL Vero medium in triplicate. Following a 2-
hour adsorption at room temperature, the medium was removed, washed twice in PBS, and 
replaced with 3 mL of 1% carboxy methylcellulose in Vero medium. Cultures were incubated at 
standard cell culture conditions for 48 hours. The mean plaque count for each condition was 
calculated and the mean infective titer was generated. 
Statistical Analyses 
Statistical analyses were conducted using the open source software R statistical package 
version 3.0.1, IBM SPSS v21, and GraphPad Prism v5.02. The EC50 (drug concentrations that 
reduced the percentage of EGFP+ cells in HSV-1 infected cultures by 50% or reduced the LCPS 
in the VZV-infected cultures by 50%) was estimated using the R program with the drc package 
(http://cran.r- project.org/web/packages/drc/drc.pdf; version 2.3–96). We first assessed model fit 
using an F-test by comparing to an ANOVA model. We chose a 4 parameter, log logistic model 
that provided the best fit to the data (results not shown). Statistical significance was calculated by 
first testing for equality of variance using Levine’s test, where two-tailed Student’s t-tests (where 
variances were not significantly different at α < 0.05) or Welch’s t-tests (where variances were 















a) Detection of HSV-1 genome (red) by fluorescent in situ hybridization (FISH) in iPSC-neurons 24 hpi in the 
presence or absence of test compounds. Nuclei were counterstained with DAPI (blue). The data represent an 
average of three independent experiments. b) HSV-1 copy number in iPSC-neurons exposed to compound 7 and 
acyclovir (ACV). c) Analysis of HSV-1 DNA polymerase and immediate early gene ICP4 by RT-qPCR. d) ICP4 
Western blot analysis. Vehicle is DMSO. The data represent an average of three independent experiments. Error 
bars represent standard deviations. 
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Solvents and reagents 
All chemicals and solvents were purchased from Acros, Aldrich, J.T. Baker, Caldeon, 
Cytec Industries and Fluka and used as received with the following exceptions: deuterated 
solvents were obtained from ACP Chemicals, Toronto, Canada; tetrahydrofuran (THF), diethyl 
a) EC50 estimation for 7 and ACV in iPSC-neurons. b) Comparison of cytotoxicity of 7 and ACV in iPSC-
neurons. c-d) VZV infectivity at different concentrations of 7 or acyclovir (ACV). c) ARPE-19 cell lysates 
were assayed for luciferase following infection with VZV in the presence or absence of 7 for 48 h. LCPS: 
luciferase counts per second. d) Cytotoxicity of 7 in ARPE- 19 cells. Cytotoxicity was assessed by flow 
cytometry using fixable viability dye. The data represent an average of three independent experiments. Error 
bars represent model-based standard error. 
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ether (Et2O), and toluene were distilled from sodium/benzophenone under an atmosphere of dry 
nitrogen; dichloromethane (CH2Cl2) was distilled from calcium hydride under an atmosphere of 
dry nitrogen; methanol (MeOH) was distilled from magnesium turnings under an atmosphere of 
dry nitrogen; triethylamine (NEt3), N,N- diisopropylethylamine (Hünig’s base) and pyridine 
were distilled from potassium hydroxide under an atmosphere of dry nitrogen; solid sodium 
hydride (NaH) was obtained by filtration and washing with n- hexanes.  
Reaction handling 
All non-aqueous reactions were performed in flame dried round bottom flasks or in non-
flame- dried amber 1.5-dram vials. Reactions were magnetically stirred and monitored by thin-
layer chromatography (TLC) unless otherwise noted. TLC was performed on Macherey-Nagel 
silica gel 60 F254 TLC aluminum plates and visualized with UV fluorescence quenching and/or 
potassium permanganate (KMnO4) or 2,4-dinitrophenylhydrazine or p-anisaldehyde stains 
(Sherma et al., 2003). Concentrations under reduced pressure were performed by rotary 
evaporation at 40 °C at the appropriate pressure, unless otherwise noted. Column 
chromatographic purification was performed as flash column chromatography with 0.3–0.5 bar 
pressure using Silicycle silica gel (40–63, 60 Å) or EcoChrom silica gel (12–26, 60 Å; Still et al., 
1978).  Distilled technical grade solvents were employed. The yields given refer to 
chromatographically purified and spectroscopically pure compounds, unless stated otherwise.  
Melting points 
Melting points were measured on a melting point apparatus using open glass capillaries 
and are uncorrected. 
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Nuclear Magnetic Resonance (NMR) spectroscopy 
1H, 13C[1H], DEPTq, COSY, HSQC and HMBC NMR spectra were obtained on Bruker 
DRX- 500, AV-600 and AV-700 spectrometers. All 1H NMR spectra were referenced relative to 
SiMe4 through a resonance of the employed deuterated solvent or proteo impurity of the solvent; 
chloroform (7.26 ppm), acetone (2.05 ppm), DMSO (3.33 ppm) and methanol (3.31 ppm) for 1H 
NMR; chloroform (77.00 ppm), acetone (29.84 ppm), DMSO (39.52 ppm) and methanol (49.00 
ppm) for 13C NMR. All NMR spectra were obtained at RT (ca. 22 °C) unless otherwise specified. 
The data is reported as (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, br = 
broad signal, coupling constant(s) in Hz, integration). 13C-NMR spectra were recorded with 
complete 1H-decoupling. Service measurements were performed by the NMR service team of the 
Nuclear Magnetic Resonance Facility at McMaster University by Dr. Bob Berno, Dr. Dan 
Sorensen and Dr. Hilary A. Jenkins.  
Mass spectrometry 
Mass spectrometric analyses were performed as high resolution ESI measurements on a 
Waters/Micromass QTof Global Ultima (quadrupole time-of-flight mass spectrometer) or high 
resolution EI in a Waters/Micromass GCT (time-of-flight mass spectrometer) instrument by the 
mass spectrometry service of the McMaster Regional Centre for Mass Spectrometry (MRCMS) 
at McMaster University by M.Sc. Sujan Fernando, Tadek Olech and Leah Allan under the 
supervision of Dr. Kirk Green.  
Enantiomeric ratios 
Enantiomeric ratios were determined using an Agilent 1220 Infinity HPLC manual 
injection with a variable wavelength detector, using a Daicel Chiralpak® AD-H column (150 x 
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4.6 mm, 5μ), n- hexane/iPrOH (75:25) as a mobile phase; flow rate 0.75 mL/min, column 
temperature 40°C, λ236 or 287 nm, sample 0.5 mg/mL dissolved in the mobile phase, or a Daicel 
Chiralpak® AS-RH column (150 x 4.6 mm, 5μ), water/ACN (50:50) as a mobile phase; flow rate 
0.75 mL/min, column temperature 20 °C, λ236, sample 0.02 mg/mL dissolved in the mobile 
phase. The sample was filtered through Parr 0.2 μm GHP Acrodisc (13 mm) syringe filters prior 
to injections.  
Diastereomeric ratios 
Diastereomeric ratios were determined using an Agilent 1220 Infinity HPLC manual 
injection with a variable wavelength detector, using a ZORBAX SB-C18 column (150 x 4.6 mm, 
5μ), water/ACN (75:25 to 35:65, 30 min) as a mobile phase; flow rate 1.0 mL/min, column 
temperature 20 °C, λ236, sample was evaporated and dissolved (0.01 mg/mL) in the mobile 
phase. The sample was filtered through Parr 0.2 μm GHP Acrodisc (13 mm) syringe filters prior 
to injections. 
Optical rotations 
Optical rotations were measured with a Perkin-Elmer 241 MC polarimeter, [α] is given in 
degcm3g−1dm−1 and c is given in gcm−3.  
Fourier Transform Infrared Spectroscopy (FTIR). 
FTIR spectra were obtained from the Combustion Analysis and Optical Spectroscopy 
(CAOS) facility using a Thermo, Nicolet 6700 FTIR.  
Differential Scanning Calorimetry (DSC).  
DSC was performed using a DSC Q20 coupled with a refrigerated cooling system 40 
form TA instruments by Laura Dodge.  
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Synthesis of (+)-trans-Dihydrolycoricidine (7).  
The title compound was prepared following the procedure of McNulty et al., 2013.  (+)-
trans-Dihydrolycoricidine (7). 2,3,4-Triacetoxy-trans-dihydrolycoricidine 0.0058 g (0.012 
mmol) and potassium carbonate (0.0002 g, 0.001 mmol, 0.10 equiv) were dissolved in water 
(0.104 mL) and MeOH (0.011 mL) and stirred at RT until a white solid precipitated. TLC 
analysis showed full conversion after 6 h. The mixture was concentrated under a flow of N2. The 
white product was dissolved in 9:1 CH2Cl2 / MeOH and filtered through a pad of silica. The 
white solid was recrystallized from methanol to afford 0.0035 g of fine white needles. 
Yield: 92%; M.P.: 296-299 °C (solidified material from MeOH) [lit.14 
303-304 °C (recrystallized from MeOH), lit.15 303-304 °C (recrystallized from CHCl3:MeOH), 
lit.16 294-297 °C]; TLC: Rf = 0.10 (CH2Cl2 / MeOH; 95:5; UV); [α]
22
D = +61 (c = 0.18, DMSO, l 
= 1 dm); 1H NMR (600 MHz, DMSO) δ 7.28 (s, 1H, H-Ar), 6.90 (br, 2H , H-Ar, NH), 6.05 (s, 
2H, OCH2O), 4.97 (s, 1H, CH2-CH-OH), 4.92 (s, 1H, OH), 4.80 (s, 1H, OH), 3.86 (s, 1H, CH2-
CH-OH), 3.70 (br, 2H, CH-OH, CH-OH), 3.31 (dd, J = 12.6, 9.8 Hz, 1H, CH-NH), 2.86 (td, J = 
12.6, 3.6 Hz, 1H, CH-Ar), 2.12 (dt, J = 13.3, 3.1 Hz, 1H, CH2eq), 1.62 (td, J = 12.7, 2.3 Hz, 1H, 
CH2ax); 
1H NMR (600 MHz, DMSO, D2O) δ 6.69 (s, 1H, H-Ar), 6.29 (s, 1H, H-Ar), 5.43 (d, J = 
4.0 Hz, 2H, OCH2O), 3.31 (s, 1H, CH-OD), 3.12 (m, 2H, CH-OD, CH- OD), 2.70 (dd, J = 12.5, 
10.0 Hz, 1H, CH-N), 2.28 (td, J = 12.5, 3.3 Hz, 1H, CH-Ar), 1.54 (dt, J = 13.6, 2.7 Hz, 1H, 
CH2eq), 1.04 (td, J = 12.1, 1.7 Hz, 1H, CH2ax); 
13C NMR (151 MHz, DMSO) δ 164.30, 150.65, 
145.95, 138.04, 123.26, 106.92, 104.33, 101.58, 71.68, 69.70, 68.61, 55.12, 34.27, 28.32; IR 
(KBr, cm-1) ν 3206, 2948, 1657, 1577. 1403, 1307, 1079, 1040, 900, 645; HRMS (ESI): exact 
mass calculated for C14H16NO6 [(M + H)








Figure 61.  Supplementary Scheme 1. 
 
2,3-Epoxypropyl benzoate (SI2).  
Benzoyl chloride (1.668 mL, 14.373 mmol, 1.05 equiv) and DMAP (0.084 g, 0.68 mmol, 
0.05 equiv) were added to a solution of (±)-glycidol SI1 (1.014 g, 13.69 mmol) and pyridine 
(1.162 mL, 14.37 mmol, 1.05 equiv) in CH2Cl2 (10 mL) at 0 °C. The reaction mixture was 
further stirred at 0 °C for 4 h after which TLC (CH2Cl2) showed full conversion. The solvent was 
removed in vacuo (35 °C, 0.1 mbar) to produce a yellow oil that was dissolved in EtOAc (20 
mL). The organic layer was washed with ammonium chloride (10 mL), sodium bicarbonate (2 X 
10 mL), and brine (10 mL). The organic layer was dried with Na2SO4 and concentrated to yield 
2.293 g of a translucent oil. NMR analysis showed that the product was pure enough for the 
subsequent reaction, and the crude mixture was used without further purification. To obtain 
spectroscopic data, a small portion of the crude was purified by flash column chromatography 
(CH2Cl2) to afford a white semisolid. This compound is known and matches the reported 
spectroscopic data (Cisneros et al., 2007).  
Reagents and conditions: Yields of isolated products (%) are indicated. a) BzCl (1.05 equiv), DMAP (0.05 
equiv), py (1.05 equiv), CH2Cl2, 0 °C, 94%. b) NaN3 (8.0 equiv), NH4Cl (2.0 equiv), MeOH and water 8:1, 
RT, 24h, 92%. c) TEMPO (0.02 equiv), NaOCl (5.0 equiv), NaBr (0.1 equiv), NaHCO3 (5.6 equiv), CH2Cl2, 
0°C →RT, 74%. BzCl = Benzyl chloride, DMAP = 4- Dimethylaminopyridine, py = Pyridine, TEMPO = 
(2,2,6,6-Tetramethylpiperidin-1-yl) oxy. 
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Yield: 94%; TLC(CH2Cl2, UV): Rf = 0.30; 
1H NMR (600 MHz, CDCl3) δ 
8.07 – 8.00 (m, 2H, H-Bz), 7.57 (t, J = 7.4 Hz, 1H, H-Bz), 7.43 (t, J = 7.8 Hz, 2H, H-Bz), 4.46 
(d, J = 5.2 Hz, 2H, CH2-OCO), 4.21 (p, J = 5.2 Hz, 1H, CH), 3.70 (ddd, J = 17.2, 11.3, 5.4 Hz, 
2H, CH2-O); 
13C NMR (151 MHz, CDCl3) δ 166.60, 133.32, 129.64, 129.38, 128.41, 69.65, 
65.64, 45.97; IR (neat, cm-1) ν 3459, 2958, 1721, 1275, 1122, 710; HRMS (ESI): exact mass 
calculated for C10H10O3Na [(M + Na)
+], 201.0528; found 244.0520.  
 
3-Azido-2-hydroxypropyl benzoate (SI3).  
To a mixture of 2,3-epoxypropyl benzoate (2.012 g, 11.29 mmol) and NH4Cl (1.208 g, 
22.58 mmol, 2.0 equiv) in MeOH and water (13.3 mL/1.6 mL, 8:1) was added NaN3 (5.872 g, 
90.33 mmol, 8.0 equiv) and the reaction mixture was stirred at room temperature for 24 h. The 
reaction mixture was concentrated to 1/10 its volume, diluted with water and extracted with 
EtOAc (20 mL). The combined organic layers were washed with brine (2 X 10 mL), dried over 
Na2SO4, filtered and concentrated to yield 2.298 g of a yellow oil. NMR analysis showed that the 
product was pure enough for the subsequent reaction, and the crude mixture was used without 
further purification. To obtain spectroscopic data, a small portion of the crude was purified by 
flash column chromatography (35% EtOAc in hexanes) to obtain a yellow oil. This compound is 
known and matches the reported spectroscopic data (Acquaah-Harrison et al., 2010).  
Yield: 92%; TLC(CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.47; 
1H NMR 
(600 MHz, CDCl3) δ 8.04 (dd, J = 8.3, 1.2 Hz, 2H, H-Bz), 7.62 – 7.56 (m, 1H, H-Bz), 7.45 (dd, J 
= 10.8, 4.8 Hz, 2H, H-Bz), 4.44 – 4.37 (qd, J = 11.7, 4.6 Hz, 2H,CH2-OCO), 4.19 – 4.13 (m, 1H, 
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CH-OH), 3.49 (qd, J = 12.6, 5.4 Hz, 2H, CH2-N3), 2.70 (br, 1H, OH); 
13C NMR (151 MHz, 
CDCl3) δ 166.69, 133.41, 129.82, 129.70, 129.41, 128.49, 69.23, 66.15, 53.56; IR (neat, cm
-1) ν 
3465, 2951, 2104, 1721, 1274, 1114, 712; HRMS (ESI): exact mass calculated for 
C10H11N3O3Na [(M + Na)
+], 244.0698; found 244.0686.  
 
3-Azido-2-oxopropyl benzoate (SI4).  
3-azido-2-hydroxypropyl benzoate (3.122 g, 14.11 mmol), NaHCO3 (3.320 g, 39.52 
mmol, 2.8 equiv), NaBr (0.144 g, 1.41 mmol, 0.1 equiv) and TEMPO (0.044 g, 0.28 mmol, 0.02 
equiv) were dissolved in CH2Cl2 (45 mL). The mixture was cooled to 0°C, and cold 0.83 M 
NaOCl (36.08 mL, 70.57 mmol, 5.0 equiv) buffered with NaHCO3 (3.320 g, 39.52 mmol, 2.8 
equiv) was added slowly. The reaction turned from red to orange and produced a white-yellow 
precipitate in the organic layer over 30 min, of which TLC analysis (CH2Cl2) showed reaction 
completion. The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 
X 25 mL). The organic extracts were combined, dried with Na2SO4 and concentrated to yield 
2.274 g of a clear oil, which was filtered through a silica pad to yield a white solid 
(Bischofberger, 1988).  
Yield: 74%; M.P.: 58-61 °C (solidified from CH2Cl2), [lit.
19 61 °C 
(recrystallized from CHCl3/cyclohexane, 1:1)]; TLC(CH2Cl2:MeOH, 95:5 v/v, UV): Rf = 0.32; 
1H NMR (600 MHz, CDCl3) δ 8.12 – 8.07 (m, 2H, H-Bz), 7.61 (t, J = 7.5 Hz, 1H, H-Bz), 7.48 (t, 
J = 7.8 Hz, 2H, H-Bz), 5.15 (s, 2H, CH2-Bz), 4.02 (s, 2H, CH2-N3); 
13C NMR (151 MHz, CDCl3) 
δ 195.88, 165.78, 133.68, 129.95, 128.82, 128.57, 66.51, 30.50; IR (neat, cm-1) ν 3000, 
2098,1721,1277, 1131, 704; HRMS (ESI): exact mass calculated for C10H10N3O3 [(M + H)
+], 
220.0722; found 220.0716; DSC: Endothermic transition at 61.6 °C, exothermic transition at 
155.8 °C (onset at 138.4 °C);  
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Figure 62.  Supplementary Scheme 2 
 
(1S,3R,4R,6S)-3-azido-4-(1,3-benzodioxol-5-yl)-6-hydroxy-2-oxocyclo hexyl benzoate 
(SI6).  
A solution of (2E)-3-(1,3-benzodioxol-5-yl)-2-propenal (SI5; McNulty et al., 2013) 
(0.4246 g, 2.410 mmol, 1.05 equiv) and (R)-(+)-α,α-Diphenyl-2- pyrrolidinemethanol 
trimethylsilyl ether (Cat A, 0.0747 g, 0.230 mmol, 0.10 equiv) in dichloromethane (5.0 mL) was 
stirred for 10 min, after which it was cooled to -10 °C. 3-Azido-2-oxopropyl benzoate (0.5032 g, 
2.296 mmol) was added dropwise over 5 min. The yellow solution was stirred for 20 min at 
room temperature and quinidine (Cat B, 0.0745 g, 0.230 mmol, 0.10 equiv) was added in one 
Reagents and conditions: Yields of isolated products (%) are indicated. d) SI5 (1.05 equiv), Cat A (10 mol%), Cat 
B (10 mol%), CH2Cl2, -10 °C →RT, 73%. e) DMDC (3.0 equiv), H2, 10 % Pd/C (0.075 equiv), EtOAc, 50 psi, 
RT, 79%. f) Me4NHB(OAc)3 (4.0 equiv), AcOH (10.0 equiv), MeCN, RT, 90%. g) AcCl (100 equiv). h) Tf2O 
(5.0 equiv), DMAP (3.0 equiv), CH2Cl2, 0 °C → RT, 73%. i) K2CO3 (0.10 equiv), H2O/MeOH 9:1, RT, 81%. 
DMDC = Dimethyl dicarbonate, Tf = Triflic, DMAP = 4-Dimethylaminopyridine, Moc = Methyloxycarbonyl. 
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portion. The reaction was stirred at room temperature for 16 h, after which HPLC analysis 
showed full conversion, the d.r. was determined at this stage (96:4). The product precipitated out 
of solution while most of the impurities remained in solution. The dichloromethane was carefully 
evaporated (30 °C, 32 mbar) yielding a yellow solid within a brown oil that was purified by 
filtration using MeOH (3 X 5.0 mL) giving the title product as a white solid (0.427 g).  
Yield: 73%; M.P.: 189-190 °C (material crystalized from 
acetone); TLC(CH2Cl2:MeOH, 98:2 v/v, UV): Rf = 0.62; [α]
23
D = +75.4 (c = 0.11, Acetone, l = 1 
dm); 1H NMR (600 MHz, Acetone) δ 8.18 (dd, J = 8.3, 1.2 Hz, 2H, H-Ph), 7.70 – 7.65 (m, 1H, 
H-Ph), 7.54 (t, J = 7.8 Hz, 2H, H-Ph), 7.08 (d, J = 1.7 Hz, 1H, H-Ar), 6.92 (dd, J = 7.9, 1.7 Hz, 
1H, H-Ar), 6.85 (d, J = 7.9 Hz, 1H, H-Ar), 6.02 (s, 2H, OCH2O), 5.81 (dd, J = 3.0, 0.9 Hz, 1H, 
CH-OBz), 4.72 (d, J = 12.1 Hz, 1H, CH-N3), 4.70 (br, 1H, CH-OH), 3.44 (td, J = 12.5, 4.0 Hz, 
1H, CH-Ar), 2.58 (dd, J = 14.5, 1.9 Hz, 1H, CH2), 2.23 (dt, J = 14.4, 4.0 Hz, 1H, CH2); 
13C NMR 
(151 MHz, Acetone) δ 198.76, 165.80, 149.06, 147.78, 136.16, 134.28, 130.73, 130.65, 129.38, 
122.00, 109.10, 108.39, 102.10, 80.05, 70.76, 70.60, 45.18, 37.73; IR (neat, cm-1) ν 3475, 2907, 
2101, 1709, 1505, 1494, 1444, 1328, 1248, 1128, 1100, 1040, 935, 821; HRMS (ESI): exact 
mass calculated for C20H17N3NaO6 [(M + Na)
+], 418.1015; found 418.1015; e.e.: was determined 
after the filtration. τmajor = 12.8 min, τminor = 8.7 min (>99% e.e.), Daicel Chiralpak AS-RH 
column (150 x 4.6 mm, 5μ), Water/ACN (60:40) as a mobile phase; flow rate 0.75 mL/min, 
column temperature 20 °C, λ236; d.r.: 96:4 (HPLC). 
(1R,3S,4S,6R)-3-azido-4-(1,3-benzodioxol-5-yl)-6-hydroxy-2-oxocyclo hexyl benzoate 
(ent-SI6)  
The title compound was isolated by filtration, as a white solid.  
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Yield: 70%; M.P.: 179-180 °C (material solidified from 
acetone); [α]24D = -67 (c = 0.46, Acetone, l = 1 dm); e.e.: τmajor = 8.7 min, τminor = 12.8 min (>99% 
e.e.), Daicel Chiralpak AS-RH column (150 x 4.6 mm, 5μ), Water/ACN (60:40) as a mobile 
phase; flow rate 0.75 mL/min, column temperature 20 °C, λ236; d.r.: 96:4 (HPLC).  
 
N-[(1R,3R,4R,6R)-6-(1,3-benzodioxol-5-yl)-3-benzoyloxy-4-hydroxy-2-oxocyclohexyl]- 
carbamic acid methyl ester (SI7). Into a stainless steel hydrogenation vessel SI6 (0.1950 g, 
0.493 mmol), dimethyl dicarbonate (0.1984 g, 1.480 mmol, 3.0 equiv) and 10 % Pd/C (0.0394 g, 
0.037 mmol, 0.075 equiv) were suspended in EtOAc (8.0 mL). The vessel was sealed and 
subjected to 50 psi of hydrogen gas with vigorous stirring for 36 hr after which TLC 
(CH2Cl2/MeOH 95:5) showed full conversion. The suspension was filtered through a Celite
® pad 
and carefully evaporated (20 °C, 0.1 mbar). The translucent grey oil was purified by flash 
chromatography (eluent CH2Cl2/MeOH 100:0 to 97:3) giving the product as a white semi-solid 
(0.1665 g).  
Yield: 79%; M.P.: 196-197 °C (material solidified from Acetone); 
TLC(CH2Cl2:MeOH, 98:2 v/v, UV): Rf = 0.17; [α]
23
D = +58 (c = 2.17, Acetone, l = 1 dm); 
1H 
NMR (600 MHz, Acetone) δ 8.17 (d, J = 7.1 Hz, 2H, H-Ph), 7.66 (t, J = 7.4 Hz, 1H, H-Ph), 7.52 
(t, J = 7.8 Hz, 2H, H-Ph), 7.06 (s, 1H, H-Ar), 6.89 (d, J = 7.9 Hz, 1H, H-Ar), 6.78 (d, J = 7.9 Hz, 
1H, H-Ar), 6.25 (d, J = 9.3 Hz, 1H, NH), 5.98 (d, J = 3.1 Hz, 2H, OCH2O), 5.86 (d, J = 2.6 Hz, 
1H, CH-OBz), 4.81 (dd, J = 11.9, 9.7 Hz, 1H, CH-NH), 4.69 (s, 1H, CH- OH), 3.44 (td, J = 12.5, 
4.0 Hz, 1H, CH-Ar), 3.44 (s, 3H, CH3O), 2.65 (dd, J = 13.6, 1.9 Hz, 1H, CH2), 2.20 (dt, J = 14.3, 
4.0 Hz, 1H, CH2); 
13C NMR (151 MHz, Acetone) δ 200.19, 165.75, 157.51, 148.70, 147.36, 
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136.87, 134.10, 130.91, 130.69, 129.31, 122.18, 108.77, 101.90, 80.39, 70.82, 63.57, 51.87, 
44.77, 38.22; IR (neat, cm-1) ν 3373, 2922, 1705, 1531, 1505 1489, 1449, 1248, 1126, 1066, 
1038 935, 712; HRMS (ESI): exact mass calculated for C22H22NO8 [(M + H)
+], 428.1345; found 
428.1346. 
(1S,2S,3S,4R,5R)-2-Benzoyloxy-1,3-dihydroxy-4-(methoxycarbonyl amino)-5-(3,4-
methylenedioxyphenyl)cyclohexane (SI8). To a solution of tetramethylammonium 
triacetoxyborohydride (0.2509 g, 0.954 mmol, 4.0 equiv) and acetic acid (0.136 mL 2.384 mmol, 
10.0 equiv) in acetonitrile (5.0 mL) was added a solution of N-[6-(1,3- benzodioxol-5-yl)-3-
benzoyloxy-4-hydroxy-2-oxocyclohexyl]-carbamic acid methyl ester (0.1019 g, 0.238 mmol) in 
0.5 mL of acetonitrile. The reaction mixture was stirred at room temperature for 12 h before it 
was quenched with 1.5 mL of saturated aqueous ammonium chloride solution. After 
effervescence had ceased, the solution was treated with 1.5 mL of 1.0 M aqueous 
sodium/potassium tartrate solution and stirred for 30 min. The aqueous solution was extracted 
with CH2Cl2 (10 X 2 mL). The combined organic extracts were washed with 1.0 mL of saturated 
aqueous sodium chloride solution, dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. The yellow product was purified by flash column chromatography (CH2Cl2 / MeOH; 
100:0 to 98:2) to afford 0.0921 g of a white solid.  
Yield: 90%; M.P.: 198-210 °C (material solidified from CH2Cl2); 
TLC(CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.13; [α]
22
D = +50 (c = 1.69, MeOH, l = 1 dm); 
1H 
NMR (700 MHz, Acetone) δ 8.11 (dd, J = 8.2, 1.1 Hz, 2H, H-Ph), 7.62 (t, J = 7.4 Hz, 1H, H-Ph), 
7.50 (t, J = 7.8 Hz, 2H, H-Ph), 6.91 (d, J = 1.4 Hz, 1H, H-Ar), 6.78 (dd, J = 7.9, 1.6 Hz, 1H, H-
Ar), 6.73 (d, J = 7.9 Hz, 1H, H-Ar), 6.11 (d, J = 8.7 Hz, 1H, NH), 5.94 (dd, J = 8.1, 1.1 Hz, 2H, 
OCH2O), 5.11 (dd, J = 9.8, 2.8 Hz, 1H, CH-OBz), 4.47 (br, 1H, CH2-CH- OH), 4.33 (s, 1H, CH2-
CH-OH), 4.25 (t, J = 8.2 Hz, 1H, CH-OH), 4.17 (br, 1H, OH), 3.83 (q, J = 9.9 Hz, 1H, CH-NH), 
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3.40 (s, 3H, OCH3), 3.30 (td, J = 10.8, 3.4 Hz, 1H, CH-Ar), 2.02 (t, J = 13.1 Hz, 1H, CH2), 1.95 
(dt, J = 14.0, 3.8 Hz, 1H, CH2); 
13C NMR (176 MHz, Acetone) δ 166.56, 157.86, 148.41, 146.88, 
137.84, 133.63, 131.80, 130.55, 129.11, 122.14, 108.99, 108.56, 101.65, 79.87, 72.06, 67.60, 
60.12, 51.61, 41.93, 38.81; IR (neat, cm-1) ν 3407, 3062, 2947, 2899, 1714, 1540, 1504, 1489, 
1315, 1248, 1039, 930, 734, 713; HRMS (ESI): exact mass calculated for C22H24NO8 [(M + H)
+], 
430.1502; found 430.1495.  
(1S,2S,3S,4R,5R)-2-Benzoyloxy-1,3-diacetoxy-4-(methoxycarbonyl amino)-5-(3,4-
methylenedioxyphenyl)cyclohexane (SI9).  
2-Benzoyloxy-1,3-dihydroxy-4-(methoxycarbonylamino)-5-(3,4-methyl enedioxyphenyl) 
cyclohexane (0.0161 g, 0.037 mmol) and acetyl chloride (0.265 mL, 3.73 mmol, 100 equiv) were 
stirred for 16 h. After that the suspension was poured into a cooled, saturated aq. NaHCO3 
solution and extracted with CH2Cl2 (2 mL) dried with anhydrous Na2SO4 and concentrated. The 
yellow product was purified by flash column chromatography (CH2Cl2 / MeOH; 100:0 to 98:2) to 
afford 0.0169 g of a yellow oil.  
Yield: 88%; TLC(CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.33; [α]
22
D = + 
71 (c = 0.73, MeOH, l = 1 dm); 1H NMR (600 MHz, CDCl3) δ 7.95 (d, J = 7.1 Hz, 2H, H-Ph), 
7.56 (t, J = 7.4 Hz, 1H, H-Ph), 7.43 (t, J = 7.8 Hz, 2H, H-Ph), 6.75 (d, J = 7.9 Hz, 1H, H-Ar), 
6.71 (s, 1H, H-Ar), 6.67 (d, J = 7.8 Hz, 1H, H-Ar), 5.94 (dd, J = 4.2, 1.4 Hz, 2H, OCH2O), 5.62 
(dd, J = 5.6, 3.1 Hz, 1H, CH2-CH-OAc), 5.53 (t, J = 10.3 Hz, 1H, CH-OAc), 5.29 (dd, J = 10.3, 
3.2 Hz, 1H, CH-OBz), 4.52 (d, J = 8.9 Hz, 1H, NH), 4.01 (d, J = 8.4 Hz, 1H, CH-NH), 3.50 (s, 
3H, CH3O), 3.01 (t, J = 10.9 Hz 1H, CH-Ar), 2.13 (s, 3H, CH3CO), 2.11 (dt, J = 14.8, 3.7 Hz, 
1H, CH2), 1.95 (m, 1H, CH2), 1.95 (s, 3H, CH3O); 
13C NMR (151 MHz, CDCl3) δ 170.99, 
169.73, 165.40, 156.39, 147.90, 146.73, 133.57, 133.35, 129.63, 129.30, 128.52, 120.92, 108.38, 
107.79, 101.05, 72.96, 72.01, 68.56, 56.85, 52.21, 42.63, 35.21, 21.00, 20.67; IR (neat, cm-1) ν 
3363, 2950, 1732, 1522, 1506, 1490, 1276, 1242, 1093, 1039, 931, 714; HRMS (ESI): exact 
mass calculated for C26H28NO10 [(M + H)





enedioxyphenyl)cyclohexane (0.0169 mg, 0.033 mmol) and DMAP (0.0121 mg, 0.099 mmol, 
3.0 equiv) were dissolved in CH2Cl2 (1 mL) at 0 °C. 1.0 M solution of Tf2O in CH2Cl2 (0.164 
mL, 0.164 mmol, 5.0 equiv) was added drop-wise over a period of 10 min. The reaction was 
stirred for 16 h at RT. The solvent was evaporated and the residue treated with a mixture of THF 
(1 mL) and 1 N HCl (0.25 mL). After stirring for 1 h at RT, the mixture was partitioned between 
a saturated aqueous solution of NaHCO3 (0.5 mL) and CH2Cl2 (2 mL). The organic phases were 
combined, dried with anhydrous Na2SO4 and concentrated. The brown product was purified by 
flash column chromatography (CH2Cl2 / MeOH; 100:0 to 98:2) to afford 0.0115 g of a white oil.  
Yield: 73%; TLC (CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.17; [α]
22
D = 
+91 (c = 1.2, MeOH, l = 1 dm); 1H NMR (600 MHz, CDCl3) δ 7.96 (dd, J = 8.3, 1.3 Hz, 2H, H-
Ph), 7.60 – 7.54 (m, 1H, H-Ph), 7.52 (s, 1H, H-Ar), 7.44 (t, J = 7.8 Hz, 2H, H-Ph), 7.08 (br, 1H, 
NH), 6.69 (d, J = 0.7 Hz, 1H, H-Ar), 6.02 (dd, J = 5.1, 1.3 Hz, 2H, OCH2O), 5.72 (d, J = 2.7 Hz, 
1H, CH2-CH-OAc), 5.71 (t, J = 10.1 Hz, 2H, CH-OAc), 5.15 (dd, J = 10.1, 3.2 Hz, 1H, CH-
OBz), 3.60 (dd, J = 12.7, 10.2 Hz, 1H, CH-NH), 3.31 (td, J = 12.6, 3.9 Hz, 1H, CH-Ar), 2.61 (dt, 
J = 14.5, 3.8 Hz, 1H, CH2), 2.11 (s, 3H, CH3O), 2.05 (s, 3H, CH3O), 1.86 – 1.79 (m, 1H, CH2); 
13C NMR (151 MHz, CDCl3) δ 170.73, 169.80, 165.60, 165.51, 151.49, 147.04, 135.18, 133.49, 
129.68, 128.98, 128.55, 122.99, 108.34, 103.98, 101.79, 72.94, 71.10, 68.25, 56.97, 34.63, 29.03, 
20.98, 20.92; IR (neat, cm-1) ν 3344, 2916, 1727, 1666, 1505, 1488, 1450, 1274, 1227, 1038, 
932, 714; HRMS (ESI): exact mass calculated for C25H24NO9 [(M + H)
+], 482.1451; found 
482.1454.  
(+)-trans-3-Epidihydrolycoricidine (8). 3-Benzoyloxy-2,4-diacetoxy-8,9-
methylenedioxy-1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one 0.0011 g (0.024 mmol) and 
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potassium carbonate (0.0003 g, 0.002 mmol, 0.10 equiv) were dissolved in MeOH (0.022 mL) 
and water (0.198 mL) and stirred at room temperature until a white solid precipitate formed; 
TLC analysis showed full conversion after 16 hr. The mixture was concentrated under a flow of 
N2. The white product was dissolved in 9:1 CH2Cl2 / MeOH and filtered through a path of silica. 
The white solid was recrystallized from methanol to afford 0.0058 g of fine white needles.  
Yield: 81%; M.P.: 298-299 °C (material solidified from MeOH); TLC 
(CH2Cl2:MeOH, 9:1 v/v; UV): Rf = 0.09; [α]
22
D = +38 (c = 0.14, DMSO, l = 1 dm); 
1H NMR 
(600 MHz, DMSO) δ 7.30 (s, 1H, H-Ar), 7.04 (br, 1H, NH), 6.93 (s, 1H, H-Ar), 6.07 (d, J = 1.4 
Hz, 2H, OCH2O), 5.09 (br, 1H, CH2-CH-OH), 4.69 (br, 2H, OH, OH), 3.95 (d, J = 2.0 Hz, 1H, 
CH2-CH-OH), 3.59 (t, J = 8.9 Hz, 1H, CH(OH)-CHN), 3.25 (dd, J = 9.2, 2.7 Hz, 1H, CHO-
CH(OH)CHO), 3.01 – 2.91 (m, 2H, CH-NH, CH-Ar), 2.38 (dt, J = 13.6, 3.1 Hz, 1H, CH2eq), 1.47 
– 1.39 (m, 1H, CH2ax); 
1H NMR (600 MHz, DMSO, D2O) δ 7.26 (s, 1H, H-Ar), 6.85 (s, 1H, H-
Ar), 6.00 (d, J = 2.9 Hz, 2H, OCH2O), 3.99 (d, J = 2.4 Hz, 1H, CH2-CH-OD), 3.58 (t, J = 9.4 Hz, 
1H, CH(OD)-CHN), 3.28 (dd, J = 9.4, 3.0 Hz, 1H, CHO-CH(OD)CHO), 2.99 (dd, J = 12.8, 9.3 
Hz, 1H, CH-ND), 2.93 (td, J = 12.3, 3.4 Hz, 1H, CH-Ar), 2.33 (dt, J = 13.7, 3.5 Hz, 1H, CH2eq), 
1.45 (t, J = 12.9 Hz, 1H, CH2ax); 
13C NMR (151 MHz, DMSO) δ 164.13, 150.65, 145.98, 137.63, 
123.10, 106.89, 104.54, 101.57, 73.78, 71.47, 68.14, 59.06, 33.70, 31.18; IR (neat, cm-1) ν 3464, 
3261, 2895, 1642, 1608, 1472, 1355, 1270, 1067, 934, 778; HRMS (ESI): exact mass calculated 
for C14H16NO6 [(M + H)








Synthesis of (+)-3-deoxydihydrolycoricidine 
 
Figure 63.  Supplementary Scheme 3. 
 
N-[(1R,2R,4S,6R)-2,4-Dihydroxy-6-(1,3-benzodioxol-5-yl)-cyclohexyl] carbamic acid 
methyl ester (SI14).  
The title compound was prepared from SI5 and SI11 as shown above following the 
procedure described by McNulty et. al., 2013. 
(1S,3R,4R,5R)-5-(1,3-Benzodioxol-5-yl)-4-(methoxycarbonylamino)- cyclohexane-1,3-
Reagents and conditions: Yields of isolated products (%) are indicated. j) SI5 (1.5 equiv), Cat A (10 mol%) and 
Cat B (10 mol%), CH2Cl2, RT, 65%. k) DMDC (3.0 equiv), H2, 10% Pd/C (0.075 equiv), 50 psi, MeOH, RT, 
82%. l) Me4NHB(OAc)3 (4.0 equiv), ACN/AcOH 96:4, RT, 77%. m) Ac2O (6.0 equiv), py (6.0 equiv), RT, 
83%. n) Tf2O (5.0 equiv), DMAP (3.0 equiv), CH2Cl2, 0 °C → RT, 51% o) K2CO3 (0.10 equiv), MeOH /H2O 
9:1, RT, 87%. DMDC = Dimethyl dicarbonate, ACN = acetonitrile, py = pyridine, Tf = Triflic, DMAP = 4-
Dimethylaminopyridine, Moc = Methyloxycarbonyl.  
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diyldiacetate (SI15). To a solution of SI14 (0.0820 g, 0.259 mmol) in pyridine (0.125 mL, 1.56 
mmol, 6.0 equiv) was added acetic anhydride (0.146 mL, 1.55 mmol, 6.0 equiv). The reaction 
mixture was stirred at room temperature for 16 h. After that the pyridine was removed in vacuo 
(0.1 mbar). The residue was dissolved in CH2Cl2 (5 mL) and washed with saturated NaHCO3 (2 x 
10 mL) and water (5.0 mL). The solvent was removed in vacuo (35 °C, 0.1 mbar) and the 
product purified by flash column chromatography (CH2Cl2 / MeOH; 100:0 to 98:2) to afford 15 
(0.0843 g) as a clear yellow oil.  
Yield: 83%; TLC(CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.47; [α]
21
D = +35 
(c = 5.10, MeOH, l = 1 dm); 1H NMR (600 MHz, CDCl3) δ 6.70 (d, J = 7.9 Hz, 1H, H-Ar,), 6.68 
(s, 1H, H-Ar,), 6.63 (d, J = 7.9 Hz, 1H, H-Ar,), 5.90 (dd, J = 3.9, 1.3 Hz, 2H, OCH2O), 5.21 (q, J 
= 2.73 Hz, 1H, CH2CHCH2), 5.13-5.09 (m, 1H, CH(O)CHN), 4.50 (d, J = 9.9 Hz, 1H, NH), 3.84 
(d, J = 7.7 Hz, 1H, CH-NH), 3.46 (s, 3H, OCH3), 2.87 (t, J = 10.8 Hz, 1H, CH-Ar), 2.24 (d, J = 
13.7 Hz, 1H, COCH2axCO), 2.09 (s, 3H, COCH3), 2.03 (dq, J = 14.8, 3.1 Hz, 1H, CH2eqCHAr), 
2.01 (s, 3H, COCH3), 1.81 (d, J = 12.3 Hz, 1H, COCH2eqCO), 1.79 – 1.72 (m, 1H, CH2axCHAr); 
13C NMR (151 MHz, CDCl3) δ 170.87, 170.05, 156.57, 147.69, 146.38, 134.50, 120.80, 108.18, 
107.77, 100.87, 71.15, 68.54, 57.85, 51.98, 43.41, 37.88, 34.90, 21.22, 20.90; IR (neat, cm-1) ν 
3353, 2952, 1733, 1533, 1505, 1490, 1444, 1372, 1247, 1038, 933; HRMS (ESI): exact mass 
calculated for C19H24NO8 [(M + H)
+], 394.1502; found 394.1485.  
 
(+)-2,4-Diacetoxy-3-deoxydihydrolycoricidin (SI16).  
5-(1,3-Benzodioxol-5-yl)-4-(methoxycarbonylamino)- cyclohexane-1,3- diyldiacetate 
SI15 (0.1442 mg, 0.319 mmol) and DMAP (0.1171 mg, 0.958 mmol, 3.0 equiv) were dissolved 
in CH2Cl2 (8.0 mL) at 0 °C. 1.0 M solution of Tf2O in CH2Cl2 (1.597 mL, 1.60 mmol, 5.0 equiv) 
was added dropwise over a period of 10 min. The reaction was stirred for 16 h at RT. The 
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solvent was evaporated and the residue treated with a mixture of THF (5 mL) and 1 N HCl (1.0 
mL). After stirring for 1 h at RT, the mixture was partitioned between a saturated aqueous 
solution of NaHCO3 (1.0 mL) and CH2Cl2 (20 mL). The organic phases were combined, dried 
with anhydrous Na2SO4 and concentrated. The brown product was purified by flash column 
chromatography (CH2Cl2 / MeOH; 100:0 to 98:2) to afford 0.0398 g of a yellow oil. 
Yield: 51%; TLC(CH2Cl2:MeOH, 98:2 v/v; UV): Rf = 0.15; [α]
21
D = +24 
(c = 1.17, MeOH, l = 1 dm); 1H NMR (600 MHz, CDCl3) δ 7.54 (s, 1H, CH-Ar), 6.69 (s, 1H CH-
Ar), 6.54 (s, 1H, NH), 6.01 (d, J = 2.2 Hz, 2H, OCH2O), 5.37 – 5.34 (m, 1H, CH2CHCH2), 5.15 
(td, J = 11.0, 4.6 Hz, 1H, CH(O)CHN), 3.44 (dd, J = 12.5, 10.1 Hz, 1H, CH-NH), 3.18 (td, J = 
12.5, 3.8 Hz, 1H, CH-Ar), 2.53 (d, J = 14.0 Hz, 1H, CH2eqCHAr), 2.44 (ddd, J = 6.6, 5.1, 3.2 Hz, 
1H, COCH2axCO), 2.14 (d, J = 3.9 Hz, 3H, COCH3), 2.09 (d, J = 6.2 Hz, 3H, COCH3), 1.64 – 
1.56 (m, 2H, COCH2eqCO, CH2axCHAr); 
13C NMR (151 MHz, CDCl3) δ 170.55, 170.13, 165.28, 
151.46, 146.91, 135.95, 123.00, 108.31, 103.97, 101.74, 71.39, 67.99, 58.17, 34.99, 33.63, 30.65, 
21.24, 21.16; IR (neat, cm-1) ν 3197, 2923, 1737, 1667, 1464, 1382, 1364, 1246, 1040, 931; 
HRMS (ESI): exact mass calculated for C18H20NO7 [(M + H)
+], 362.1240; found 362.1241.  
 
(+)-3-Deoxydihydrolycoricidine (9). 2,4-diacetoxy-3-deoxydihydrolycoricidin SI16 
(0.0085 g, 0.024 mmol) and potassium carbonate (0.0003 g, 0.001 mmol, 0.10 equiv) were 
dissolved in CH3OH (0.153 mL) and water (0.017 mL) and stirred at room temperature until a 
white solid precipitate, TLC analysis showed full conversion after 16 h. The mixture was 
concentrated under a flow of N2. The white product was dissolved in 9:1 CH2Cl2 / MeOH and 
filtered through a path of silica. The white solid was recrystallized from methanol to afford 
0.0057 g of fine white needles. 
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Yield: 87%; M.P.: 255-257 °C (recrystallized from MeOH); 
TLC(CH2Cl2:MeOH, 95:5 v/v; UV): Rf = 0.08; [α]
21
D = +32 (c = 0.527, MeOH, l = 1 dm); 
1H 
NMR (600 MHz, MeOD) δ 7.39 (s, 1H, CH-Ar), 6.86 (s, 1H, CH-Ar), 6.03 (dd, J = 7.5, 0.9 Hz, 
2H, OCH2O), 4.33 – 4.27 (m, 1H, CH2CHCH2), 3.96 (ddd, J = 11.5, 9.1, 4.5 Hz, 1H, 
CH(O)CHN), 3.11 (dd, J = 11.8, 3.5 Hz, 1H, CH-Ar), 3.09 (d, J = 9.0 Hz, 1H, CH-NH), 2.42 
(ddd, J = 13.7, 5.5, 3.1 Hz, 1H, CH2CHAr), 2.21 – 2.13 (m, 1H, COCH2CO), 1.56 (ddt, J = 14.0, 
11.6, 2.5 Hz, 2H, CH2, CH2); 
13C NMR (151 MHz, MeOD) δ 167.64, 153.20, 148.13, 139.52, 
123.79, 108.43, 105.32, 103.28, 68.94, 66.65, 62.63, 40.59, 35.50, 34.52; IR (KBr, cm-1) ν 3243, 
3080, 2919, 1732, 1675, 1487, 1457, 1355, 1240, 1040, 934; HRMS (ESI): exact mass calculated 
for C14H16NO5 [(M + H)




APPENDIX E:  INDIVIDUAL CONTRIBUTION 
My personal contributions to the work described in this thesis are outlined below, by 
section. 
In the additional methods section: I cultured Vero cells, CV-28 cells, fibroblasts, iPSCs, 
NSC/eNPCs, and iPSC-neurons and performed viral propagation and quantitation of HSV-1 
(strains KOS, HSV-1 from Dr. Kinchington, and HSV-1 from Dr. Homa) on their respective cell 
types.  I performed viral plaque assays on Vero cells.  I performed HSV-1 infections in iPSC-
neurons for lytic infection, inducing quiescent infections, and viral reactivation, as well as lytic 
infections in Vero cells.  In addition to the FISH studies listed below, I also performed FISH in 
suspension and RNA FISH.  I performed PCR in situ, reverse transcriptase quantitative PCR, and 
DNA sequencing.  I performed the lytic infections in Vero and the quiescent HSV-1 infections in 
iPSC-neurons using Dr. Homa’s HSV-1 replication defective virus. 
Manuscript 1:  I contributed to cell culture work, immunocytochemistry of the 
neurosphere-like objects (NLSs), microscopy, and preparation of the manuscript. 
Manuscript 2:  I contributed to and analyzed viral infections, plaque assays on Vero cells, 
the pathway analysis for the microarray data by using Ingenuity Pathway Analysis program, and 
preparation of the manuscript. 
Additional virological assays:  I contributed to the design of the project and analyzed the 
viral copy number (Experiment 1).  I also performed the 2D and 3D FISH studies (Experiment 
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2), the Co-ICC/FISH experiments (Experiment 3), and the CHART-PCR experiments 
(Experiment 4). 
Manuscript 3:  I contributed to the design of the project and analysis of drug testing on 
Vero and iPSC-neurons, plaque assays on Vero cells, viral copy number assays, flow cytometry 
analysis, FISH on iPSC-neurons, immunocytochemistry, viral attachment/entry assays, statistical 
analyses for IC50 and CC50 calculations, testing for VZV efficacy and toxicity, and preparation 
of the manuscript. 
Manuscript 4:  I contributed to the analysis of HSV-1 viral infections, flow cytometry 
analysis, viral copy number assays, statistical analyses for IC50 and CC50 calculations, and 
preparation of the manuscript.  I also contributed to the design and analysis of antiviral activity 
of selected compounds on VZV infections. 
Groundwork for moderate throughput drug screening.  I contributed to the design of the 
experiments, and performed cell culture, viral infections (lytic, quiescent, and viral reactivation), 
NSC purifications, immunocytochemistry, and preparation of the cells for microscopy at the 
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